var title_f10_7_10352="Classical whooping";
var content_f10_7_10352=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/57822/Classical_whooping_conv.mp4?title=Classical+whooping\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Classical whooping cough with lots of whooping",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.whoopingcough.net/symptoms.htm. Copyright &copy; 2010 Dr. Doug Jenkinson.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_7_10352=[""].join("\n");
var outline_f10_7_10352=null;
var title_f10_7_10353="DAH CT";
var content_f10_7_10353=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse alveolar hemorrhage CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_7_10353=[""].join("\n");
var outline_f10_7_10353=null;
var title_f10_7_10354="Psoriatic skin findings in a child with psJIA";
var content_f10_7_10354=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F57017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F57017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Psoriatic skin findings in a child with psoriatic juvenile idiopathic arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cracking and scale behind the ear of a child with psJIA. As evident from this image, the skin findings of early psoriasis can be subtle and ambiguous.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Nigrovic PA, Sundel RP, Petty RE. Juvenile psoriatic arthritis. In: Textbook of Pediatric Rheumatology, 6th ed, Cassidy JT, Petty RE, Laxer RM, Lindsley CB (Eds), Saunders, Philadelphia 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_7_10354=[""].join("\n");
var outline_f10_7_10354=null;
var title_f10_7_10355="Locking handle needle holder";
var content_f10_7_10355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Locking handle needle holder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 489px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These needle holders have a squeeze-squeeze locking mechanism in the handle to lock and unlock the needle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_7_10355=[""].join("\n");
var outline_f10_7_10355=null;
var title_f10_7_10356="Gastric folds";
var content_f10_7_10356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Gastric folds",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 459px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gastric folds seen upon passage of an upper endoscope into the stomach during esophagogastroduodenoscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_7_10356=[""].join("\n");
var outline_f10_7_10356=null;
var title_f10_7_10357="Cefadroxil: Drug information";
var content_f10_7_10357=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefadroxil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/6/17508?source=see_link\">",
"    see \"Cefadroxil: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/32/32259?source=see_link\">",
"    see \"Cefadroxil: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F146996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cefadroxil&reg;;",
"     </li>",
"     <li>",
"      PRO-Cefadroxil;",
"     </li>",
"     <li>",
"      Teva-Cefadroxil",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F147039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Cephalosporin (First Generation)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F146999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Susceptible infections:",
"     </b>",
"     Oral: 1000-2000 mg daily in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Orofacial infections:",
"     </b>",
"     Oral: 250-500 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pharyngitis, group A streptococci (IDSA guidelines):",
"     </b>",
"     Oral: 30 mg/kg once daily (maximum: 1000 mg daily) for 10 days (Shulman, 2012).",
"     <b>",
"      Note:",
"     </b>",
"     Recommended as an alternative agent in penicillin-allergic patients; however, avoid in patients with immediate type hypersensitivity to penicillin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prosthetic joint infection, chronic oral antimicrobial suppression, staphylococci (oxacillin-susceptible) (preferred) (unlabeled use):",
"     </b>",
"     500 mg every 12 hours (Osmon, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F147018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/32/32259?source=see_link\">",
"      see \"Cefadroxil: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Susceptible infections:",
"     </b>",
"     Oral: 30 mg/kg/day divided twice daily up to a maximum of 2000 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pharyngitis, group A streptococci (IDSA guidelines):",
"     </b>",
"     Oral: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F147000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F147001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-25 mL/minute: Administer every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 36 hours.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F146973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hemihydrate [strength expressed as base]: 500 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as monohydrate [strength expressed as base]: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as monohydrate [strength expressed as base]: 250 mg/5 mL (50 mL, 100 mL); 500 mg/5 mL (75 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hemihydrate [strength expressed as base]: 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as monohydrate [strength expressed as base]: 1 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F146957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F146977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer around-the-clock to promote less variation in peak and trough serum levels.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F146976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible bacterial infections, including those caused by group A beta-hemolytic",
"     <i>",
"      Streptococcus",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F16032479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chronic oral antimicrobial suppression of prosthetic joint infection with",
"     <i>",
"      Staphylococci",
"     </i>",
"     (oxacillin-susceptible)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F147037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, agranulocytosis, anaphylaxis, angioedema, arthralgia, cholestasis, dyspepsia, erythema multiforme, fever, nausea, neutropenia, pruritus, pseudomembranous colitis, rash (maculopapular and erythematous), serum sickness, Stevens-Johnson syndrome, thrombocytopenia, transaminases increased, urticaria, vaginitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Abdominal pain, aplastic anemia, BUN increased, creatinine increased, eosinophilia, hemolytic anemia, hemorrhage, pancytopenia, prothrombin time prolonged, renal dysfunction, seizure, superinfection, toxic epidermal necrolysis, toxic nephropathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F146980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cefadroxil, any component of the formulation, or other cephalosporins",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F146961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F146966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F146991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Concomitant administration with food, infant formula, or cow's milk does",
"     <b>",
"      not",
"     </b>",
"     significantly affect absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F146969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5944424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Cefadroxil crosses the placenta. Limited data is available concerning the use of cefadroxil in pregnancy; however, adverse fetal effects were not noted in a small clinical trial.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F147005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F146983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Very small amounts of cefadroxil are excreted in breast milk. The manufacturer recommends that caution be exercised when administering cefadroxil to nursing women. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F146982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Cefadroxil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (50): $186.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Cefadroxil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/5 mL (100 mL): $60.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg/5 mL (75 mL): $63.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cefadroxil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (50): $350.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F146971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor renal function. Observe for signs and symptoms of anaphylaxis during first dose.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F146984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adroxef (CN);",
"     </li>",
"     <li>",
"      Alkil (ID);",
"     </li>",
"     <li>",
"      Androxyl (MY, SG);",
"     </li>",
"     <li>",
"      Baxan (GB);",
"     </li>",
"     <li>",
"      Biodroxil (AE, BG, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, PE, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Biodroxyl (VE);",
"     </li>",
"     <li>",
"      Cedrox (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Cefacar (AR);",
"     </li>",
"     <li>",
"      Cefacell (KP);",
"     </li>",
"     <li>",
"      Cefadril (IT);",
"     </li>",
"     <li>",
"      Cefadrol (IN);",
"     </li>",
"     <li>",
"      Cefadur (MY);",
"     </li>",
"     <li>",
"      Cefalom (GR);",
"     </li>",
"     <li>",
"      Cefamox (BR, SE, UY);",
"     </li>",
"     <li>",
"      Cefat (ID);",
"     </li>",
"     <li>",
"      Cefixin (PE);",
"     </li>",
"     <li>",
"      Ceforal (PT);",
"     </li>",
"     <li>",
"      Cephos (IT);",
"     </li>",
"     <li>",
"      Curisafe (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Cyclomycin-K (GR);",
"     </li>",
"     <li>",
"      Dacef (ZA);",
"     </li>",
"     <li>",
"      Drocef (BR, KP);",
"     </li>",
"     <li>",
"      Drovax (ID);",
"     </li>",
"     <li>",
"      Droxicef (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Droxil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Droxyl (IN);",
"     </li>",
"     <li>",
"      Drozid (PH);",
"     </li>",
"     <li>",
"      Duracef (AT, BE, BF, BG, BJ, CI, CZ, EC, EE, ES, ET, FI, GH, GM, GN, HN, KE, LR, MA, ML, MR, MU, MW, MX, NE, NG, PE, PL, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Duricef (PK, TR);",
"     </li>",
"     <li>",
"      Erphadrox (ID);",
"     </li>",
"     <li>",
"      Ethicef (ID);",
"     </li>",
"     <li>",
"      Fadrox (CO);",
"     </li>",
"     <li>",
"      Gruncef (DE);",
"     </li>",
"     <li>",
"      Hanacef (KP);",
"     </li>",
"     <li>",
"      Justum (PY);",
"     </li>",
"     <li>",
"      Kleotrat (GR);",
"     </li>",
"     <li>",
"      Lapicef (ID);",
"     </li>",
"     <li>",
"      Lapricef (GT, NI, PA, SV);",
"     </li>",
"     <li>",
"      Lesporina (CO);",
"     </li>",
"     <li>",
"      Likodin (TW);",
"     </li>",
"     <li>",
"      Lostacef (ID);",
"     </li>",
"     <li>",
"      Lydroxil (IN);",
"     </li>",
"     <li>",
"      Maxcef (ID);",
"     </li>",
"     <li>",
"      Medicefa (KP);",
"     </li>",
"     <li>",
"      Moxacef (GR, NL);",
"     </li>",
"     <li>",
"      Nefalox (GR);",
"     </li>",
"     <li>",
"      Nor-Dacef (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Odoxil (IN);",
"     </li>",
"     <li>",
"      Oracefal (FR);",
"     </li>",
"     <li>",
"      Oradroxil (IT);",
"     </li>",
"     <li>",
"      Qualidrox (HK);",
"     </li>",
"     <li>",
"      Rafemox (CN);",
"     </li>",
"     <li>",
"      Sofidrox (MY, SG);",
"     </li>",
"     <li>",
"      Ultracef (IE);",
"     </li>",
"     <li>",
"      Vepan (IN);",
"     </li>",
"     <li>",
"      Versatic (AR);",
"     </li>",
"     <li>",
"      Vidcef (KP);",
"     </li>",
"     <li>",
"      Vocefa (ID);",
"     </li>",
"     <li>",
"      Vocefa Forte (ID);",
"     </li>",
"     <li>",
"      Wincef (TW);",
"     </li>",
"     <li>",
"      Wincocef (PH);",
"     </li>",
"     <li>",
"      Xianfengjiu (CL);",
"     </li>",
"     <li>",
"      Zolpra (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F146960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F146979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely throughout the body and reaches therapeutic concentrations in most tissues and body fluids, including synovial, pericardial, pleural, and peritoneal fluids; bile, sputum, and urine; bone, myocardium, gallbladder, skin, and soft tissue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1-2 hours; Renal failure: 20-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 70-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&gt;90% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/7/10357/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cutler RE, Blair AD, and Kelly MR, &ldquo;Cefadroxil Kinetics in Patients With Renal Insufficiency,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1979, 25(5 Pt 1):514-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/7/10357/abstract-text/436355/pubmed\" id=\"436355\" target=\"_blank\">",
"        436355",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 318(7):419-26 and 318(8):490-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/7/10357/abstract-text/3277054/pubmed\" id=\"3277054\" target=\"_blank\">",
"        3277054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marshall WF and Blair JE, &ldquo;The Cephalosporins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(2):187-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/7/10357/abstract-text/10069359/pubmed\" id=\"10069359\" target=\"_blank\">",
"        10069359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/7/10357/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman ST, Bisno AL, Clegg HW, et al, &ldquo;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 55(10):e86-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/7/10357/abstract-text/22965026/pubmed\" id=\"22965026\" target=\"_blank\">",
"        22965026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith GH, &ldquo;Oral Cephalosporins in Perspective,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1990, 24(1):45-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/7/10357/abstract-text/2405586/pubmed\" id=\"2405586\" target=\"_blank\">",
"        2405586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9212 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7CC26F0507-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_7_10357=[""].join("\n");
var outline_f10_7_10357=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146996\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147039\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146999\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147018\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147000\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147001\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682515\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146973\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146957\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146977\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146976\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032479\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147037\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146980\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146961\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298984\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146966\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146991\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146969\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5944424\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147005\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146983\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146982\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146971\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146984\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146960\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146979\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9212\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9212|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/6/17508?source=related_link\">",
"      Cefadroxil: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/32/32259?source=related_link\">",
"      Cefadroxil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_7_10358="Adenocarcinoma of endometrium";
var content_f10_7_10358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adenocarcinoma of the endometrium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 483px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHjAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5vitoDBGTEu4qMnPXinfZrfvCv60635gTB4CjOPpUhJzmgzIza2/TyE9zzQ1rbBeIV5HvUpbgU0Meo7dxQBF9mg4zCuD9fypTa25OFhXjjqaefmIz270oy3ORnoKAIPs8HP7leenWnG2t8f6lR9an5zn06004wAPu5z+NAXGG1twgIhXOeOTQba1AJ8peOg5qQgEnnnH0JpDgqRu5HTPegLkf2a3YgLCo/E04Wtuc4hX361Js7qMEjnuKQg7j8x/CgLkZs4MAmJBnn6ULZREbvJQjPHWnjJbjk+/rTg5K7QSE9O2aA1IjawHlYEI9s0G1txx5K59RmpsYxtJzj0ppxgnOfU0BciFpARzCv05pPs0Ax+5T6nNSgEsM8noM8UrYywPGO1AERt7bHEC5696RbSAnPlDH+eKlAAOP165pOBkAjPegBhtrf/ngOuO9Klpbk/6lcE+9TBSxxkMfTFdDa+DPEFzaC6i0m9MJGd/lHBHr9KHKMdZOw0pPZXOZNpbj/lgPrTTawAf6hSfbtWhdW09rI8VxE0brxtcYNT2GkXuosq2drLKzHA2r61b5bXuKN27Ix1toM8wpxz3p32SAc+SuOnOa7q28B6hDfCHV4GtGUAlHGGwa6RvDOlxW21ERmA5OeTXPPE04eZ2UsDWqK+x5ELSB/wDlio7Z5pEs4GziFOvvxXqP/CLQ8MsA2deua29N0bTbcxuLWMv1bcOprKWMgldK50Usqqzdm7Hif2SFWAMKep6/lSC2ty5xEg9Ac17pefDlfEl75llD9mRfvlR19cCsvxX8JzpFkl7Z3TSwKwWSNxh0/D0ohjaMmk3ZmNXL61O/VHkBs4RjMKk+2actnA2cQKR04NeiaZ4IS8kUF9iHuavHwra6XqGwDzihzkjg1csVSTstxLAVmrtWR5f9gjVgGthzz3oFjARn7OPTvXtSaAl5KRsRFxkMF/T3p2peGBp88MU1siwPhmkP8IrL6/C9ram8cqqTdkzxIWMB48gdOpBoNnbrjMKHr617jN4R0u4hRreaFmZsYz2rnL/wdbi5eNotp9YzkU4Y6lMirllameXG0t+giXnpnNH2S3BwYRXrOjfDOGZne/vGSAZ2jAyfr/ntXa+DPhp4SvLi5sNR8yWZ0zFIHIKk9xjjipqZhQp63uRHLq7i5NWsfOYtbbBPkL+uKRbSDK5hT6c12PiXwXqek32opHA81tZylWmUZG3PBNcoVK4LKRz0rtjKM1eDOSdOdN2mrEJs4FBzCufTmgWlv/zxHHXrU/VSMnvz1zSdMEjjHWnZmdyE21qeRCv0pDbW5JxCo796nyRgEYNN3fL7elINSIWtv/zxX8c4oFtb45t1yemOakYkYGf60pU/Lj5h6g0DIhawE/6hMAds0G1hI/1EY+pNSZOeozinIpZSSwGByD3oEQfZoMf6lBx3zzR9mtj/AMsVz7ZqU4Xbz9PanKOQ3BGcfjQFyIWtvjHkoSO/NH2W2BI8lR9c1Lxv6gj0PFNztJ6j696AuM+y25U7YUz684qOa1gELsIlBCnp24qwT8pbHPsaZKM28n+6eR9KBq42AnyIuRnaP5UqsOynjrmmwqGt4vmJG0dvan7doHIAoAUtubKqR6fSk5Iz6jBApxx3OFpN3AA/L0FACbsALgZ9KEyASAQR1yKMEjjt3obAwQfwFADlIODjJ7e9J/CuD9cU3jkEjHU5OMUKcHAOfSgBQQASSTkd6a2cc5HrmnHrjPGeRQCGOBznp/hQAoyBgfp60pbGcY3e3WkOBkZX3oU5Bz0PY0AOAXkMRnHGeppuTx2z+VOCjHJw3vSkjBJJ470CGZ/i5xnnFSYXhsjP5U0r6HBzkYFIAOR6GgYZ6+nvUkUMs0yxxxs0rHCjHWodxU8Ng/0rrvhsFTxFDOY/MEZyQecVFSXJFy7GlGn7WoodzDvdG1C0Xdc20qA8klcVQwxIJUc8c17j4v1kapdGKKICELtxgc1kaF4Ii1a8UvEUQfMcDqK54YxOHNUVj16+SzppSg9PMZ+z14TtfEni131GNpLezTzSjjIZs4ANfRPiS+g065FurFYkUDaD90ewrM+H2k6f4bvBb2SorPHtYk9e9YHjy1mk8RRkSMYnODtOcDrxXmV6qxE79C8HhkpqDelijr2gWfiANKbWOSZxhXK4JGK6j4X+FdP0SOSae3ja5ODG55AX2/xrlbnxLb2kGy2t7iRrdhGxC11GlavNfIsqrNGAvyhuAPwrByqQik9jrq0Gk7K3n1Kfx0tra6sbW5QYuUyBIDjK+hrxDzXRcMTx0r1rxrfT6jYpYTyKY4m3IO+feuIXw6HBcsT6gdq66FVKNpk0ozpxSQyy1KOayI2kSJ94+taGkSW5vbWSUEqrfOMdqg0nTYI7oxFWLnrmum/shRFiEKpb+KsqsoK6R2Qm95Ho+lX+j29t9ogeGMEf3uTWHr15aala3EwnjaSMfdI+8DXCyaclllcSSHO47m6msG/NxLI53mONuNqHrXNToOTvzfgZuhCL5rl213eeRFtCZJHNTXQKRO7RxmQ8D6VkafN9jKsrBtpyQxyD+FejeB7ZfEOozLdW8S22zJ7YPtXTU9z3twlUXL6HHWZu3QtHAwZeeOmKsSW2p6zDhIZJBna/P3eOK9attH0/QjczhVktCM5IzsriLvXLG31y+ksA0NrLtOwdGIHXFYTq6txWxdCfPdQXzOGl0a70a6C3MZUuMqc9RTorkllBXBHtWjrN1e6zqLzzfNCq7YsdhWTJG8CbgWUjqG4rpUnLWW46ntHo0aYu2Mflnk/17U3StQv9J1IXUAWVV6qTzz1qhJZXYCTMOCeMVbtra4VDkMSOSe9S4xcbdGODcdJI39Q8Q2Mml3zJHOL2bjyyoKMO+a4a60DTb+ASlI0J7YwRWuWLY3qc9D2pfs6u6q5xkc54IqqadP4Wc9RU6is0cg/gS3nGYJtoJ9fw5rMufAV6oY27RykE8Z+Y+4r0uHTmidCJ8rnGBwRUs9u6zGMMoOOpHUVssZUXU4pZdSn0seGaho99ZMVntnGOpPaqDKV9VI7V9AvbzbXEiRyxAcnYDx6GsG58N6beqWmjUH0UV0wx6a95HJPK5Rfuv7zxcA9uB0oyPUZPevW5fAemzQMsZMUvVXBrhPEfhe/0d8yIJLcniRRkV0U8RTqOyepy1sFVpLmktDnyx2gEcd89SaABkEcenFDMylQeD05oUD3/AMa2OUXOQcAYApnYZ5FPI4IPQ+lADE7RyT19aBCA87TxnvQDtODgY5HsaG4JyCMetIeATnjvigB+cEg7Qx68UyUBYZScEbGxz7U/0yAQfu4pk5zHLkchG4P0oBEcHMEWd3Cj6dKkA2jJGD/n/P50y3IFsmM5Kjv7U5SSenPSgYoVgBwOtNH4kD19adkAgE//AKqQDBJHpnkcUAOBGQOenFGCB04/2aaOOhzz1pw3fwgHnpQAjEBcHuM5xzTQCef4s9KXqCM8H1pGBCqc89uetAAM4xzgHtzSkY5HH0pOcZ28Y7U48cYBNAC4yMsRzyM0AbsZHPfNIwy5AznPIPrS9hzkD0NABjLBc5XPalA3NwQO+MYoUjaxOM9Me1LjcwG4HNADQ2S3cdeeKcyM74XJPpmr+n6PdX7jyYzjuT0rtNG8FRy4N4SAOazqVoU/iZ00MHWr6wWhwlnZy3ZCxRs24849a9I+H+nXGmPIZoVLSDC5rpNM0W1sojHa25Y9jirhSe0fPlBWAyua8+vivaJwS0PdwWWrDyVSUtUTf2EllKs9yB85/Kt+x/4lf72F8xMODjkVzM2oanMuGZCnuvJqfy9SuCDmOOMjgEE1xSUmveZ3zfPpJnSJeyLOLlZcv1AI61estUWZ5mu4wZZBhWz92uQtpNQQrFMkO0fxDipWjuw5LbQF5wBWcoeZi+V6G1qPkRy5hVSGO5gO9VH1O5O6O3UqmCMnpVC7S+mCiF0Ve/yZpz2WoRRGY30QxyY9mKXKmtWNOK3ZNBYSu0kzndJweepqO5ZYDt3AN05GKgkj1aZo3inY5GMIMUo8M6/dvi5ljQY3gSYzirSXVolyju2RCVEkXyipZiPmPauu0O0utQv7a0jXKuN0kg4Cj1rkYra+0azuZruO3lVOScZxW34F8YRwaizFVCMgGPfPSs60W1zJXSLbcovk3O91TQbXTJLbySHEgKsJRksQO3p1rz74m6ElqI76yUIrD94B0r1Evc3MyG5ILOAVUDhR6ZrkviTZXZtVTymMI5Z16ClTm3UUlscMZSdoyep4zYDe4D7genPevU/A2qW+mLL5hIbbwPU15x9ja3YMxwg5Ge1XLK+e3L7GzkYJ9K7K0faKxrG1nGR32r+J3iSeGAkxzZJVuQK87nEl1OfvqmTzjFakVw18j4IYKuSWIFQwTJJIFJwo4yPUVnCmoXa3O2E1TVl1LdpshsnjZyVTBUDqfrSadZT3epAXSAQy/Kd1TGG1Qowc7yenqa9R0DT3k8KORbBLphvHmJgn0rKTtoupNSvyLmYmlWGi6Vpa2t3CrKBgkgktmuB8VWltZ6jI9q0qwNnYCuD+tddfK+pX1veWsd0k9s0ccttMdq7SfmYdj+FdPrXh601vS3ikAMgU7Gx0btWNOU1NRfU45VFSalNvXfyPHbSaCWHa6iVT1JHIp9zZwSqph3EgYA64qne2X2e4eF3MZQ4ZQcdDUtrdGJwir8rAAHvXTJW1idHLfUa0LxxbVdgvXDCtBLSK/sCoOy8j5VsdR/Wo7pEeMgMyyepFQ2jy21ykgGSpGT2NRJtq63LjsXLXzlljtLqIW6OpDkjlvQ1lT6PPatIsQ+0RDlWXg4rZ8UX8c0ULFXSN+Fk/55uOx9jVfS7truzMMbkXUQ3RMOjjupqYycVzLZj1muZox4WRsbt6kHBBFF0P3RjkRXjI6N0xWjNLb6hc3EUNuYLyIBymOo7ms+SOQKUiLMgHQjNap69i9ErNHm/iTw9azO02nYjJ5Kfw5rjby0mtZNk8ZUjgH1r1bU7V1ZmC5XvjtWLf2kV9A8Ug+bGVbuK9WjXaST1POxeVU6sXUoaPt0PPAdx3EkkdzSHIJJOGBqzfW0tnO0UgIxwD2NVSDnnGe9dq1PmpRcXZje57+uaM5bOM5OKMMBkDqKOh4yW7k8UCHc5AI570yb/UynoNh6/Sn5HrlabKM28mDn5T0+lADLdf3MfH8A6c9qlCZIDcr65plsSYE5B+Ufyp2cDkHd6UDDYNxzn2HamKPnBUnHrUifKvJ/SkwegXI7YoAQfe6epAoJPPrTiAMjP5Cm8hueR79KAAkhR1x6UHGMjPH8qX+EkZwOtNzknjIHf1oAUenQdcg804/KDnnPtQgye3PrRg9M4PvQAuV2jIIGM+tGDltq5P+NWILWSeRVjRmJ7KOld/4N+H0+rzoLrKxg5O3g1FSpGmrzZtRw9Ss7QRwNrZzXTbYYmZycfKMnNdjoPgO/vHjeaPah7evtXrFn4U07SD5cSJuHV8d62kuLewty5Khsde9ebWzF7U0evQyuMfeqO7OTtfDn9mQKrIqjjAx3rbstPYRbiEG09G6irAS71DbKsexDwGf+gqyLPyYyJn9ySetcE5yerPXc1GPKQQMlrDJsBkk+8WxwMdqg3w3D+bPxIRjFFzcxRIyxKWPTjjFZqXgklZVXAI4GM1Ci3qZOSZcuFgTBCsV6mnwXiLEVij2nnlu9VZfK3CNX/eE5x0A9/1qS3s4E+ctlt3c44qmlbUiz6jpLtvMDSI20DIwOlQiV9xfa6ggjB5OKlu7mIOqIRk9/8A69Q3F1AEAXGRzwaXkkNU2xDfOdyliqYxkDlsUx7hXYAxOQRglueaqxPGUb5wGHOByTRM0eSSHyTnhavQfsn0NTR7+G2mYMFznapP8NLfarJNcBlmbeijJB4xXPvCSRIgYrmnqVYksjKMY6dTT5I3uZ8uupony9YYxzF9pOGUNgGqlroUem3f2iJ2kKngAZIqBGEecvjJxwOlXrK7COI1AYMOScjim+aKaWxUW46o73RPFEsCESorbhtBY5IqvrWtXl9bNbtKrnJKowxxXHao7BlCFQByrKeelVprtxHsMuXHBB7/AOeKxhQS1iZygr8yRma5cTR7UaPaUJ49f89apWUouiS0nl4Geep/CumOmrfoounARiMtkHA61TfQLazkfZcls5GducDPauqNSNrdTNqXN5GHNPsdgCfQkHmp9Gb7VdeWzgJ3Y9CK1orXTFTYFjd3JXc5Jwa3vD+l6Xax+ZPbrLNnPmN0UUTqqK2HFNO7Leg2+lzatazajtVLZsopP3uK9IfxdplurR+YMpxXDWeq6dbu813HFKy5A2KOB2P4VzfiGSPWXFwpy+3adoweOlcicpO12jSdKNaS59j0e68QWt3OCgVEA5Oepp9l4ptrG3CtJuUHAwc15Db2mwYMsox2J6+1a1kPMAijUsV4bHTNS6Ti73KeGg1boO8RSJqHiC9vIRiCVsqCefx96SN5JIVEMYwn8WMGr8WmQO6i480dCQD14qcabaeaDHK8QB6ZqnNW1NE1FWKd4ts1rGf3huRjI7Gq8bSOG8mEnAxzVu50G5BE8NyHQdQVp1tbGJTHIwMhHJHBpX0ve401bQydQiN1aNaySgbuoHrUOkwSWcnEzso4U9a1JtKkdvMyFdeDno1atksax7WiAwONvJolUsrbovnSWg2wv7SG58yeCORypUttwcHtmq81uqXRlgjLxk5AzVyWG3uchFWNj0J9e1N0+0nLvHICFXuP0rJytt9xCSWpn32nxzBpHg2kjoBzWaumWmfLmtwMngkckV6Fp9nFIC5I3r0/wq7HpysT+6XaTjnqKI13awlWULo8Q8V+DUtrb7RDGbiGUEbe6HHBFeNX1lPaSlZ4ZI2BONy4r7ibQorm2MEiI4A645rxr48RW/8AwidvbC1C31tc5aXaPuHsDXr4HFzuoSV7nm46nDEwc4/FH8UfO+3O7H4ihuV5OBjjNPKn5l7HpSKMrjoR617MkeCNw3XGGHamyD/R5M54Vun0qUsSck0yR8wS4I+43HTsakBkAxbxnr8o4x7U4gbOSRzxTID+5jJb+ADJ/DipSCFyOh6Y6GgY1WygypB9fagEYxuoBYHAOPpSYzjOOf1oAVioXHPXgY6+9OyM85GeDxnFJjjn72KFOQB0PYigBCVGOPbig9cgZ79MYpxxwODmtjw9ppv7n51JiHLE96TkkrsuEJVJKMd2ULWynuTthjLH1xXXaJ4NnuWV5enpXcaN4esXISxBbau4pnmt6Ai0kACZVSMivOq41vSB9FQyenTV6ru+3Qo6L4VtbSEERD6kVt6bfyaXfhoISwHUkcVvaJYNrUjiLNvDjdyM4xV+70uG1/d7492Ml8Dn6V506nMm5nYpQh7lvkcffyX2qO5gbyhI2WJFbljpaRxLGcuQAWLDJzVG81OC1mJUbmHQqOnvVGTxJtTI+UHrjuayvKWkUVUk2rLRHXSPBDHtLAEcACsudWuyxDELjg+tcRdeJLiN3cFGX0q5beJGFlveNjIR8qgVfsZpXZl7O2qdzZvYYYUKjliM5Nc3qGorbRnywN2eMVQvtWvryRifkQ9ADyfxqqs3yEFAcnnjJreFO3xalKDa0HjXWtpC8MQ3MeS3U0R67eXUnlAqgbpgVnSW+5jgHGepHSnQgQSKQx3Lziuhwp20WpMIzctTobXTru7xI9yRtHCqKjv9DmDFkuW3HsT1rW0LU4wCHGG/u561oXMsMmXUY29lridacZHRyWdji4bGeFWc7yVJ5Dd6ja+nVwszkhecHjFdTYyfa5HcWzrtPU8CqGr2Ec0CzSRNGkrFUkPcjr0+taRqpytNFSjJbGE1/dXG8wGRUU5+X+tTWWrm3Qm4Vnk7GmLbXWnpI0bkxMPmA6Niqa3a/Mdi4PUEda25Yy0S0EmvtG2NVsJNrSA5PX2q7b31rcYEN1hlHRu4rlEnQNkxjBPPFTXRt3QGKJkY9CPWodJbalqnBo6k25kAMMuQetQHTpjKSAfQEd6oaJd3t3dQ6fbRia4b5YweOas6VqV/9tkjujtZHKsjDkYODWbU431WhDw6lsW5Le4iRNkZAXru70K0jrnjceoPStu5uh9mRgQcnp1zSwC1kt1V0HmDuKy9r3Rzcljm2haKTcy/e4xjvnrT1vHhGzzCB7Guik0cSRloj8vfNZc2hTl2KlGOc4HWtI1YyWpPIugQtHJGrM5CZJJIwakgS3W4BCNJHjLEGol066gUCRHdc9KZLDKsqhchM8jqM0nZ7M0ULmtc2SsnmpuIIGMda0dMls7Ky/fBGfPA6EfWsY30ohWFmwg6+1Q21wjTfvFYpng5rGSbWo+RvRnSz3C3tmsduipLEhYuOd31rGtobuTc5y/cknAFW/7QW3j3RKpGMZHpV9Psslr9otZF5OHjHb3xUXUVZiScNkXdMm22oHHmAZIzkY9KZdtA0m9ADkZbjpVGZxCcj5SB/DVW7nQvGyFh5gwR7j0qPQUad3csSzPvKmIhAeG7UxhnozKcc4qeGULCqlgcjBz3p8bI8pVucjqOai5drGaschuMjJYd6347qTYQreWTwwNVCoiRtg4IJxTbFFkKAZUdz6CiTW42uZG1pbbJsgAEjHX730966GylICKCWbOcbecfWsMGC0uRHtScKMHBwpOK3NPcOiuMhwOP8K520pXOSrqrmtAxibcQRng85xXnvxt09bnwbqF5HEuY15ZjzjPPFegweZINo2lsZKmuZ8Z24uPDd9bTkEoDjJ4x3r06MuWzOWjFudk99PvPiZsq/uO1MHXA/P3rT8QWTafqtzbOhHluQOOSO1ZhPdcdP8mvqG+ZJo8KUXBuL3QjDn5QNxpsqr5E3psJGfpTjkLk56cHHWmTcQy8Y+QjB+lSSJAStvHxxtGOPanEAnoeOhHFJbjEMZ5+6On0pyn5egHHTpQMTOO3HvSHGzjv6ihSSdpwTjAzSgYI4xjqKADPT0680gwSM859KcVyx6H8at6dYveyhEQtk89sf4UDSbdkGn2Ul7KqRjJzzXrvhLw0sVjgrkN3NM8D+FkYplCQOST3r1S10yNAkUa/JjnArysXieb3Yn02BwSwi56nxv8AD/gnNaXokkVwPsKkO3BK966i08Ox2nz3zqMcn1NWY7g20gSwjVuMNIecHvVaeBJBvnd5CevP9K8mdZ3Oyc5z8if/AISCLTong0+ENkY3AVzWqXt7qUrecPLXrgcAVfvPLiAMeBgYxXNarquwkyPx6DmlT959x06SvdIgvSIlJYk/Sst3a4m8mGMySnhVH+eKqXd819KIbcHlucd67jw5paWEIYrvncd+tdv8ON5blSgjBttA8sGW+Ibv0wBU6QBsBIm2/wB811D6Q90zG4d1ycfL/SltdLhtolji3OR1JPWspVW9yoypwVupzp0xAg3qMj2qNraJc4VcY64ror62CrtO4k9eKxLyyVQWw2PWkpNlRakZ1xbQY+VBk9jwKo3aRLgOi5JBVu/0+lakkRZAAfpnmsi9hcPsYkL2571rB9GzZQTGLL5OChUN/Fhav2V4Z2dS+1OxNZnlMI2y52g8DHNRuhhTcpJfPI9RVyipKxSVjrbOVT8qvtKnBGeDV24toroBUChupPTNchp90I43SUmLf0cjoa6DTpCiqHcyMozux1rlnTcXoZzj1QjOkQEMyoVAK5xyfrXC6nGltqE0UTZQMdp9q9AuIBM3nJlCecdjWBr+li4Cy2yJ5p+8AeQPcV0Yeooy16mE6fOvd3OVBOPvVYgkZSPmOO1QywyQSlJAQR2pF7Hvmu5pNGEZNGraofNDo7I4+66HBB+tTWt7cWmq29z5gLRMCjOoIb6jv+NZ1vM6ZCkuDxt9aJZAQVPLCsXTu2mdCrcq1Oiu9QV4mlSVUYc4A4NZq6vJ93GR1OTWdAGmlEMZOD3PQD1Jq1fWVvBNepHfRTrAyiJkB/e56/lUqlCPusKclLc6vwzq91qVzHZQR77lzhVzgHv1rQttXGN3fOMemK5zwBbJN4nsvtEnk20YM80hbZhFHJB/wrIv3WPULv7DcFrUyMY2AIyucjiueVCMpuK02/U15IuVmekf2jG/BbGAOMc0m+GYYdV3HmuCs725Zt5Q42hXYnr71dutRlQjY6qe3vWLoSi7JlPCrodXc2UUpyVwVHOD1rPktjGfl3DjIyKg03xAkqBXbDqRg11oEi2qztGpj8vzAQQflzjms3KUHyzMZQdPRnPwRiSPa8u0jnOMVEUe2YsrAgjOB3zWnPdxGNVKhS3AAXp7UxLAPJgsxUdsUKfcLW3KthNIVIK7jnnNXTCs7R4OCvJx2qxa6bDG2Wyecjmr8cKbdoVcH9KzlJJ6MiU10MuZUjUBmPpxRDJFBGXG884G1ck5retdLjnA3gYx1AxzTP7ISPLEkEHHWlzJkKpHZlSMh2Ea54PUjGTUqxvhdi8DOR61ejsUMRUSDIPIqRLQRvvMiuOgx2x2rNtNXuT7RC2ccbqVztZeQPwroNK2LGodgWI3Ef3ay7aBGHy/LLnIOOlXbNGjcllGR1Oawb6owqe8mjpzMrIzRMuVHWuY8ROk+mXVrP1mQqccEE9CK1YRjkMUHbB61l+LkEU1nKqsd5ILZ6DFehRqOqtTkw8VCol/Wh8vfELSZkUzTfPPb4ilOMEjtmvO5EIfmvonx9YD+2LgN5T22pW5Vdx5Dr6V8/XKeVcOjkrtJHTpX0GCqudOz6GOdUVGqq0dpr8epXI55ByOPpTJA32eUnONrdPoadyOMnd0zSSkm2k6fcbIH0rrPFG275t4xgDCgYHelYZPJ5/UUQLm3jPBOwdRjtSquBk9PSgYFducg8dqXHKtg556GlYFTxx6dxSAfxBc+woA6PwzoKaw22MlXXk5r1TR/BsVppUcoiYyrzke1eT+ENWbS9XjlZsRnG4e1fQfh7xTFJY7IwkivyORXmY2pUhJW2PoMp9nyc0V76/I1vA+mxtalnzGSwzjuK6LU4IbO2kSBwWlJGcjIXvWPDekzSJYxiKErlh6EVXnuJJiuMtI3LZ6gV5dSfVHoyjKc+Zses0ZTZCu1QepPWqtxdLbwYxhs9R6UPIsK7c5NZF/ctIhxgnPOK446s2jC7MrUr2Vsuqgj+XvXGXk0k0zNMc4PQdBXS6tcmOEgMMj3rl9jTyhYxnc3SvUw0Ulc6mlY6vwRpaTs1xIcemegrvoY1yEjw23qxrH0CAW1hHBGoztAb1ro7OAJFufcpIOcD9KwqSc3c460rOw4g7ueuOe9KkOTkDp3NWY493LJtAx1NRTsCvGdvvWT0ObmKxj3uSwV3XgZ6VXubCNkckAu3Oc5q3GDtzjNKRlSMHnrg96Wo+Y52fTY/J7BgevtXPamiW0u5oyQDjpXeeWFUZz361l3+npcIWYNznHtVxnrqdVKtZ6nntzeW7SFVViT7dKiifJHytjPft9a37zSk8x9i/N7iq7WgRf3fQn5s10KcbaHapxtoY8sYnbByWHY9BV63vDZIi7iykYYdcVbFjv3BMKSOpNVwBHI4ZPYGnzKSM5ST0L8eoksWxuB4JxgVSSdZLyYRL5iFQHbuDVmB/LOMcY9OlRlBbs0kCoQfv+9RZLYUXYpa7phYF4fMlQAYZ8b146cdRXMMuzjByOvvXpNtrSSaUbFrWKTLb1l/jUntn0rkNUtRDcOScq3zY7itsPXfwTRz1oN+9bYxQST8vUelRs2T9fenSfKxI4zxioZRtIwwKkZ47V3pHnVahIkrqGCtjcMEA9R6VLCwXYSMoCMr6iq69iOQelP5PQ0NDo1Xc3tV1VrzV1vGthFbgDy7fGFCYxjPv61PYWUkuntfQeQqtcrAsG75yW6YX0FYc0qSFDGZNgQDDnOD3x7Vq+GDAniKxS/Li381Q5jOSM9MfjiuSpDlhePT9D04VbaIt+I5bi3P2JIBDbqxKgfMWYcMd3XGaxFeV2+Yk9jmu9+IGk6fbwaZPp91qbNK8sJgvE/wBTsOSM44OTnHNcy8UamJk8wqEO8sM5btiphOKgrdTqozU4XRUsrlbN3WeMGN+CT2rrNNv0EICMGTGOeRiuPD/aJxGQArcZbtWjZaTeTrcGwLyGJC8ihckKD1xWVenGXxOxpJRa1O/D20vlPIwyvIGeOlXtPVpxI0YVgoJPzAdBnPPauV8OanJYyJK8KTtsZdj9DuGPzqxolncXIkhufkaJsInTH1/CvOnTcb3exyTpb3ZqRX32i6liWMRsib+T94ZxxWnaFJIw7Yx92ktLS1i1Wxu7qLAt2GcHge59R7VQ1a5RdVujbNutpJnkBPoTnApOKktNzCVpPlijp7d97CLYwIPU981cgtpJW+dF8ncY9xPR+AMj0rBsNSeR/MkfzAVG1z1GOgoOqSrdEQznAwSvbI6GsFzJ3OeVKTdkOhlEd5MI8HYSmR3xwaWSYRXDBuud2M57U2wga4DSEYZmJJHqeTxRfWUttL5jL+7LgZI6+1Wk5t2LVr2ZrWs0b/vI4ihJBAZsnPfmrcDCSQgkhyfvAZzWbbtvhGOQBn6GtfT9jODuACgncehrKzMKnu3NOKJvJDMp2cZbH61Sv3s762ma9lYwRnau3+E9MmtVpRNaud4VEGeR19K4zVW8yVbOEvvkJ4Xq5H0rupKMUnE5qEXNtvRo4TxtbxSaXBdxzIXtX+Ug/f5wa8Y+IGlxWuqi5tmDWtyvmDA+6e4r3e806Gz1q40/XXMcAQsdp3HJGRivMNWsoBpt9YXBy8aebETwQew/KvUwlV052f8ASf8AkeljMPHFYVpPWOqPKSoGfb2ps4BglJ67CMgdeKnIwexz6djUMv8Ax7yqecIcZ+le0fFjICPs0W7JGAQPXipCQOeT6YpkGTBFnO7aBz6YpxbC5wc96Qxzdg2PYUgXuCfT0xSA5YE8saBjAOOOhz3oAl3YAwCoJ/Ou/wDh3p2pXt0J7KZY4o25D8g/hXnyrliACeOB6V7Z8IY5bbTpVubZ0RjuWT1/CuTGT5KTaPQyyl7Sur301O8WJ7e2VmcmVjggcA+tX7SF0RmIJY8EA9Krwf6bMiRr8oPCk8/U1pzSLFESuBx09favm6kmfUTb2MHVZkQnDcjjFcne353naRyCcg9DWh4ondyyxLg981xm9VDCQlXBxW+HoqS5mddKFo3Yt9cSSEAnjqRVzw9bia8Xn5h90e9ZTsGbI612/wAPtElu5BcOGWJmwMjGR7V3VPcgTKaScmdfpNpIse1ADkAFif5V1VparFEgYjOOfm61JbWKRwqhAynQAd6syW+QCzZHTAA615jk2eLUq8zM+YLIxjjZCfbvUD2uSAXx2z6itJraONw0aYPQnFV3RVIAY7s85Hv2x3oXMtSebsV1tAgZuW9c1VlBG7apHf61fIXI4bb1/wDrVXnZA2V4BGR9KHK5cWZcnmKpx94c8d6awcISDzjAq9JGnBDdPpVWf7oKAAEdqk1TuY8kAdmMnBPesm6gyflAyDW9cxKCfmPP+RVWSFTx39TVxlY6YTsc/NEdpx1HHFUJ0cgtnLDjFdE0O5WDZznoOwqi8KB/mwB2OOorZT6G8ZGN5h2gAHcfepI85AycHjJ71YlRNzKoFRXDIiKffjHetE09AkOtlEKAdTVDWJY9iFwDg8gd6nS7DPIN+WXHFVbyEXChw6gpyc9CKIxtK7KRz10QGZdvI6VSbp81a2qrE8ytC2dygtj1rLuVIGSfrmvUpO6R4mKXLJojUnIHHSpgSp6nNQAdM1Ip5POMVo0c0JcpZiYjJB2nGM0+J+FPII6HNVhjGPWpowcYrKSO+hO71Oh1PW9R1TSbS2dC8dhukeVCSSXI+Zz68AZrOe/lkT5sccZAxVeMyhGVHZQ/ysFPDD0NSy20kWGYDnjINc6hGOlj2KVktCO2ceaGYsGDAg+ldv4PkMc17cjU/sUscLMrHkyn+7+Ncf5O1lA4Pc9q2LEBvlBXAPOKwrpSjY1qLnjZmhNrUdpZNB9jjeQyrKtxtywI7fSrfheZyTLIHBdixJPJzWGp83Uf3pBjA4ro7OSONQIz7CuWqoqNrbinFKNktzobm4k2KD0HJwOtSKbSbQbtLu6jilWUSW8aRhpNwHJJ/un+lYktxhFJY5xziuev9XMEx6/XFZU4Nv3TlVBy0RsW19JC4V8beoxWhYljeeZu+Yiuf0adtSdWWNmyQCF9a6aKznF7EiQu7E8IOp9qKsdWiqiUdGdNp29AgG0jqQe1bH/H3Hcae0iq8yHy2IztYDg1z9reRx2qPhSG6Z7CpoLpWuRPyWQ5GOOOhH41zfA9VqedOm5XZPJd2Wj6hDBqzrJDIqtDNGR5TnvuPYZ/CpbS9ju7oQW0XlTuTMEx1X0HqtUbWC3kWU6bHNvjjPm2bKjRzpnlFJ5Xuc1Rh1UWOvWt3DE0sENu0EUZj2SJuOQpOcMoq5PmTadvQpU+a9tZf10/r9Dt7W4zbTEAHchH4Y5rzHU/ETWGobrR1jkBKBjyQD1r0jSZntrNnniAaRCVH4dq+d/E12z6xdhcAFvWujCUo1E1/Vi8DTi5zUlodxdtPJaNrVziSKRhAzlhuDY6kelcZ4rgd4hdqu6MxlGYDOPTPpWZFPNLGIy7BO65ODXTIHhsba3VBKLliH3HjAFdMYui1f8ApHpulyxaXU8IuBtdxycH061XmI8mUYIIQ9fpXX/EnTY9M8Ryw2yIiNGrkL0GRXITBhbyHsVPH4GvoITU4qS6n59WpulUcH0YyEf6PEB/dH8qlwN2WyD3xUVuW8mHj+EYI57VIM4HTHqetUZiqozwRt65NO52DOMjsaTocDr6U+JGkdQRyTj3oA3PBmlyanrUMYTegIZ8DtX1DaaLBZeHFmDxqUXiMYBJNcB8EvC8unyR3V8i7J+R6gV6P4ttRDeQIsivE48zKfeA6YIrwcZXVSo7bI+mwFL2EIwekpav/IreHlZS8j7Q7ZPzAdKXUWUq8inj09BTbJ/K4w2SMbcZNZ+rTsqP1APUAV5UrtnoW5p3OK8S3O1i0ZIJPFcm5yWySe9bGtPJPeMu0CMHANYzqFPJINevh48sUj0GuWJo+HtO/tLVLeIDILjcD6V9BaTZRwWy7E2xIABgYA46V414Fj8iUXL43M2APWvWbTUGNp5MfGWy2TxXPiKl526Hm4zmdkjbZ0UjCkkccc1JC0cswV2VRnqT0rK+0kZ3gYIzwevtioI5CysY/ukc54OPauNtt6HB7K6NvUr3T9PgAlYTTEkKpJ/PFYEuqRyqixxlGUct/e9OKs3NrKpYSxSgBQ+7bng96zZkWPPGR6+1aThOW7LpQilrqWWkIjLfMAf4gOtUnuR/CdxBxj3qF76Z41tzMxiXlEJ6VRmcq25SM9cd81i10OiMO5daTG7j5m6k05WJTI5UDlRVG2uUMZV+Tk9OMfjSNMhckMVjBySKaRXLqS3YXPt2z1rMZ3DYbPpVuabbJgEbD3IqtdANgg5PXrWsfMuKIblcemcevas+5lG0L39qdNMd7biT7iq1yytgkYJrSK7m8YtFV8AnCjBPFZ95IQpyAGHAIq3KJGQsiSNtBkOwE4UdSfb3qnFGtwVlEpKEZyK6ILqU9Ctp6qzFmYncfmqxqBEVuI0ILOMEe1aWhaWmq3csHnGDZFuWYp+73dlc/wAOcHFYNwPOhWTePOY/MB3Fa7y1JhNN2KUMeRlecngVXvYiCwPTtWsI47cKJiwSQdSOhrOlDeWEcdOM4/Wt4S1ujgx0NbmS4x9e1OXJ/CnOu18UoOK7Nzyku40Z79BU6Oy8A8GoFOSeoFPX73TtWckdFFtM0bEs0nTIPrWmluXQbjkdeKybGQRSfMOPTNdJpEUs8yRW0TTSNkhE6nAya4qz5Xc9ilN23JIbE+RgRknqdw6CopDHaN9xsnrxWzbOZrYksAT0XuPanz2STQhnUnAzkGuTnu7M6lO25gM8cpDKwX1A6j61WuNQubXbGJBgcnFaev3UF0NN8mBInt7c28rKgXfhsgk9+KzoLCO6nZ33FRjAHStI8tryR0Rfu3Zbh1bzYDJMQO341m6iDcBSOOefxrSk06EQ+Uo561S0+CbzZ4XiWQMoCs7EBeeo/lRHlV3EcXHodr4Nhht4UReq85xXplktjFm/uJRCII85PRT0475/nXk/h6dFkAGUkBwQT0rtLi5ure1tpYJeJiWHy5CshwM1wTbjVPKxlNzlvuRavHZyIGs1aOd5PMeIOSmCOdv45P401IJIlDYIUdcHrU0D+c6ybBvPJxxk961YZwsJbyzjOSGGR1rGpUcmZ3cVYxor9Le7jl3JFtbJZxxjvn2qvpDmae7nCoEIZEd1JCk919COtXNZaWzurma1t42srmIFmZQ2CSQyiqulfIGUlfLP5DilN8sdOpqrOPMjtbeZLYQhWFxFBah1OOWToCfUkg18z6rEE1C58vJQyMVyc8E19I2kSfaDPDOrXNnZJDNbEjasb5bccfxcdK8K1PTGi1e+tJodkwmYLvOAoJyP0r08C+SF5dUiMCk3JJ66f1+JzsLYILE8V1Gl6gI/KEi5RWzyelZSaa7W7s4Clfun1rm/EOom0tmiDfvG4GO1dTpqu+VHoYmvDD0XOfQqfE/U7bVNfke1ViqfJuJzmuLmUmCU56I3T6GnvIx5Ynd3yajlybeUgEKVbp9K9enBU4qK6H5/WqutUc31G2//AB7xdwUFSHjqfmPrUVt/x7xHGflHH4VICTwRg1RmOVATnoOla3hpI5Ncs0lP7syKCfbNZCH5vlGD7VpaJuN/b7Bk+YpOPrUz+Fl0tJpn2bo9raaboRuLTbu8sAnjJP41gQxrcTGWQlWI3Mx6Aegqzok1xqem21u5RI0jAJxjI9TWfNcPLMYU3FYvkVs9s9vWvlYu8T6+EGpSu9S5oktmJ5p5ZpInRSyBDuJ6jriua1WcNhCDz1FaWqtbrFM0Zmik3gICPl245H1zXKXbkJI80hwDkZpWbZ1Uqab5zO1ONVcjGNoyBjvXMznMjHPU8V1E0ZeMlssTzn0rFFpGl2fN3GIHOR3PpXfQkktTraurHTeEbZ4liE20Ecr7V3tpMnRudvLYFcl4dvxbJKnkqTMgRlYZIH9DXWWMIiiZ9pBbkkHqa46r5panBiN9Q/tCIIrAsVORypByK6DQ7myEKXF7ICJHKpHgYAHOW9q564iaUqExknGasRx5tlU5BHPNYap3RzVIxlG2x0mna1M98GmQMkjFFdAcKB2HtWHqsguXKw24W6QN5nknKSEeinpS6brlzYW6wW0UCkE5dgSzCqU2o3I1f7c8gabcH2rwDgYx+VbKo+V9zGFHlm2lb5lC6AhnIjeOYkAh4WDKRjPWs6ebdMRgrxz61S1m7IvZwhWKNyZNo6Lk5xTrhbRLa3aC4klkMIMpcfdfPOPapaV7noxhZK49WzIqhR5QPT0NWXJALdu496z1uUgQBmK46E066vwsIbO/P8Q6U7O5Tg3sWLqcZUc4Pp0qtPIUcbMdu9Yz3TKBIZMLnGwinTXSnKuxGffHFbKDKVOxZkmUSMr/ACnNQXDqqbmHA6H0rIvpyZMxZIGCD1z+NTSzvcQx5JGDknHBrRU7G3JszorLUJtD02G/0+P/AE+SVo/OZgymLHKMnue/tUPgixtbzWFj1JxFZFmknwQoUf0GawJ1jW3kdp1VlIGxvvMx7j2Fej/DqysdQ8E3ltdwzzjULsWpeKLcYCFyrk9gDzn3p2UVbv8A8OcWJapwcur/AK/A89kuZdF8QXEdncF7M3HB4ZZFV8qSvQ0yYI97MYwfLLlwWUL3z0HApbXSJL/Uo4USe4MTus5t03NtRsFlH4VKjxyayRpUcl3bQszItxHh2RecOPwNdE7PbcKdo7lXV1LQgchQN4JFUIxm3ilP3WBAPuK7fXLW3XU42MVpHDdQeZHbwSGRYiR9329fbNcjqAVVtoEHllQQ0ZPOc8ms6U1JJIWIalS5jLkt98pxtA9apyoY3KsOh61q8IdvGCOtU7tN0hbPPQ12U5u9mePOJT2dSaQ5DcjNWAhA5FMbAcY5NbXuaRHRfdzzV+xv5bXPlMw3cEjgj1wapiNlI9vWpFU79uefaueaT3PVw0u51+l3kKlAQMEcn1roJ7yB7chCN23oBiuAiQwsm9icjgg8VdW6WOTazEMemTxXnzo63idsqSlqO1CMOZMMBgZB9fak8Ps7s6ucr1ANMunSU7SSpbPJ71Y0t4kU7Xyw4BIq5fBY1+yXmYpIdy5zWv4UWM3zmS2WcmJgFK7guf4vrWW0SyNlsMMVt+FJYrTUl80MbZ8xyhTjKn/A81yVX7jsc9R2iy1FoFtd3aXMDy+W0agHABPqTW8ulrHAPnJAHU9Ks6ZeRojQSyFwmYkYYHAPFSX92kFu5Eq4bBIz0NcjqOUrXOGdWcnymTbP5UnlO2Wzjb049amu7+NYmRGPockVi6lqERaAMWG1yxZeGIP3h/hWVqdw07QGyt/s0Xzbi0m8uT601T/E2jS5mrm99rMkMcJuGCRZG3s+emfUitZLKSGSC2/c/aJQAiZ6N6MPwz9KwfC+lvqrSrNuWOMf6yMZ+fsPxPFdOLG+skWSa2Y3MSiVQ4B6DrkflUypSs2iKrjGXInqa2r3E8mgxrbSWirPdeRcy2p3boxkOQfXjB64Ga8c8U6ii63qdtcJ5yzuuxj1QfWvX5Q76M8Es0I/5awmKPyggODgrzz1596898RWcI8QXLKjGParvkfdB4/KuqjWi2l5f5EYDlg2n5/ocjq+4nyrVJREFyST0HtXkniCdptQlBf5VOOenFe3azNbJLNHbq0ShP8Alp1xj+VeC6l/x+y89GPNe5l+qZxZ/Ubp049NSoPuZxndTZj+4lBwW2H+VPOSpAXFRTKfIkwPl2E5PXpXpHzAsOfs8XUrtHX6U4ZPTHPvxTYM+RFgYG0Z/KnqqgKTz70hgmAeT269816F8JdDGraz5sg+SEbjmvPl9cZ7Y6V7b8BHOnx3F1JDHKG+7u7EVyY6bhRbR35bT58QtL21+49Yst9lZu6FoifkBbsKgtMJJMCzurciQcYNLr11cuVZkXFwx2KvAUVVtxNAYg52rIpBOePf8K+efdH08VdXe7KWuuxLMZN8CkKB0+Y965bV98UjiN1kVT94dDXUSXIjZHvYhNaMzblj+9jBAwfauavbyGLS7+3lUl5wnluP4drZ/Wqi3zLT+v8AgHZRTWlipBMCpVuorOv4is9uytwzcj0q1veLBlQocY2sMGoVdZb5SeQgyFNdMdHc6La3R1OhALKvHUfLiu0i+ZHRc5OPrXJaGV2F1wpGBiusspI1TBG73PUVxSep5uJ3JhCEPoAOTUUm5EDMByCcA9RnrVhXUyYufuEYyBnt6d6r3MDW7LHNgErvwDwAen/6qWhyLezIAFZhIrsRUN4YyuxGzIeR7VJeWdzHpkl4zRwwsyxxhm+aTPdfQD3qKHaEKkfMo5J5zTSbXMnoaK25kXmnpPEcBS2eM1zN1LPazPblWwBkNjIFdpcN5RYjGPQ9KxdQKzISQPfFawfR7HXSqPZnPLcu8JM0iMvQ4HWpLYxWsWDMHgc5TPb2qncw/ZpPMiXPXIPrWPNdhywZMZPIHQ10qnzbbHYkpbHQX6xhVZGUjtzWdK3y49B16/jVYTgxbI32p/ckGcfSoJGZVGZAwPpVwhbRi5bE0d1GFKE59+lPS9MaBEJZT05zWc2N3t/OnqwyowMdBWzgiebuWrxmmcFiFPX8PWvSvg7ql/bi4srPT57+NSJwEmWMI3TnPXPpz0ryqbIc7jnPU56V0Wla/deELm3udJlmElzbhpYrmEhAc8FT/EPQ1nUpucVGOr6fI48V79NwNHwrrkdh48mvb25ayRWnJywVTJknawXg88YFWbK/1S+8Ha1DZ6astvg3N5dKQrRuZNx2nqf92ofhx4ntbLxBcXOti3kswkk7u0ako7NklV7kntXPa3rIbUNVTRZri30q8uGlFsWIBBxyR/SnyOU37u1vTQ43JOdrdF+ZraPOs0/mTbFVEzjt9KzNdEr6kTMqgsoKkDGV9azba8MWVblScN9K29SmWSxtZRFGTK5Mcxky4RRgoV7DPNSouE/U6sS04KxQ8nKlgCT79jVWZFOcnA9uua0Il/dKCcgnk56CoLiAEsyEH6dv85rROzPNlEoJEcbj93tiozsyQByD1qSRSG4PSo4kK5LHO7jFbrvcIrsSBs43DC5q1b2hdPMTseTnNUZixYZzuHBqSCWWEgo2B6VEovoelQXY2RCk0QVj8wb14rPuEBmIzkgZHNMe5kKkg4b271CrEDORnFYxg0ejF2LaO3lFZM7lHy+1Pt2PnxOxGMcVUMzAjB5FOilCuWVRuB7mhxNE0zeh1CJm+Z8N6gV0Wkyb0UbVw44avPZnOVIXaSM4NWtN1S5sWQ78x9Stc9TDOS90idJNaHsWmaE98sf2SYJKegkDBX56BhwelSW+nwSyRWt4s8Msl20MkuzKRBVJwGOM7uoNYvhPWdQ1MWtrZyGISgxj58BAfvN69PSta4so1lngureaG4BUxAys4KqNu8gnktjrXCm0nF7o8mopwk4yf3bnI6mJHu0jkEWyFnjEijJY7jyT34/Kt6z01XssyKGKgkcdsVrppFlJZyT3Zdo4VLvFCvzEAZzntWPfTX9vbzWxV45goeMOAMq3Q/lSm3JKSNlV5/dj0NzwdqL2lnJ9laEIGGFfIJGeQPfvWnE5/tW+ni3m4umERl3nCR/3VB4GfWuT8OS+VbSQ+Y0m1g+7Zt5I5HPWt9LhpP3jnJYbQen6VySnKDaTOerSSnJ9zT1HyZd2F2YHJdu4OOtcl4lhzqUbRCR2kg8uZYx90BuBW3Ohu1htyQoLgsW+7gc1VaS3OoyJdlFkaM7ZA2CrA5BBooTfNdipL2ZymtzWNpd2731tFcxwowlicEP0xg1826k6yX1w0a4QuxVc9Bmvefix4hSWPUJZUT7TNCEV1P6/lXz4/LgHJGc819Zl8bRcjys5qNunB72uGAeCfpnio5mYwyZ/uH+VSAk5HvwD2FRz5MMp7bD0+legeGFupMEWGAwoPH0p6o+AxIPXjpTLcf6NCR02ip1DOdo5PbNAwiiOcjlTxmvf/hPZNbaXGskZO/kkDvn0ry7wr4VvbyZLl4sQAgnccZ+le9eArm202AWkk6x7z/rHH3fpXkZnXjy8n3n0OVYWdOEq8l0sv8zWeU/afL2IyImGGM4U9fpUjhFlMqxj5wSEOSIxUmiWn9qapdLbsTarKEeRSOVqa9VI4rqOQlTGTksdxwB8vI/lXlQje9j0nNKXL1MlLOM6LfSNIqFUYqMZy2R+Qrgp7Vbm/wBOjmQ+U8gR3zgFc8kf413+oT7tMVPKYkqC/HbHFZNuG8yG/wBOnhsRHb7ZXvhmNHJK459Tj86I1Guh00pygmzgNZdZdRvGtpHki+0NsZzuO3OBz34FMi2LPLNbO5iyAC4waszSxCdzexIDMDGfmKqjHjdx2HXFNvrL7HAYLdluFV9vnxZ2Njow9q7018J3xeyZ0uit86Hfx0II612GneW8oWSTahU5YDvjgV5zoRl3iOfO/wBc12NhN85h3luxIPINcNWNpWOLE0y/eT7RgqwOM4z0qolxFNbom0xSKpDksTvJOQeelaMiBVxLgnqSfSqUqiGUqyAAjIJqOW+pzRtsQ2eox6deu1xF9oUwuiJLl0UsR/D6HHNO+2QT3Ez2mVjJyseThfbntWVdzI0jYGSQe9c7qtzJouoJh1feod1VsgA1rCm3otzb2Kbv1OxuZMht4BOOAazHAK56N3Q0r3trc29pPbPIXIJkUng/41ReR1YljxnODWkFoQk0QajA0kTeUAJO2elcjcxGGVg/3hyVrtkYsMggn1FVtStkkhPCliM7gORW8J8rsdFOpbQ4whQOASSM9KavOAD9aJAySNngj1qPIHPIB54NddglVsx5xu57UpU9entTNwY+nat3SfD8+r2SvY3EBvHukt0tGOHk3DJb2A70nJR1k7GTqK2pd8EaPb6/4gNu8SGMWzsUkn2ZcLwc+ma0dYnm0XRtLmvk0vXUS3nsra5SXzFizjqvcgZwaxBFqfgvxZGLyBY76wdZCgfKSKemD3BFYmr3a3uoXVzHAlus8zSiGMfKhY9AKn2Lc97x/wCHOCvUd73urC22nXUotXtoVvCVeVoYjudUT7xYDkDvUV8VadWhge3hdA0aOSeCOoJ6g81q6sLnQ1sIEsLrSdS+zN9ol83BuEfocdhjIrKv765vVtxdzNKtvEIYg38CDkKPzrePNP3un9fI5IytJsfZRm4uY41XJJ5A9K1dUbZFBbpYfY0TfIhY5dwxHU+nHFZmlXMlncieFcleOe1Wri7luHkmkbLnqQaymnzeR0zqc0EuosNw6rjdgr+ZqaA+auCcZ9+lZm1t4IzmpYXcSE52nvRKGmhMddyw8H7w7Tgiom/ckHBI7GtGB0kI3HknBp95bAJlPu+1ZKetmaKDRnwIksgII3A8gnqKvS26gs+0YIPGKihtwJM7cN2JqxcPJBD93ep6ZPSplK70O6nHsZUwVCFXGeuBUHqRnAobLOTwOelGTzg5rZKx13uHY8ZoyAowRQARzxnpSBSeACRnpQPXoSE71YFct2pgznrxVqO1ZpVEhYDHO3FAtX2s2047kd6nmSN7XN3wncCB96M4lQ53q2MfSvQ7bUmvPLeYEyLkNIc7nHYH6VwGhQtCgyBt/unrXb6ZKzRBAu9WweB0ryMX8d0ceJSbublnIJpJI5TKtnIhSURnDMMUupafPJdm2jhLqG3wSM5YvGVzt59PSr2mWLLtG1mZgQoHHzY45q7rCD7BbRoS3kSHc3TBIrnp63vseW6vLUSj/Xn+hy6oY8BQAc4xjFS+fleh6Y4q/Fp0JSSS7neOMR+aJAM5zwB+dZEkvkl3Zh5ajjHGaxnFPVG8ZKTsizYqftGHVmVhuO7se1edeK9dQ6rdCLJIcqPbHFd9DdXN7EGViJmjKxq5wAPSvD/Glwml7sNvupGJJruy2iqk2mae0hQUqtXoYfja8DworElmOcZriiepJyc4xU15czXEu6VizVCnC8jgetfV0qfs48p8jjcT9arOra1wj3fw8HsabMMQSEDkqc46dKeF4yR+GKZMA1vL3wpOfwqzkHwvm2h7kIMn8K7v4Y6BHq+rJJcYMUePlbua4K24gi+Y/dBwfpXpXw016106M208SO7tkE9fwNc+KclSfJud+XRpyxEVU2/XoenatAtufJtYigVc1jzCRovkPTqQea07W4md3e3Ys0qFSDz8p61NbaZLOWEa7cDksMZNfPKVtz7aL5Vqbngu3nTw3JctLKh80MFTqzA8DHfNdjqUtre+cqqAzoGOARtOORVHQLeSPRRCI4pJYW3GPO1hjvVuG1mh057i5wHY5ODuIz0rOOt+V7nlVpqVRyb1uc7Kk8RMayAMd24k4yvpj6VC0co00iDT4pIrm2McpC7ywySGP90it7WIVbTZY5YzEXAMdx94oT6juO1c9pkjLJLbxTTrbhdzmM4OMYxg9TzWUu5vB88Lo4CSaKw1OGe5txPapuVkIzuBGD171Z8PanbXSqmtQTz2Tp9kSQZUIf8AlnyOOO+e1R6/bSW8koMbAxybisi4PHPSp7G5ubea5s7kJFa3DJd+RGA0fzDG78u1dzScdtfX+u56DtKNyWex+w6jPbsmxomBHzbgwx1Vv4hXQ2SRYRh1Yferah0F9Q8D2b28ksslvMTtKeYwXOMLgZx3xWbodtLGIoL7y0huLk2qTH+BhyMjtnHes53lDme5yPEKaavqtDQk8s6PeXwUyNYL5ssOCA8fsRz7/hV6Lwm9zZC6n1OCG3AbDMufoc5HHt1p+kRPZ6ZFq9ncLvhnkW9ikbKvBkqQBj7wwGA9yK4TxTfR614oW10FBBBfEP5M0myJpe7EdAT0461dGK5bp9zlgp1ZOMHZLr+n63KyQRjxANOvNSt/IFx5TXlv02+oz09KwfFEaee5gy0KOyo57rk4P4it7UNKuF+KUWnpaWFtO3lx7YAWiy0eS5B785NYmoqIt1vJIjSwO8Tgeqkg/wAq3irST8kekmmk073S/wCHM7Sb77PE8Zzxypz0rWXUD5wjnzyMjgjjt1rAsLWS6v0ggaNZGzt8w4BPp+Na3iTXrrWdTtY7uDyLm1hS28naA2V64HvWjheeiMZSvoaKyFSccZFSvKroMkhhSXFj9i0bSr15zIl6JEZChUxyIeUPvj+VZK3ABI357FRWStJXRNOz1Rma2my5JA5bmqa20z2stwiMYI2VXfspPTNTX85mYK31BplrcrDZ3kEluk3nqFVmJHlkHO4e/autcyijKra7KvTqOnet3wVq0GjeJbLUbsO0cBLEIASeCMc1z+Tkn9K1bvT7KHw5YX8Woo9/PI6y2YHMajoSadRRkuSXXQ5eZrRncePfE+heL9J+2T2NxYatCmLaYAMJufmjJHYdea8xdtuGUng5BoMn7v73/wBaql3MI4c1pRpcitfQ4qk4048vQu6lrF1q18bjUbiS4uWUKXY9AOAPYVXdhjB5rItpt7lz0xWhDmUBjnBORW6SiuVI46dVyL9o7BT8x56r2q4jBcZ5yOcGqcWABjirCEEDPpj0rCauzspssJjjHpnmhwVkGAPfNSW5VgF5wPUUk0TGXc2SOoArG9mdtONye2fyyMYPOCcdKvm4Qrt3AE/rWQCQcgZOckZqWCbzZdrqeeMispR6nZTp33NJJSiktjdnGDVe5uT5eWI2jggjikvIgApPAHYGsy4fzG9AOTk1MIqWp1QjYbI+5skBcDHAxTM/MeR0pBtK9c9qGxjIGWOOK6LWKW44Adzzj8qs2a5YE4A9SKrqOecZq3ZyhT5ZCkdtwqJ7G1NG34bnSDWoJDYtepFueSHrvQDkc8Z71futNt9OmQwXEFzZ3SmSNUcsYlJ4VvcVDpNvp8mlyXE1xJHeQTpiJTxNEfvgeh96rpCBeytEXFvvLRbuoXsDXDJ3k2mQ9ZO2huz6rJdW6wtBboqyby8cQU5ChR+grf8AD4z/AKsgH36YrljbRNp6OLjEpcgx4IIA6H8a6PQn8teHPb7xrhrJcvunPUilCyO2soZrlGiWRonljaJJ0bmNsfe/+vWhqOk2lrbec8jmQsMtJKxUAjBIXv8A/X61yZ1OS3O9CvuCeBWol5Jq99aNJLJGjIXhLAYU7cAgdGAIPWlQquEXaJ5NSlU5lK9olC5Wf7My8hIwMqeB14zWZKyMVSfOwkBsDtXW6zBA16FJLM6RiQIMcjOT+PFNS3t9Od5YIxlWIJkIbK1Moxva5rCurJ21Z454y1WaOWCC0mwo+YkN+AFeP+Lr97vUvv7iox14z3rsvibrUMWt3/2HaoeQ4A6D1xXmErl2LMxye9fTYGgoRUkjgzjGxlFYeHTf17DGYg8/jmgbsdeKGAYYXg49aYAeQc9e1egfPkhw2BnBHX3qOfHkS8c7D1+lOX7oX69u9Nm4gk9dje/amAkIIt4iePlXrz2qe3Zo2BRirA5yDUFso8mMtn7g/CpQcnJ4pDPYvgprlzdeKLawumMkLgjkcgV9B38K6fFcTA25UqBHFj5sdz9a+c/2eyB4nMgHKjgn0r6Z1rynsk2qATwWAzivnsY4xrySXRHv4apOVOnzu9/8zh3mufMLxF4UkO0j19q6O0ZhH9lCBQzgtyTmrVxZRpYxY2MwGSQOh7YqSztPKT94V84gNv6gA9q4IwSejO2pXjOOxV1Cy88EMOQQPl7jOTXIWMsbSO8L7V3Msbg/dccA/ga7a4huN08ZwFBBjCn7/HU+/WuVm0n7A1uJmj+zuSHBXBXngilKN7muGmuVpswfGkaS6rPItybkkBXftuAwRXMWOoW2mXMUd9aGWBySxD4OcYGPpXUazDEmUthmME5OOp7n8a4jWIg5bJJ29zW2HtJcr2+49GivcUT2nw7qRk0XVYtEk8tYoxPaK65bLfeUgHkZGM+/tWH4qhm0hXe08tbK/tVXULacebJA4/iGD2BJHriuf+H+vYt7i33FZGhMIdTyueh/Oun1C/8A7Q1e7eO2UXc+nGyKFhiV8kofw5/OnGbg3Tn0/wCAcDoulWbS03/L/h/Ut+GdQtNJubb+2LdGlnINnqaIdlwCMdvuPjjGOaqeM/Dtxc+O4ZtHitVItvtpSSPKySo4G0+mRXJ6HqOl3Gi3Wka/FdKEdXikgb5rZxwSvoQa5GbUb+O4l/4mFwZzlGl80guvvz+la0oTV0n9+3qv1/A2hhJe1c4uz212fb+vuNjWdW1S2+IjX2p4hvoLgH5MY2gcdOvyms3VLtbiR2Lod0jyblXBJdiSGrFPBOSWPqeamgdAjDIPOcmuvkV1I7lBRik91oJBdyWOoQXUIjaWBhIm9cjI6ZFb/iDWmvtOEgt4f3kizrqEsOyUyKBmJMcBQSfrXNT4edRwAxAOKk1aM21rDbqFZFlkZZNxyy8Dleg6VpyRlKL6nl4j3W5Glq3ia61bSLPTpkjQW8z3BlGd0sj9WPp+FYglYMSCfQ1UDjjrmnyHjOcCtY0VHRLQyhieWLsPkZt2Sc46Ugc9sY96qpcq5ZAenNMedFJArX2ZyyxcXqmbN4EltYbwXMbTyuyywLHtEQGNp9Ofb0qpGYPLlMrOJePKCgEE55zVQ3VsLSYO0ouePK242Y759/SqMt0NiksQc446URhZWOapi1fQ29c1KTUr17udIVlcAERIEXgY6DvxXK3l08kxUc+laE8wKA57cU7QNMfUdSDMjiIMMkY6e1aR5YR8kclWUqslGPUZo2mzXl1Fbqhd5GCqoIGT269q257V7O6mtpdpkhcxttORkdcEda6TXvDZsIjc2mm3ENgziaGaVtziNvlAbHAG4HFZJtCDkbcjn0rn+sKeqeh1U6CgrFRU+XJ/HBqQKCOTxx9KuvbnaDtwcZJxUDgIy7hx2NRz3N4xsxYVbcAuAAfSrROOowe2KS2IMmQOgq+EWReSM49KxnLU76VzLnx7cdxVmxRWhBU8g4PtVhLZFLMSoAx1pJohGCytwTgjHWs5TT0R30tiKf5n2kfIeOtUpwsMiMyZKHOG6Ee/rV+F0eUhnyBzxVXUJYzL80fHbNEL3sdCRFq96mpX8t5Haw2xlbJii4UHGOB+FU+QRkfeP5VMGwCowsbkZAFT3CJHFgcnr+FbJqNolqCSKXlkKSxPHGKkUZOO3SgHJOOmOlPtwGcZUsQeoptmkVY1bC1ZXVckRdS3fPpWvCqNG4WUkoMIvduentUNisdzOrFCkQA3hepHcjPetOwRLK6uLpIopQ6lSJVyAOgP1rz6k++5lOVypbxG8k25G1OTz37CtjSUuTcyrHB5scUfmNubaGA6j8fSptEtFRPnTYZPmG4dR2roNPtbqedLaKEbW4YgdOeprkqVLu1jmq1krot6Bp0s2t28i2UeI52aeMNujRCmVwDzkNxXXarZRXDwlrZR5SHLFtqxgkHaAOv1rKk1GHTbGC208mO7kIaV3GSMHkHPftVWS+aWdpC25mOSMnGQMUvbKnHlWre54041Ks1PZLYmu7qNblnCZHRefvDtmvOvHXiqaBGtbNgDKSHKn7ta/ibWDbxNsyWc+Xu9K8t8Qyq1yMZAA5JrXB0OefNNHoUKKjHnlseZ+IvM/tGXzslt2ee9ZZLA8D61seJbxbm9zG3IGCSOtZGBtOCQT1PbFfVw+FXPjK9vaS5XdXGtkZA4+lKAcA5pUB25PakOO3C/rmqMhTk/dYZ9KZJxBJgHlG6fSn4yADwDTZ8Lby4PG0jj6GgBLbH2ePt8g6fSpEx14IHSooCPs8Wem0dOO1SKDggYoGdf8OtebQNaSYSbVOAeK+o9B8R2esmJwz/ZFA3Ajktj2r4wTK7cnjpn3r6B+Cry2+kQz3bq8RfAXPJ9jXj5nQjpWW+3qe1llT2kXRa2TaZ7cy/PlMqvUc8YqRFWSRpFPyiLBBPAx3NR6c8ctrvaN0DNg57d8VbPmTM5U5R174GR6V50UtzabadjOuLogwlHDMTjcRkH2FcxrU850+d2Ysq5fkAnb3FdFdpIYhHBEu1SN2McYrK1YYXbEqEtGMg9u/SsXFqV+h20LJrQ5dma50949kUaKPP3sfmbsFB/GuX1SAMrhVABrt4baOW123DlcFmJC8kgcf8A6q5jWIRs4GMilTfLLQ9KnKzaOU0WQWOrhCfkf5a7vUbh7qzhdV2zQIFQrgZA6c+tef6ioWRCv3wc8V0kN75cAMpJSRcEelddWN2po1nC7T7GV4rglsr+F1YI91bLNMqSb8Ocg5P4dK5zr9cd+av6mMSAB94P3TntVEkgZ5rtpK0UaNtJIY2c/wCeKQHj8acTwf1waUgEZz14rQykxu45J9OhqvO+W+dsk+vNWDgpxjmktLG61K7NtYW8lzPtLiOMZJA6nFXFpas8zFy0uUWdYxv9KhuLoOCRwTVG9meGVo5AwbPQ8EVnTz9dx5NdUY32Pn6mIeyJVmxcsc4XPNRXN3h8ZrPEp87P5A0jOd77h82a05Tjc3Y0kn3owfJ3Dg54WmByWKkgqOc1Wt3LYUjjpwOK2/Dl7HpmtWt7NZQXyQPva2n5R+vBFJ6J2Be8V4o3nKxx9zg969T8NW1tYQQxQwYbywJGLZJb1rjPDFlNez3d8lufIRi7BEOyIE/oB0rtNJmEN3m7QSwFSNgOMehzXBip3XKexgKDcednTPA+p+XptpNPaG6gaJ90m6OaVfnC+gHFcSvMa7hnPBx6/wBa7CPU0ttJ1O3idS8sa+Uc8o+eSvbOCRXKEbQcoAD09hXDSdrnZKm0ye3Abr9MGqWpQqVDDOc9qngDBsgEA+tLOykHfkE+grZOzKUbmVaRvuDYzitKKQlf+mncGltFDR7VAU9hUVyksU2EjOw9e9KT5nY76UCO7eVlwmcZz7irkMgkttpXDgd+lFoySP8ANjJ9e9OuCkXIIXIwVPes2/s2OqHYoN5NuxPO89vUVSuHMkmcAe1W5oTLKdnUDNV7mNgRvHHSt4NXNraFfofm5HpVkfNhcE/jUSqM9PxpyyBTwPaqlqaQ2DdsY7V5HUmrtqsSgkBc98VVZN7KAc7j0qaKBzMVwAOnHWs5WaLL1vdtarNGQVZjhRjgitqGCW6tDEmS7jBINQwo8sFuZDlIFKRqQPlHWug0iF47SS4C4Ug4A61wVp9Vuc1SaSuaaPdGztPtJGbaFbcDrnHf61tWN1stGc3CRTjgoQdz+hFc6FeeCKZNokYj5c8getXUIjUnDPI3euCS1ujgqRTVi6oLqjSNkk8+tNu5BHFI28DjrTUnJUbkIOMfT61zfizVUtovLXBPUj1FXSpOcrChBylYo6jO97eJEI9sQBOc5ya8g8Y6pcpfzWpyjISp9/pXomg6vbWoeW8k2hSSS3JArzj4j6za6rrsktmo8lQAGA+97mvdwEJRquLjpbc5c7qezoqnF28u5yu48t1Oeuc005LZx+vak3ZIIOPpQec5PPrXsnyIMTnuM9c0hyQMfXmkBJHGSB0JpysfukYP8qAHDDAE8H2qOXAgkB5+Q/yqQkYzxgntUcrHyJgT/Cf5GmAlsMwxnqdo6n2qYkZI6Corf/UREcfKBz9Kf8ygEjGemOn+f/r0hjo2wynaOueOa9f+GWsQviJQd6AHYDxn1rx7GVzngenWtbw7qE1lqkM0UhRtw6cZFc+Jo+2puJ24DFPDVVLo9GfYPh/W5bmFBLG25RtfByfr9K6SzkZ0iI2hVTjPPJrhvCgW60+GaKIeaF+eUfeAPQfjXZ6a6WVuIHy6v8o3c183H3dT2sXCKb5UK0nySopUeY2ckf1qpf26XEFvKP3bngMBnpxmlljmieOOJBIA3yIxwOff0p8VxcMwmvIwkSnbhDkDHb6Um3f1IS5feiYuqIsFthjvKKQWwBk8g1w+pwSC3h+Ut8vBx1rp/E90xv7lZC4jYfLGBgoc/wAqoa6rrDaMypGjwgqe5Hc1nJpOyPSotxSv1PMdSRnviD8mB6Vo3QQ6cyW7SSojBN0ke1unPBqxqMcWYpIFYzJJuMhPbjGB7VY1G+a78Q6ohlN0ZSrrJ5ezcpUdB+FdsJuVrdP+Ad3NscjIrjd5gICjriq78nAJA61uawkUluBHkTqOQO4rCjfa4Y4cKc7TyDXZTd1cqU00M2ginORgAdqRh8xIwB14pCw6Dn61oYSqKw1128Eg+tR6bfx6VrVtfzxPPDE2ZIVcp5i91yORSuTnnkiqN0u6Nht4NaxjzKzPHxsuaOnQzvHF/puo6/Jc6Bb3MFmyhmjuJN7K38QDdxn1rnrl8+5rVuLcRlmIB9v8/jWZcgoAyH5evIrupJKKiuh83UvdtlVQQcj05pxznJHTp/8AXrWXX5P+EXOjfZrYJ9o+0+eIgZc4xt3ddvtWPEDJnOAAe/rRG73RDRatWByWIA78V0Hh/R7/AF69+xaRayXM+0uVXsgGSSaztK0x7tlWMBs9SeAK9e8H6LFpNviAkTyAo8isVJB4wD6YrmxNZUo6bnZhsPKq/I0NOt2s/Ddpp6eXCUjIkeJNpkyckOf4ulVF0xoVhkkRzC2WUsvyuV6gV1Gj6U95PFZpOA3lkqZPmzgZwaoWskt5bi3lLrbq+4xnoGPceleLKo9WfRULQVl0Kd+739689vbOnmEDaqDA6ADArFuxJb3UsU6GKRW2sjDkEetd19gSDSplDnO4FVIOSPUGuV8TWs1mYnuEmWSchlZsFXjxwfXOadKXQuVnsZ4GSCvTrmnXEDiHcylMruRmXAYetR2s6iXy3Iz1Ueoq3qCNc2qxSMyhAdvzZ49K0bs1cuEDJsLpXdlOAw/Ort4TtBTOR29awo1MNyFYg84yO9bcDb1wNoPTntVVIpO6OyEdCu7Bfm5DAdMdaSOQXT4nAULznHJ9qr37sHYB1GPfNRxTO7quR6Cmo6XOmMTWYJlm44Hy4HSqtwgMZ3gsDwpHrUoOQucMMc1FcOI8Z4XHy1CWpSVmZ8rKGwBjAxTEQs4zwCc81IMNcEupCZG7jkc0+YoblxCSYtxCZ64re9tC0tR8bfM2wAkdsVr6Zpt1NKJGjB2jGen40ugac5PmOMDPfjNdppiJ9nJ25w3PtXFWrcukTGtW5NjJg01g0ZkLc8bQOBW6gf7M0CthfarNu0LJMjREzEjZITwuP8aWXy4UJIyx49a4JPnOGdRyepWTbZ2pEaF5Xb5m9Kka4higzJ/rc9fX2qnd3n2S3LFdzZ4X1NYxctK0rOGP3iCeBVqFyo0+fVm7NeFbaS7cbFHA3dzXnuuXo1GfEe1snJPrXRapDda5aolpLsgiPI9ffNO0vRrWG7igVA9zJhQW6A110VGmuZ7msHGlq9zzHxfqItbBLSLGX5c45rz+TBOQvHTiu0+LWlXGkeLLm3ndTJgMNnIriUABx2I9a+hw6iqacep8ZmOIlXxEpS/pDQoOTnPrxSMpBPHtwelP+c4zwPWlIAJXcfWtThIxlcZ6jtilBy3t2o6DHWgbio6A+9ADgp6rwabcj90+c/cPP4U4D5ARz/OkuN3kuSTnYR09qBCW+UgiLcHaOOvapHwTnOV9f6U22I+zRhuTtB469Kd0bAXntntQMUAjjH0qSM7HBzgj2qPgAbyM+lKGIbPI7euaQH0b8Gtelk0Q5kVpB+7KluW+nvXr2lXEd+GRXXaTgnuD7+9fMPwd1u3s7429yQN5yhPY19B6Rexw3atHxvIDqvf3r5jG0/Z13brqfTUv3+HjNb2t9x1Q2jMDBTsXBLDkrng1S1KIC0GCVQHdj/ZzVp2Y3AUwyKkib1Y8huen16GjVEASeMBlXyQWJOeM9MVNr77GEHaSOS1CObUILplPmSZJjdePl9Kwrq3P9nL5vLKoXJOSD6fSuxs1hgZoo2JZ0+bPTHasbULNWQqMKo6FT94k1y9D06dSz5ehxkltE08SyttiZgHYLnAzzxT/ABtdWA1HSBYmSZbWFoPtL5DPGeVVuByvIzV28jeJ1MR2SISdy/zrnvEbPd2xkbLTBt29uSTW+Hb5lqdXxSUmY16yxAyRglWJBBPPNYzKxBKjj+VTXF2zqEfgDg8VBnOQDwfevWhFxWprKpFqwzJXOP0pu4jI28e1OYjb9eDVeR9q9fxreMbnm1qijqK2DluABVO6lGAD9Tj0pJbhmVuCfetnXfDFlZaLpt/L4l01zeKWMSBmaIhcgMB3J+XtzWt1CyZ5Feu5J2OblKSgnBC+9YeoQ5c4PHarQuWdAS2OMkVTvJlI+UfWt4XTPNnNSVzX8NeFG17SdUu7bULRLmyjM32NmxLMijLFe3ArNSCEx5SLPTknvW94JbwnDrcMniKTUDYrCGdIVA8yUHlD/skcZ681najPb3Oq3smnxNBZPKzQwscmJM/KufUCojOXO1rYlRVkzd8KRzi2muUizbQlfNY9skAc16TpEiSxjdx/dx39a888FyRvf20F6k82kI5lnhibazqB612+hjc7PCf3YbMalt2FzwPf6152M6nt4FXgdeIcYKsQR0IOKLK0C3jBRjJyAKs2iGRFDIdwIye1XogI41WSNFVCTuA5bPqfavMvpqdalbRFp7TfaTyGSJEiG9lkblx6CuP8VJ9s0mPZbocu8ccqy73TAyEK9h71uX9y07iIA+Wo+fnt6ViapPEkgks3mkj+UOrgfeAwSPbtRGVmrG1GD6nnEjSLINyMHAwQx5qx/aEwUxHkkYBzXV6nZrqSNKscKvaoA6qu1nUn7x9TmuVvrbySOBtzjI616EKkanQ64RKZJAJZcsTkmrMMzqQvGD/eFQRyAP8AOC6nsae2BuaMEJnHPatJK+jOmFrEbnLsSf0pkeYjnGe/WrGUWPIPzf3fUVD1c9l+lCd0behpxv8AufmHLDOap3BDHcWwOtOgdnyoI2KPzqwLIzYC5zjgVlpF6misimhku36lmJ6nuauWdgwmJYhQuM+uauaJpsqSeYwGAOAe9dRp+lRu7SuVUkbjnocdqwq4hR0RE6qgSabbr9jAAxgdWNXmlaGyKRjLMCMgVpX9wt2sC+VHF5cYjVUHBHrVSTbHI2wbiPfgewrz3aVmjzvaOWrRLZKsFsgkf5gPzqnql+kCDdkSZOB7UjsJcYPIycL2rn/EDiFHAXcxXoe1XShdl04c0tSrc6ur3EcDDf8ANgEdjSyLeG1kuUtSbONwsgXr9ay9L0+V3j8sb5ZSK9QtZbHRbBbbyUmjkBVvM6liOp+ldM3GnJJanTVmqSSirs59PKs7MzKPKUjIQnH415r4l8WtZ6iTbSZlj6Fal+LuvzW+ppaWZ8uAICAO9eVTSPM5Z23MepJr08JhE4qc+p81j80lCTp0tH1Zd1zVrnWNQkub2R5JG+85PNZ7cDqC1Ic+xzxxQFG7ao5PX1r00klZHz7bk7seSCmMHNR4PQjGegzTjnHPTOAKCQFO8H6+9MkaB83AwfWhugGMg8ig4KjjtninHOOSOO3oaBjSSMZ6jrSzNmCXBPCn37U0fN8/IHuKJRmGQ8H5D047UALDg20Q7kDn8KkYDseD+dRwKTBHk5+QdfpSkYXA/CgB2MDowx60D0Oc4zShdy89fWgE8YAPqKALens8V3EyHDKwwR619UeDo1jttKvZ5yYnA388jjHNfKljhrmMdiwz7V9SfDmAX2jqsj8RrtxjOa8nNFpE9zKL8lS+2n6noyTyvbOBLG0kUhVTnB9s/gayNT1Bp7R1mUJJgEOp+UketZAS6iwbr54I227xyQB0zW5HFFJADwwYcDt9K8So5dTv9lGm77lSGdYtOjkLEuQFL7e5qreB1RGI+XAzz0rTWzWC1kSZSImAMZz7/wBKqT2zISSZC3J+cjp9axs0ilKLd0c5eAFWO7HGK5fUImVSVHBHFdZcqQzo6kbsBSxrAv1ZWKgE4ran7rOymzhdWiwomQYBODx0NZe7kg11mpQ7rafuFGDntXJyDHIzXt4eXNExxDad0RSybSS5xWdcXGUPIIq5PzGd2c1izMolJXOP5V2RR4OJqybsNu7wqoUnJ6fWq9vqixW91HJCsvnR7EZ8/Jz1H5Va1/T7jTrk29/btDchQ5R/RhlT+IINYk67VA4Iz69K2ioyjc86cpJjBIwYgj5famspkflSSeRir2lQWdxqkEWqTyWtmzYkmjTeVHrjjNSRRRwzttIePcQrEdRng1bkk7EJN2K0dsv2R7g3EYkWQJ5DZ3nIPI9u1aenWbS4KjGeRmq1zsnliCxqu3AJHO6uo06NYyvGMDFZ1JWR0YekpTsz0/wXoSabpGnXWj3Nr/auzzlM5CRzHdiSFix67eQcetQ+S9rrNzFsgjhE7MBA2UTJyQp9K5KyWW4YZYBQcCumsImCrGpHu2ccV4lWLjJuTvc+kpU1b3djrYGxEG3qcY5JPTrzU9xcbfICujh03ZU/dPcH3rJsLQtD80rlfY9vpVy6tUt04Dk4GAOhzXFbzL5Ipld75QHj3gbeoB5NY1zcR/Z2GS0m7gA4A/xq1DpMKymeIHzW+bDDIJ7Umux2CWaGGK4F15jGRTjbjA4H481UVFSOqKinZGTd6jGG35BnxtP0qOC2g1AyJcXK26CF2VyRzIBlQc9jVe2g826yU2kjp3/GrR06C4mMhUn0we/vXRpDROx02VrHOTKJ2e4WFYAcHy0ztBqSdnaPacbn5wB1rY1GFbcQ+QEC+WfNJOec1lX+GMHkOZCYwXG3btbPQetdMZc9jSKXQqEMBggDHBxUY3BcnGf6V0Hh/wAN3etpK9rLbwLCQjyXUm1TIxwiL3yTxWbNby2V1LaajC9tdwtsljcYZT/noatSTvboVGUXJxvqh2m5AwuCQdxOK6CzhV5FzgEjGBXLQTtCWMTDA5Ge9dDoV15/y8iTPNc2Ii7OSKne1zYtxvuPKQfd9q24k3YGSEHWq+nWoiaRh/rH4LVdmcLE0cfzHvivMk7vQ4akruyGSSyRQu3y7QMAiqq3kPGQxyOcetNDHYfMOSfvY7U+2tNzMzjg8jHenypEpLqUbUTvO4OVjxkMRVTUVWZigbcCfzArV1ScWsOy3+8Rjjqax/KeO1D8ed6A8ZraHc6KevvFrTpI94kRVPkkA47f/Xra1+MppUdxsV/m3tg8hTWToghhgMfG4nLP/fY1u67OkHgnWr1lZxHDlcDgdqzb/epLvYxxFRU/feyPnP4hX/27xJcuV2BMINvIwBXMbenODnpVu/la4nkmcnc5yeaqBsjAA6V9dCPJFRXQ+GrVPaVJT7sAMNweT60OcAHnpQemGoA2E4zwM8iqMgADAtk/4U3jGDg980MBgbuD7UpXoM//AKqAGqAAd2etCjAAbjn607aTznAA6mk3HkqOewzxQMTIwR/kUkxzDJ6bD147UuST/Dx6Dk0kh/cS9ztPXtwaYC20hEEa842gkfhTuCcn86ZBxBFjj5Rk/hT87gMDPqKQChiGPU54wKFO4ZB5HejA74oKgZ7dOKALujx+bfwoScs6/wA6+ofhm7WKNbhsTMu4Ec/pXzLoGF1O2zwQ45r6d8FQpH9hkdWLTAKWB+5715eY62R72UpexqX8jv7O3YwymVl2yZ/hxnPU1k3dk9giSRkmHdx83C+o9ql06+ntdWezvH3QsTskbofQfWnXLvEZ0+SSFySAecZrxmrJo6o88ZeppWwhkiYAsdwyo9KzZEaO5eNlEitkgMT0/wAas6cC0aRnMYZfkfHBpb9FQK20OwOPZv8A69ZuD5bMzXuyaOU1J3aXYQuw4XLDkY9DWHqWBJhuT6H0rqdXtB9nE0Ug81m+eJ+v4VzVyWEe4YcjocZqY2PQpO60OY1C3EplUDBI7c/pXM6rZGLa8Z3IRziuyvkdv3i4BPOBxXNaiheFiBgjoBXo4abTRpVXunJ3q4Q4rBuMk8DIHGDXRXiE5XHNc3ezlJSoPHTnivap6nzOMjyyJ9d1q71q6F1qcgkuBGkW/aFyqrhenfFYLsCx4yPT1q1LIoc/u8g9qgYxs2Uzlua2jFRVkrI8+TvqyLByQSePWrtvLmIAnn0I61CpD/KOOO9WrWyd5E3DJHPFNtdRRTb0FgjdZV28liMc111spJAA59qoxW0O1CEA28VrWcYDjdxxkYrmqzuj1MJRcWbOnRlSnynb2z6119k2TGAY2yMYx0Nc/p43x/7RHHHetDQmaG5kaWUTRbfLKsuNpz1HvXjV9bs+hp0rQOwtsxKVC8Y/GlE43BWxuAwT2xWWdVEERCyEoDxkZz9aq213I2obiM9/rXHyu1yVSe7NOVtjOEDM/UgDJrN02GXVIr6+EkMdrbEL5kjYLSHlVQdSa20SSGQXQ2uyg43rkHI/+vXOQmbS8PCY2TeZQhUH5tpGf1q4y+81pq8XbcytR1F7++urmfy0mkYF9oxyO/41GJnhTzijkBe5wBVa2eNLidpoGeSQYUscbGz1963Z7VXgG5crjkEV0SSi7W0OrSCSsUNL1lbdoDdQR3dpHIX8hujA9QTWK7xPNKy5hj3Hy48cIpPAz7U+7WW3YrKF8vnaB1qkspIEeM+mRW0KaV5I3UUndGzo2r3uizb7ds28rI0sTqCsu05HXofetP4jztqEtrqi6jbXiXZZyiKFlgOBhG9QBwPxrmRciEus0QYbCoDc8nv+FR2Ns1zcBEXIzzx2oVNRl7Tb9TOdNc6mtyOJUK9ec4IFdT4YtowVMYJB5zWSNGle6wF2rnqa7PS7IadZoWzu6D3rHE1E42T3HVmoxsjRkuVtoeQpYnC1XM7rPCqkFn5ZsdKrYluH3OPutlfQVrI1vbWrzToCMAY65riSS3OJ2iUDZNeHYkjJEh3M4PX/AOvS6hc/ZykMQbb3A6moLfUTLKBOfLUnKqvTb/jUSqJLn7SsjbNrbQe3vV21940UXfUaqLJtlckSYPyEfdqlfzHCoSA4GAB1qzNKbaDn7xFYaLJNM0seHkzgE9FHtWsF1NoK+rNGGYqRASM4yMevvXS+Kg8Xwo1pMsGaIE57cg1y9npxkvbUmUbi2ZR7Vb+Mmpyaf4MXT7IHN048xgc/KMHFSoc9enGPe5xZpJKiz51lY7j2J/KmHkYYDd2z3p0hAUbc7ifzqPB28kn69q+rPhxT0B43eo7UgPT2PPvQpI7c88DpQMDqDn0oAVmLYGM4796ackj0x1NPH3eg65GetM+ZehGPSgA5DkDAHuaVl3Z55znNLnA5wcU0kngYzn0oAaFzg+/5USYEU2P7jfnin4JUce3NMmz5EvHIU8enFAwhXNtFzj5BxUu0dV4OKjgH7iMg9EHT6dKkAPJHXGAKAD+IHpg5INCkepHoTQQc4xk+/SkGT1GfWgRYtpTFIjKfmXkV9GfDbxDFqWiKgkVJoU5B6sfavm0gk9M/SvUPg04l1WS381Y2I3At6jtXDj6alT5uqPTyqry1vZvaR7Y0807ybLVpUjOAWB2qfX3qeG4ntjYSy7X3bhIM5JPuOwqJNXlSzCld4zg7OMVQOXnFwM7s42gcV8+3d6H0qi3o1od9bXBFmkN4FQNyh9qbeXIWzdDjdH0kJzx34rDsJRIbf7Y5dixG1s8Y9+9WtQsor62QQNIZFG5oieG565ppN2PPdJRlqZd7dwecHMe/K4zkkGsmZEYllBAyPlNbOo26RQI5Cliu4BORn09qzWJb5pUw3b2965+Wx2QatoYeowMsRIG0+lcpfROhb0PUYruL5fMycHHHUVyl/EzM6ktjHeuyjI3j70bHGXKjfjbtrndTtMvvwcjrxXd3mnHG9h1GQw6Vi3VthyrJXr0ay6Hm43C+1Wm5xy2DTkqm0HBOScAVmPFhiuc4ODXYRx2cF+P7SWZrI53iIgN04xn3rlZVJlIAPBOMjtXfTm5XR85VhyaEdsgMvHJzxkdK6vRrciLc/fgAVk6TYGZs/dUda7K0hQQDJwy9gO1ZVqijoduAwzqS5nsQLCd2FU1r6bp8k89rEwKfaZhFFM4/dhsjqfbOapRt5UoyNyn+VbcVzcy2sFnHNmyilMwT0cjGfyrhqzlY+ghhktjfudKOk6jc2dxNFPJCcCWE/Kcj07Gq14zxsCqgMO56UC4W3Utjcx/EipYbgTRBjg5OMGuB3dnI6INxWpROrq5ii27XXqXHA+hrU0yVZJgwOWzk1majNZ/Mroq8c4q14NBeKUYJQMQufSicFyXSNG043OxkuitmdqhmPTiufu3jQEyHg9O+TVXVr6S2fygrqitjk4GahimWXdK53noOeCKxVNoVOlyq4+xiU3cgjjJEmGBI+7VzWIwbQRBckjadrYx9DUFjMGvX8oD72FAPSr2rR4iG1ss3AUdqq+oN++jjdVj8m2ReZGB4Zjk4qrGYVila5jYI0Z8tlODu7fhWxc2ZjPJDKDyG61Vu7N5Y1ONseckHtXTGaskzrjO6Kdvep/Yt1pz26ytNKkyS5wYyuc/gQa29Ft47Ox8+fKE87v5VUtreFXaONflxksOnvW1p8X2xkDgmPqo7cVlWmrWWxM3ZF/SoVmUzuCYweOKtXZkCKzkhOuM9KvwqvkbAFQDsPSo1hSd9gG7HY1yJ31Zwup71yta7m/1SjB7+hqPxDK6wrFBgsBz9a1okWPqSo6BcVi6u8kl0Y0BAHBbsD6U4/FcKbvJMzre0cwM0ssaOVwMc1cjj8qFVJyUXaO351Db2zCdQWBz0BFXb2JIoctICSMkf0q93Zm0p9DB1aXZAzPjA4zT/AA3BBJaMXbkZIK/1qpdoL5gu7jONnatEQmx02KKLK7sgn1rWXw8q3Nr2jbqXLWaOBA68sWwrevNZHxBZZNLuPtm3IGVJ57U3VRKNKKwbt+QeK4Tx3r7z2MVkzkzD/WZ61rhaDnUUl3OPH1I0aEpy9Dz+XHmHkAZ7VHyFPUD36U4khiRuOeKGPYd+nNfRHwxGDu5/OlG3JIYEfzp2wknaOM96A2B7gcUANxtyDnk4HtSnaBk9e9AzjnqfyoIG0nHNACccAc96AOeR0FHlkkYOT3JpyjGB/FnFACMCcfoDSS/8e0vOPkP8qCTg4wR602Ulrdyw/gb+RoALcDyYcYOVGR68VIp7MefQVFCcwRjq2wdfpUgG772eBQMdtBGc49M80wnjHfsacOMcH/69EvBztGP60CAEEAgEn071r+HdUfSdSjuYzgg/MPb0rGG4ZPfp7U5W5BA4pSipKzKhNwkpR3R9I+EPEdnqKL5LKWPJB6118s5vGHlqsSgDKgY4r5d8Law+l6lHKGOwkBu3FfReh6lDe6cJULElOCp6j1r5zG4T2MrrZn1WExf1qDk17y3/AMzrdN1KBNPis51jGyTIY+hP860nmhWeVYiFY58vHPFedSN5hwGOSeCO/tXReG1t7mN/NaRNQiI2Atw4P8Irl1XXQ1q0FFcxLErrcFb1MsWycHqKpahAkc0kiqY4pCSAP4eela189xDci0ntmExPmK+3gL7HpUN20txYmIlWSM79pXn86J0+XXoyYyejOfkRS7q0m6McKcYz+FULy3jaEsVOAOeKvykLI4CbE3fKvUipI5disqsxDDafl5xWabizo1Wxw9/busPU+Vu27uwNZzxpjaBv2nPBrq9Ys0ijkIXduXA5xz61z2lW48yZJATgZXNd0J+7c1tzaljUvAM8+gwavNJEtvcNsEYOXBOcH0A4rjL3wfNas+VLquSSvPA716xpxjGntDNCZkZfkDOwETZ+8B0zUazmxuDJauFk2lCSM8Hg1UMbUgrbnFLB06rbmrs8yttOMVp5uMRj0qxBErgkPhx0HrXRX1sDaStGynqCByDWDCj2dyBIpO7+EDrmumNX2ibOyNGNKyitBkpMMhWeNgh5HHJptrdMjZztHtWnexzXLWqSiTaBhAy42gnPftVmfRozHhTj3A5NLnjZKRrZpjbO8hRW85i7HkE9Vp10fIj3KxIfkAcGsu6t0t5/KU5PBJx0qtcXMm/aW3KDx7ikoX1RE4qJbZftcg+cjOck9BXYeDlzaAK+WUlTkdfeuG05/wDSgSdqdzXRJqK6bIZYW3I3UDjBqK8X8KHFOcLI6HxhYx3dvlm8twBznv8A4VzFrqLNpUdl5dvHJblvKn8o+ZKhPK59B1ya0tW1iK70/Mp+Y/d2nrXP2WoRLAIbq389kfdE5cjaO649CeaiEW4arY1pQajaR0WnSRWrBgRuwDlqkl1ZZZpN+FYfdA9PauWa7P2kZZFXsByBUkV0ftJ3EEqOCo4NS6HVj9mm7mpLKZrhWOQnqaL+4UFUUBmJxz2rMa9XiMMfvZxV61gE03mSghuMMTRKPLqy0raslWK4XS5jF1YYPHUV1um2ghsYlXrtGSOpqtYWyyqm4YjB5966GOERxB4s8nkgYx9K5ZSctDjr1tLGe8ckeeQQeqjqKkimgjnSOSUwI3BfGcVajJiWRpecnA9c1IlkZgryxGMt83zDrUPY5uZdStvjk3JEsjY6SMO3rVS8xE/lIoDuDj29Sa15QVYR2cXnTyMFCg8Cnz6JPCZWu48zYEsUkco2gL95SD/KnDVczYKaW5wazPFdSFlYkd24Bqpqd1czRKbbBUHBA6iul1RE1KOWadAnmYCYXAArltVeOw0yOJVblsb14JrpppNppandCSerWpb0+BIIw0mGYnk55rq7e3S7iBSPzFjXIA5Oa83sb+SeQRBzyeM16p4RntrG38+cgsvPPSssSnB+8RXbUeZanH+KZRo8siXgAZ03IA33a8G1+6+26lPNkYZs/Wup+LPiR9a8X3slvKDbBtibehArhHzjkDJ75r3sFh/ZR5nuz5fMse8Ramlog9SCPw7UxsqARj8PX2oOFJwPy70meR0rtPKFkU8Lnk01ecA9v1p4J3fT1H60bWAOMg9Oe1AC9Rxn14pM7cf07UoyVY4Bz+tM7gkHigBxHHUn0oGRkAnk01T/AHv50/GWzjBHr3oAQDP/ANfsKZPj7O/zfwn+VSqQx5HQ1HMgEMpBIAQjpz0pgMgH7iPjHyj+VO3HoOp6HPGKLbCwR5GW2Dv7UoCsenb15pDEGeCMn6cU4DIwDk980i4BA79OaUg4wcj1oAXHctj60KNpwTzQpPHHJ9e1KQozuGR9eaBCqdowPpxXrfwx1zFhLbNIVljP7s98V5Dwc56gVs+G9Q/s7U0fLAdGrnxNH2tNxO7L8R9XrqT22foe5EzzMZgTg88dK3LeQrDFJGCsuQQwNc/4VuYblSC5Mbdcnmt66lt7e0CNuEwPBB4Zew9q+elo+Vn2dSzaS1LFx4h1OaGe3jzKJNodjksMenpWhpl1P5Y8zmXBG488GsjSpPJPmKcMeeK373MaxmaPykZA8bf3vUVl7ONrJHLUUY+6kZ+p2wCecpG4feGeTWas0kfzBz8w2nHPBrq7ieO+tpHSBIyY9gXGea5aSNnVjkhkGGXpke1RdNBSd1aRHqL+bahQAzDuPSuZUCG964VxjOa6pVQQ7ByDwa5/XLJ1gcqBuBGB6VrRf2TaDWxt6ewWJUJyexNZ+oJvmkRiFyOoqhp99IsB3qcxcMO9Z95q6hpGTJY9MirjSk5aFwpu7Zcih8kLHGxYsTnIqtqMos722uViG6Eggk9SKLd5Lry5N+Oee2RUGtIxuUDy4iYZxnNbRXvWkaNXepLJqdxrF9HcTtuaNduOmAOgrorWOOWEn5Vc9j3FclaQJHOGhlGOnzdq1jPLayF5CPL2gYBH50VIrRRJlHSyKOupKr7htAHU9655wDyK6LWJo3gVS43Nz1HNYMcak7QPvGuqg/dMamujHW+WuIxIxCHjj0rVn02Jg0kc/mID8q0/wroj65r9rpyOEEjgGTGdg65rb1rw9PpV7JYXw2zxtkMp/wBYvZhj1HbtSnNJ77DpSiny31ORME+cqjbB69BVflSeorpn02ZE/ePuiA+71OPeqU1p+72jkMeeOlRGsmdd0+pj9VyRgGlR/lwGx/jU8sI38kAYwOKm021NxOBt3DPFauatdi1DSbV55d6YJHOD3rsdK0qQsZ7jaOwUU3SNG2EMQV9vUV0eyMFEQk7a8+tW5noc9at9mIttbkSIAT8p6Y61u20K+WfOkC8/U1mWwdyoXHLYLVZnQwk7ZPMQcbiMZ/Cud6u6PPm76Fq1VFvPPhi3CI5VpBnB+lMv7hC8khcHOSdowAe4qok7j5I8cnP1qtqMsUcBR1/eqeWPoe1Snd6sShqPh1E6ZukgKruBViwz171DDtvUlE140O1cRkjduzXNX88jSxJ5TCIn7x6VPPKVtSuTk8dKtwaasdioq1+pqeJjb2wEenyt5IVQ27u3c1hR2Md/DJJeKGgznJ4/KoJL1DbeXIA0hOPWqOqaubOwe1ztkIxgds10QhN2tuVbkja5gNsh1Blh+4rYGD1FeheH9citYY45o1eMdj39q8vhkw2SelN1HWILWMMsp3gdM1118K69ohOtRVLmqOyOa+ILW7eL9SfT4lghaQska9F9q5wg4FWL27a5vGuG3BmJJ7mqqhs7Sc5r2oR5YqPY+GqyUpuS2bFIyxzjP1puDnGOvUmnYI4AwMYoHv68A9KogB82eecZ4pc7cY6UgOCePrikGO3pgUCHbgSOcEcCmlefmJx3pTkY/nTdpyNwP1/z0oARsgZxTmXPfv60jE7AQB6Uq4IPt0z2oGGNqgruxSy828vJ/wBWefwoOFAIJPemTf6qUjgFGP6GmAyBQbeIjP3RnH0qVQcZJH1qCAkwxkf3QMipQoVSCTzSGLyo+bI9PrQc4wM5oPOM/X8KQMu08HHUGgBc46E49RTlkyQGxSblHDjnHSkGMnO3A9aBBjvnjPPtT0ODjf0zjHrTOMDgnNIwUHvjrQB3HgzXxaoI5JNpXkH1rsIfEK6ndIFlyinlhXjCMQMgEdx71veGNRktb5FGdshAI9DXHWwsZXn1PcwGbTpclKfwrS/Wx9D6cYWjUht2VBzXQvdQXOlNDOWM8Q/dsfSvLNE1Y2csYnI8pzjk/dNd7Z3MUqrIjqVAGPcd68KpTcHc+gr0WndktrcNE+RgxnqewJqW7iQEOvB96mtb+Gz862ltI5o7g7ue3H+TWabiUSCOQdOc+1YSS7GSTbvYgIMUijbwxpNTCzWzEgK4GPrVnh3LKB06GqkkZWFzgszZ4FJb3LW5zGm5SWZWI3Zqa8s7dyfNjBB7Y6fjVGcSQ3BfGM5IJ9KuRyCWAl8g/Wut3Tumbu9yFI1gUiMBQDxzWRqzmWRHQhtpweOlO1C5mjn2feB6VUuAyseD83auinCzuynpqMSU/aS0bKufXgVHcPLJkyOxHqaTy9pIdSAOtIysc/LlQP0roSVwvoMeRmC5PQYFT2kTTFQqgAHJJqsQ3fmtSxikEAAGC3IOaJvlRzqLk7s734fWC2k1/qkhnRNPtjJ5kG3O9uMAHg8Zp0ML3V81xfSSSXEzbvNkbk/4Vgadd3FvE1v5khhkZTKgf5eOmRXbaYqXNmWHzNjBYCvKrTa0fUmScG5Pr/X5mFeubWaRGGWK/XNYF2E84dm67c9a6PXtMuIL2QIdowAy4+Yd6yjcPHay2WFaOSQSnK8gjj739KKbtqjog1ypoybmJNu5VXceFAFamkW4idWVOSME9AtUAimfAGM9h2rasgFjxtz+NaVJO1hzbsaYleHI3hie3pTreX/SMHPJ6iqkbkzEhcMT1PYVai+bLr64OeKxaVjkka1vLtCYA45zRPctNLtjOFzgVThntlRkkIftw3SmPeBYtkJO3tUox5bshnE1petBLht67gynp9agvZQZ1QNuYfeHWrsamPHnEOxH3j1zUdzpbpOrnrIoYAehqlZu5vFpbmbJLPdwpbpkoDnpViHTh9jllup1R05VD3rRhRIcIMbvWs7XJoTH5Yy/qM4zVLeyKU23yxOI1sMbjEJxgbiR2rlL7VIIXYyS737981Y8T6ubGGaGI4848DuBXn7uzFs8mvdw1FuN5HkZpmHsp+zp7rc2LzXJpWKw4Vf1x9axZXkdj5jMxz6/zphbOM88daBjjcOemK7VFLY+fnUnUd5O4ZI6jnp9KXOFGRj0zQRvzntQxyehBA4HbFMgGJyMnHHFICT/ALoPegjPzds5Pc0mOmABz60ABJJ6fNTvmwNpOOcnHemt2yD6GhW+Yclee9AD1AKYPbpTTwMhiQfTvQzHJAJIoUZbryOQaAEXIOScjtTt2RyKTbzz1HXijHI6j2FACAnHtimyAmGQnI+Rv5U/OQSDj2qKYjyJT1+U9evSgBIV/cRdT8o6/SpORxzk+tJCA0EQPXaOD9KcwHA5x60DFcAZxnHrQM7Rlhz1AFKPkfCgk9KZzjr7ZoAkIUEluh64oIIJGQfSk+8dpPJORxSk4bgnA6nvQIG6nHX1pCQMc0Z2k5z+FHDEMQQenNAAGLdWxjnn0qe1fy5o3OMA54qDfj156/SlXg9ue1A9j2Pw1fWEvlkRx3LkcK49R3rUhv30y8hVl4P8Gchea8t8GO63jkNgkdjgiu3mt5nnXa/nu43cHmvIrUVGbTejPu8sxDxlHnmtdj0S7uvOhV485wCCD0qldai0kkY3KWClT9Ko+G7iWSHy5EYt93GOamuVjeUx+WYZVOfrXnOmk7PobqHK7M07e6UIoBLZwp5rRgxIu5sKDnFcvE7W9wFcAZ6HtW1ZvuCqCTjrmsJw5dTKpCy0KmtWcYOONuDXLqzwtIoOCDwO1dnqcYkAKk57jtXJXqO0z7V+VT+db0ZXWoo6xKc5LzqZtvJ4xVlbZ5Nm04UAkimQRguGPOTwT/KtOJCc+h/iPHFbylbYOZlO4t4xCwCht3XPrVCURksF5OM49TWpdqQMYJHqPSshXD3KqSNq9eKcHfUvdFS6hJnjj2nnnGeua27S3EcYYAA4qF4dt3HOzKVPAA6j61NNcqAQOCO+ac58ySQWsUr692M6J8rcE+9ek+G50TTImCjG0E4ry25uxIGX5duMNkck12Hh3UIFtEgWTlV4yetY4mn7q0FUjzQsdJfgXE6SFgjKhU5zhsdM1y9yB5hCk/K3Jq62sIxeNB5rg4yO1Z4V2ZgByxzxWEFZaihFx3G2EBkJZwBk4961MIAqoeehNV9ojiSJHCluvrViGHy0CAkZ7kVTZM5X1LccClMByHB6AdadInlxkPjGOQD1oiMg2lfvDue9SXAaWLzCAMnHB/SoTOd3uVIot02yJQSxGc9s0/VdOfTZt63KzDfsEXccfqKmgSWJdyoAAckk8mklnE26SSPe7DCnpsPriiMnfyLV73LFnMWi+dEMrLgZrSk2zad5kUYMsQAxn7o+lYCKE3B3+ZeV+tXdGuLiGbzsL5hO4Z6YqbNe8hSh1DUAsMBkd8yFdxOMEe1cNrWqRxpNKTlyCAM9K3vGeoPcQOY1KNy2R/F6jNeWa3Kw0+aQHkjBNelQoc1my7ulRlU6pHH61eNfXTOxyCeBnGKz+45yM+vWgglsHoTnikOB7H0r3ErKx8RObnJyluxwC5wTz1HHGKaBxgEY7ZodR9c88mnqQevGO2KZJGCTwGX8RSqeRz09RS7VA64JPIoPAztwOnAoAackDZgYojAPfP4UMSMcde9KAoPABoAFAwRnHfpSMAevTqacR90847n3poOX6d/wNAAEIbufShxxgNx0PGKcechuT3oOBtx1HAoAb1J2fgcUpJxyAc9famt3Cnj1oGAwI9eaAFHIAIGPWknwIZeh+Q9vY08jDY5I68/SmzcW0gyfun+RpgMt1Ihi7DaOfwp45brgU20I8iMc42gH06U/+LpgeoNIYgO7pk+/SnM3ykkDtgU04JGOnpSEhWyQaBCg4bPQ+vWnZBOM5yeKauBtJBx0IFBwW46Zx1oAXOfpjNIp4H8qcQNpxk5OfrTo8FlznHXigBAOw/E0o5DEcmmu3PXAx2pqsQe59zQBv+FATejB7GvUfD9pp93Y3L3WoCwu4VLwMRnzD6fSvM/Bcu3USzAHC8Cu6ntJkljeeMJHN8yEdxXnYvWVr2Prshi3h5WdtTovCF2z3JMrHzCeo7101/GIZMXcfyE8Shcla53wYFtr94441kyOM9q7+/ia/gLKu2JAEePPzH1OK8qs0ps9KvLlqLscesALSeevmKOAV4x6EVasYjBG7MrBQeCe5qxdReQqoqjk4x0okkiFv05/iHrXPKdwbutChqly4jCqDnqCTWBPvMm5m2luMelbJ+aZlHJPTPX8Kp3ls4LKwwRzkda0puxSSSsUJMwkAAkE9quudoDA5Uc+9Zb3Wz93Jw+eDVsXG5VAO4nqB3roaehm4ksxb5SuST29RWLPB5UhaPO7Oee9axmfzoxGv7s5z2xVMKbmcqmRszknvRBuJcVdFKNXmkEgJ3nqtWIrUTzNu3ccnFatraJGCzjEh6kVftYATjaATSlVtsDmcjc2Y+1JEi4HdvStOCzhRCrv8ynjB6VrXNogYggBjxwKjhswuADkZzzSdfmQ1JD7BY7VgwVTk9j0q3vO2R0XAb1NCW4Tae2emKbJIFygBIzWHxO5Encp5fzstuILZBB6VtxSk8bSfT2rIh5cPkrk9MVrgtFGG2jPf1onvYzmySeVoPmXOeeTUP2wTriMj3qa9ZP7PElwNu7jGaxV2IwNsTk9fQUKCav1M4JM1PPkbCq5Kg85PWnGZyfnwC3QVDbRNI6Kg82UAnYO5p0AluCGKqCMjHpSskacqRJa3ZtrlWaIOvQg9CKvwala29/5pjdbbcQI85KrWTdusC5fgCudmuRqmpx2iTGG3JzLL/dHc01S579i1SU9WdN8Tte0vVLW2ttE8uJIIzuccFgf4cCvMfGVzbPpcTQ2aWv7kRMAc+Yw/iroNH8Oy6qupyWc6NFZKWDudpcDvivOPFmoJKwtlOQp5J9a9bCwTlZO9tzjzCdPC4VwT1en3nNnG4449aRgRndj1yKDhT6n6Uqkbhg89/avVPjRuMkYHzCnuORjk96aQo6HNLwVIOQe+aBCDd2BHGPY04uXUD06AU1sEdSOOtK3ygYx1xigBBu4PoOlOXG5sdvXsTSbsnqD/ShchQeoPBoAQDt3z06UjZDAA4HtTmUZOOnqKaMEkgdqAA5z0yPX1pzL8/J+uaYpGQc4x2NP3bX5U/WgA2fMSCdp70hznPy56HPFKCpxxg4pvTIABNAD85jCkZA6GopSTBIf9g9Poaep6jJGetMmQGCbrwh6fQ0wGW+TBGFHO0c+tSMu7OMZHGKht2Hlx9fujAx7VKCDkEgYH50ihduM5HXqaTDNnCZHfFG3Jbk4I4pQSCQDz04NAg+YkZ69cjtTmyrEHGcd+9I2CfmPJ7UgIVj1PtQALnac/rSuTvG36HFJtXAb9PWlVWLkKMtigBNp5Pb2pNvfpkZOe9KwGOOc9e2KU5GOenegDd8KEjUQDnkH8K9R0uBZtSs4dQuils+BuIzsBPWvKfDUgi1WEsTgtg5r125jm1e2haGPZFGMEr6e9ebjNJK59bw/L9zON+v6HSwaTZab4taDTL/7dAqh/MzgqO4Pb8a6XUd8QkmgztdcEZ6iuW8OahDava6ddGKYO+S6rtO0eprt4I4p4Zo+keTtHWvJra2ud1bmjJc2tvxOY2GWFWY9ehHY1VvLdzuZctn0rZSxaN5SrBQj4COOD9KcYQoAc4B4A6c1ycyTNFJdDnre2LCX7yyjhaWfT7qSPZIdx/vCuhezVHyucuKglikiUjn0HvVKpd6ESqO+hwd7pJXzEkY8cg9xUNnmGVUkB4711l3a/wCjPKVIyeprPa0ieL5XDFh+tdaq3VpF+0TRQjQRkqz5QnPPepkKbcxoMk4NRxoSxRuMHqatwhck4yOnNEmA7yQIs+npUkUyxlRglmwAoqFpgIyGOPrTY3VwrowJHGRWTV9ws+peli3ucc570kcTIM4OQOBS+aTCSDkenpU9lKJI2WQZx6nrWbbSId0h0O9lBkGGHIFV3j8x9wUAkVeYiVVXBLH0OKqS5WRlUEHt704Mi5AyFJVYgNtPHuas/aNq7XA3dc+lUbtpog2dvA4x2rNkuWMTsynI6kHrWqhzCaubN/Klxp4yrSbOfqazNPnaZnVEZG7BhUOlTXKIZZIy0DfmKtxOoAMf7vPcd60typxNIRUS5bSG1Ds6vuU8lTgirMu2xfi4ExlQPlD0z2PvWcZFbcxbLfdfNZmp3sdrC/lku+OtZqDnKyNnHS7KfiTUTJJ5KOfU4P6ViQKzZAYjP6+1RNP5spdskn1qdJsx4UbRXpKn7OPKiKVaM3psS280kDMI3KhxtYA9RXEeMdKXTdQCKwPmL5g56Z7V3NuqeS0jcnPy+ua5T4gXrXt1bPKqB0j2HaBzjoTW2Gb9rpt1ODPYQlh1LqmckMhj8oIxzQSQCcZ9KXGD/wChUmDzn079q9E+PCPIzkce1OPUlcZHeoz1x+tOYAkZ6e1ACnGeBQ/Tpk+9BOCMcbj2NIcEYJJI70CBc7MHp7UucDjoaQYwOSRSNgEjFAD2bcclAWxng0xuO2MClOc8EfWg+h+7k96AGgdOcY64p2QTyfak64ypz6jinMRj5uec9KAGt15xjFOOSVH8X86YOSeASRxkUuOgznuPegYKMYzxg/nTbgk28hA/gPT6VIOQM8YqOY5glJ/uNzj2oAbEP3EWMY2DP0p235gR+NNhYeRH/uDj3xTgTkEn2oGKo7jPNCg9xz1xSAgbvrxigHKYJyR0oEObtg5x+VHQgHvSEggHnb3PvStn5T2HGaAGsSR2B9ac27kkj1NNYd+n0703DAkHHNAx4OMg/lTlTJIUZyM8UzIwTtYj0NKrN1GceooEWbKb7NcRyckKa9b0XXCltCtsCysc4z19q8aBx14GenvW/wCGtSkhvYIS+ImcA57c1zYmiqsdeh6mV436pUtJXjLc9w8Ios93cy3dsF8wjaD0Fd7EJrW62zCIxlQY2Q8n61jeGEsjaRvJKGDLhMDv712WkW743zRxSNt2g9Rj2rwJtSPo8XV95sz5LQOJCzKMrkBqqfZlnkCN82zvnBrq5rIQyEHByMgZ/nWRqC7P7pJ67TwT7VyVIcpzUq/NsZkkbA7V5GOaguo5flcOMt8vHb61djdS4Q4XPB54qpebVT5D68j1rKLTNm3exn6uwOltGVw65P1rj7ceZOApGK7C/wDmtwGLEAZ5rnbKOMTGQ7QATgV00Ze6awfLFlKe3Ky8nt0qaNCAqHqTzU1+6tIrqSfrSxuEDMOvetm7o0i3Ygu7BJiE+bkdR2qtHAIUC9AOK02uZETbFwX4P0ogtPtCkFjjHWpU3syuZpalNHbYyhuvFWrRdquByxHFQMmJBGoO7oc1qWduQy4Tnsamegm0kLbQZcLK+09ye1E6CLDNgjOFrWFk7usRH7xiAM8Vma7E8JaEBA8RKnBzk/Wpg7s5+e7sYl7OHDAevLY4+lUjbGVNijPfP9KuI+wqsqfKeT3z71vadbxyWrBUA3eo5roUuUrm5UU7eKOKzVZEx8vI9TWVfxqAXiIVeufStLUhJHkbsnHQ+lcjrd0yIVXgkc4NaUoOTJ5rK5kXutESMPMGBxnoaoPqbSrgHcDWTd25MrMc5JzgHrRFlcIACelevGnGK0R4tTMK8nyt6GlBkjnk5qSe4S1QSTnCHiltUGCc1zfia+E8wt14EZyT6mmlzysbTq/VsP7RP3nsbkuuWkan95uPoK5PVrwX12ZQNq479aoE7GBLD3pFfnnp2HrW8KUYao8nE4+tiko1HoKpBfIA9MUA5YfL8ucZHem7gMYIx06UrBiApJAP5VocY5tq5xj05pAw4C4GaZtGADk57+9LgAYPTqKAFDAg7jk46GkPTgjnnjmkU7cEfKM0MQOg9uKAFAwPxzTh0PIJHPNRkZHHOR1FIBu+YZ+lAEigluuPpSsCRjjpx7VGN2fvcnvS4OMEkZ/nQAq8jBHPrilzgjAOaZ84OQeB3ow2CGbBP60ASgEoOw/maapzxjn+lMYPkjt246UbccF8HOcUASBwo4x+Peo7hsQSAZAKtx+BoEf4+wpssf7mTHZG/lQAsHFvEOAdo4/ClI6c8dqLcA28ZyfuDP5U4gb88HPFAxvQ449OvSnkfxenrSEAZOefSkxwM53dKBDgcHJ/KkUZPTv0peeo4pM5J5yf0oAUgHvk031yPy708DCkPnnqTQ4KuMnBHTFAAowP9k9TSAZycH3IoQkAnPy9M04NhsHHsT2oAUKSBkZxT7UESphjjPSmISW6HP8AOtjQ9PlluoXETmIuNxNJuyLpwlOSjFH0P8NkW70uOKaEHcgw3p716pp8KxKih9wC45PevPvh/OqwpnbHtTB9Wr0O2GXI3cAfjXzE5aux9TjVKL5X0IppZIZHkb5kZf4sZrDv3leLeY8Z6duK6K7g84DYM4GMA8ZrJ1WISRrhicDB9q5al73MsPKN0c/PIEjJYA8dvWqOQwOWJBOQKvtEzSgBlUDJwwzuxWPMZUuTIo2D0HY1zrb0PSSTLV6v+hliGxyOa5axC5ffnOSR3rdv7iRrSQ8g45FYFqM7SRx1rpop8pUVaLuNkDAk9s8jFPgPmExqwx6VI8IPI+79e9FhbLHN5inJY4x6Vu2rFq1idCIiMhSMYAxT9PZnkuCDwF7dqt3G1ECptMpOeeoFReV5SfLgs5zkDrUKzI5rooebifg4bsDW7pcRkKlvlOclh0rBkhMt8q44zjFddbQG3jRv4VXg+hqKtkTVdki1exjjYyngE+1Yr2ccl5ELuX7PBJ0kPOT7VZuZMKWOSo6YrCkunkkwF3qhJALZxUwv0MoQdiGePZduiyCRVYqGA+9z1rbJWG2KgEnA7YwaqWVtGyrKpHHP41amVpZNpJJ/iNa83Mwm1scxq92yKx6f1ridRuHkkJZsnsa7PxMm1mjxtdRkE1w91HtJD8lq9XCxVjOpKTj7plzA7ssfvU6GHuCCaW/mjtbdpXBIHYVztzrk5AWD5QenHNd8YuS0PFqTp0Ze/qbmrakmnQlV5mIwB6GuJmkkmkeRhkscnNPnledy8jlm9TUIOG67h61tCHKjixGIlXeuy2Q4E7Rlcn0pgOMkr15qRT8oycgHmnYx/Fwew5qzmIV3Bssv0JHSjIL4yQR1qRiC/XHqMdaMDIxkjHSgLiMB/DjHtSBuPYfN+HpTyvBwBxzUeCW4oAcW4wOnXrTggboB0+gpgU7eAQc8mjnjGcHqKAJVUISWUcdu1N28nJOQcc9qYoyuCSO/1pSPlyCeDQA84ORjPtTMc4GOelPI4I43ZxnPamkDHI57nvQAnbgjFBIHXGc8eoo64xnFN53ZPA/nQA4tyDnBI54p2dpC9s9TTAvO4dSOOaXbnpkdsUAODDB6VFMw+zyhTztP8qkCjb9eMUx0CwS45Oxun0NACwZNvFxk7R29qe3JBH15qOEk28QwQNo/lUnHGGxjjj0oAMLyGB56MaTb8p7DHU96Xphe3r3NCruBDZzjigBOCQFGfxpeFQjHOe9NPGBxTslvYdsUAJk9dvHpmkXI/hxTj9QMil6qAwA3c80ABwfcUw4AwT09qcME9qCp7AD+tAGloNqt5qEUb5xmvXdG00xeWkUa7eDivMPBvzaquF3YHIA619CaQYnKukQiYoNoPOTXl4+pJNRR9TkSjToyqW1bsdN4Q0JhbreOqqr/ACjnvXVO2JVCBQyjA96ydAWcxlXkRrXbuRQfunvWja8uzunyjhSTzivHlK+gV5SnNuTJLmZrQIJiCzngCs6+kZ3CiQEdWAPSr08iXA29OeM1myiGXeYgQpGSTXHNr7OwqUbatamdKjGTfGdhBOMdqo3MYwd2AePpWnM2cIevY96pXK7Y25O6so6s60zmNbuPIgk2Dc7cAVQ0xY/IZZdxkIBXHQfWrWthyVdwODziqAYxyAj7vpXfTVo6HVFXiaVoEf5cYD0t2qwRHYN3TgVW81VYMc7j71bF1CtozFP3mPzpsizTuVLGXF0XnUnPVa0LqWGOLKZY9uelUwgLK6N+8bqtV7g4kKyA7u2Kas9i+XmZJptyX1CNGGWZuw5z613KQgWrbmGB26Vw2l26S6hG/wBx1OQBXbSHjAyRjGfSsKzV9DHEJXSRzGq3Mq3TJHHuQDJbGKxFLu7OThc9B1rqbqOLcSRuBOck4GKpR6fGT83yKzbiD2/GrhOKRcZqKJdLbai7PujnNRXk7W87SKygEdjVtlW1j/djcnQkc4rA1NhMXEbhMDPJrSnG7Mox55XMPXNT+1zkyH5x1rLuLyF9FFmLaMz+bv8AP/iA9Kk1S1thbpLHM7XRb94uOMVktjIPSvTpwVlY25Vaxg+KTstFQdWPXFcgw9sj1rd8VXJluxGhOI+v1rnmDl8r2r1aStFXPj8bNTrycdh24DcGA59KbgA/LjHrSHdzkA9yaXfgYIwenStDlFVehHrwfSjawGeCPUUB1HIIJIyKXdwTkfjQIZgk8Z9qlPytkj5sc+lMIG3IPNIw+XkHr07UASHlht4wck0wbt2AB1pFO7vg044AUg+/pQAAEHjIpiBi5IoYnbnOalRuDk4zxzQA3O4sT36+9Iqs2Mc+1OGCSO44oRgOF5z2oAUpgZyAPp0NI2eNufxp24lgOM9ceoph6+gHUZoAARyBnn0o2naccgHvR3PbNJnuD04oAcFKn9eaVsAYJIGccUgJ6EYGM+9JuyTu780AOVe4fp0z3pkzEwS46bG/lR/B/wDX60TcQSr32tx+FACQE+TDxnCDr9KkKgg8cnvTbfi3jAOAVH8qeOcduPXpQA0KS4UAljwMClKEHoRn8DQBj+Lp6GndOpyMcZoAZycnI59qDgEnBAHPFKAAMEkc96CD3zx+lAC9MkAj0pAi5HXOOvoaVucc8nmm4KjJ5PagBGQgED6ClxxjPB4p5I2rj6U/5cY5z296Aud/8I9Le61YSldqKwBYV9M2em2tpANPjtEjjkO83JGT+Brwz4L2Zuh5CF98mWCIeWAr3PSp7hIkRn8xkynlNyVrwcZNutLyPpsPBwwsEn5/eT/ZI7ZjHuYv0z0FW5YAbdHSRtzfLikC5tV+cLKW6EZP0qFpREWjlk2yEcA/zrzaj6hdy6iyQbEw3y7j2rOu/LQ8YCjj6mr0l06ZLuvmAcDHAHrWFql0hYAlcjJ4GK5pa7G1JSb1GXd3gkIRuXoxqk0zysBncOORUUhMjKo53cEmrscfkAFlGwYODxRGB0O0UZOvQqApJXB7VzwXMm4N8oORnvXQ31zBPcNu2grkfSuem2qxCAkfXpXXB3VjeinazLiW6llk4APPHenMInQupG5CQFqrFdRxxbMMPT2p1mnyszFlLHgVfqXytbhARFJuL5zzxUojSaQkkqSONxpNQiEKrHH8w7sBS6VGXkdh8zKMgH1qZaK9yunMbGh6eFmLcEeprrFszImGU89h/jWV4YgZyWk5fPA7V00ihAozjj5sDpXK25Ns83EVHzWOevdOWVljjjeGZj9085X1ql/Zs16zx26kqGwxHaug6SFyzELxuzkkfWo9Mjie4InZ1gJOVRiC3sTVwltcXtGlc5a6klsjIgA2gYK1zV89oZZfOST7vylOua7LXLfEknlxhRzglsn2rjVYxXkmWIBG1uO1dMEk20dmHfMrnH3ciSNwpD5/SsTW7z7Fas5HzNwK3tRiCzyGPO0NxmuN8ZSYEUZ+8ecZr2cOlJpGOaTlSw7lE5i4laWQu3JPX61EDgYAzzyKC24HHH1pjBmUbjg+vrXpHxg8AAE4OOwoJ+fB4B6/SmsnGRkjGelPC465PPbpmgCP931Jxz19KCCM/N+fWnbB7fXFKQcYFADd4C8524wPemMSeMD6elSt83PXpk00jPY57n1oACM8Y4b0FJjIOcdeMdqdyMZLc5wTTWz8qjHH4ZoAeu3oQcDrT8jj1HGDUexhgnHNPILAZPPoO9AhGKngZ9qaq9s+1PCE9O3PSkAG3djg8GgBByOfm5pSBgEYOe1KVyTtyQPWgrhsj9KAG7Sf4c59TSOTkYzn0pwJJ6gelBHoDj1oGM3cnOM9M0ucqCelB5OD1zxS7SHxk4oAWNRhjwAOaZKf9Hl542t2z2p4AG7n8Kimz5Um3jKMTj6UAEJPkRjPZR+gpxYhgAeM4oooAexJXPfcR+lRq7EZJ7f1oooAQMcg55xUjkjbjv1oooBin/WY7ZpuT170UUAKrHjn1oZiOlFFAI9k+EM0lsI54HZJQwAYHkZr2bw5I0ly8rnMjMxLHuaKK+cxv8Zn11BL6pB+RqamSlpvXhlkwD6cVTsv9IW6lmJeREG0k9OKKK4n8aFH4GxsjHyM554NYGosRdDmiioXxM6KW5HZsVvBg/xYq7fOxnUE8EHIooptalT+I5eLm+nU/dwTj3qA8Fj3xRRW/wBpHQmRhQSQR3FKkriMgMcDGKKKpFssvI5kiBYkFMkU/TySxOTmiisn8Iuh3Hg4kwsxPzE9a3r6VxA2D+lFFc0V7rfmeVXX70z53bI59O1Q2bEvLk9/60UU6e6/rqLoyLWhtKAdNorhdSAAlwAOTRRXYjpwmyOP1U4kcDpzXnfiz5rxc9loor2MFuYZ7/uy9TE2r83A4IH+fzppA3KMcZx+lFFemfIAoGF/GnKBsA7EHNFFIYhA+f2AIpkgHmkdulFFPqCEfhhj1oPQnviiigB6/NEgPOBx7VC/DSH0AoooW4Ikk+R8LxSHq4/2gP1oopASwjPHYmmgkAY6EEmiimgGNwRjuOaHGC3tiiigB6n5M9xSR8ySA9AcAfjRRQHQQn7w9UJqMMTJz/dzRRSBEqqMEYHB/wAKWYfuJ/8AcP8AI0UUIXU//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This tumor, which occupies a small uterine cavity, grows primarily as a firm polypoid mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Silverberg SG, Kurman RJ. tumors of the Uterine Corpus and Gestational Trophoblastic Disease. AFIP Atlas of Tumor Pathology, version 2.0, American Registry of Pathology, Washington DC 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_7_10358=[""].join("\n");
var outline_f10_7_10358=null;
var title_f10_7_10359="Insulin NPH: Drug information";
var content_f10_7_10359=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin NPH: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/55/42868?source=see_link\">",
"    see \"Insulin NPH: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/23/3446?source=see_link\">",
"    see \"Insulin NPH: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2135494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HumuLIN&reg; N;",
"     </li>",
"     <li>",
"      NovoLIN&reg; N",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2136088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humulin&reg; N;",
"     </li>",
"     <li>",
"      Novolin&reg; ge NPH",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2135498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Insulin, Intermediate-Acting",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2135530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Insulin NPH is an intermediate-acting insulin formulation which is usually administered subcutaneously once or twice daily. When compared to insulin regular, insulin NPH has a slower onset and longer duration of activity. Insulin requirements vary dramatically between patients and dictate frequent monitoring and close medical supervision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General insulin dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses are utilized and guided by blood glucose monitoring. Combinations of different insulin formulations are commonly used. The daily doses presented below are expressed as the",
"     <b>",
"      total units/kg/day of all insulin formulations combined.",
"     </b>",
"     Insulin NPH is",
"     <b>",
"      not",
"     </b>",
"     intended for initial therapy; basal insulin requirements should be established",
"     <b>",
"      first",
"     </b>",
"     to direct dosing of combination insulin products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     SubQ: 0.5-1 units/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Division of daily insulin requirement (\"conventional therapy\"):",
"     </b>",
"     Generally, 50% to 75% of the total daily dose (TDD) is given as an intermediate-acting (eg, NPH) or a long-acting form of insulin (in 1-2 daily injections). The remaining portion of the TDD is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting or short-acting form of insulin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. Treatment and monitoring regimens must be individualized. Also see Additional Information or Pharmacotherapy Pearls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Diabetes mellitus, type 2:",
"     </b>",
"     Augmentation therapy (patients for which diet, exercise, weight reduction, and oral hypoglycemic agents have not been adequate): SubQ: Initial dosage of 0.2 units/kg/day or 10 units/day of an intermediate-acting (eg, NPH) or long-acting insulin administered at bedtime has been recommended. As an alternative, regular insulin or rapid-acting insulin formulations administered before meals have also been used. Dosage must be carefully adjusted.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2135529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/23/3446?source=see_link\">",
"      see \"Insulin NPH: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     SubQ: Children and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2328823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2186290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8102728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HumuLIN&reg; N: 100 units/mL (3 mL) [prefilled pen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HumuLIN&reg; N: 100 units/mL (3 mL, 10 mL) [vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NovoLIN&reg; N: 100 units/mL (10 mL) [vial]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Novolin&reg; ge NPH: 100 units/mL (3 mL) [NovolinSet&reg; prefilled syringe or PenFill&reg; prefilled cartridge]; 10 mL [vial]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2135496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2136098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ administration: In order to properly resuspend the insulin, vials should be carefully shaken or rolled several times, prefilled pens should be rolled between the palms ten times and inverted 180&deg; ten times, and cartridges should be inverted 180&deg; at least ten times. Properly resuspended insulin NPH should look uniformly cloudy or milky; do not use if any white insulin substance remains at the bottom of the container, if any clumps are present, or if white particles are stuck to the bottom or wall of the container. Cold injections should be avoided. SubQ administration is usually made into the thighs, arms, buttocks, or abdomen; rotate injection sites. When mixing insulin NPH with other preparations of insulin (eg, insulin aspart, insulin glulisine, insulin lispro, insulin regular), insulin NPH should be drawn into the syringe",
"     <b>",
"      after",
"     </b>",
"     the other insulin preparations. Do not dilute or mix other insulin formulations with insulin NPH contained in a cartridge or prefilled pen. Insulin NPH is",
"     <b>",
"      not",
"     </b>",
"     recommended for use in external SubQ insulin infusion pump.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2136092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     A universal sterile diluent, Sterile Diluent for Humalog&reg;, Humulin&reg; N, Humulin&reg; R, Humulin&reg; 70/30, and Humulin&reg; R U-500, is available from the manufacturer for SubQ administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Insulin aspart, insulin glulisine, insulin lispro, insulin regular.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Insulin detemir, insulin glargine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2135501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM) and type 2 diabetes mellitus (noninsulin dependent, NIDDM) to improve glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8102725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gestational diabetes mellitus (GDM)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2136087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HumuLIN&reg; N may be confused with HumuLIN&reg; R, HumaLOG&reg;, Humira&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       NovoLIN&reg; N may be confused with NovoLIN&reg; R, NovoLOG&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2135511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily symptoms of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy or hypertrophy of SubQ fat tissue; edema, itching, pain or warmth at injection site; stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, local and/or systemic hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2136091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to insulin NPH or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2135506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from increased work or exercise without eating; use of long-acting insulin preparations (eg, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage or even death. Insulin requirements may be altered during illness, emotional disturbances or other stressors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Insulin (especially I.V. insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium and supplement potassium when necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Insulin NPH is",
"     <b>",
"      NOT",
"     </b>",
"     intended for I.V. or I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Diabetes mellitus: The general objective of exogenous insulin therapy is to approximate the physiologic pattern of insulin secretion which is characterized by two distinct phases. Phase 1 insulin secretion suppresses hepatic glucose production and phase 2 insulin secretion occurs in response to carbohydrate ingestion; therefore, exogenous insulin therapy may consist of basal insulin (eg, intermediate- [insulin NPH] or long-acting insulin or via continuous subcutaneous insulin infusion [CSII]) and/or preprandial insulin (eg, short- or rapid-acting insulin) (see Related Information: Insulin Products). Patients with type 1 diabetes do not produce endogenous insulin; therefore, these patients require both basal and preprandial insulin administration. Patients with type 2 diabetes retain some beta-cell function in the early stages of their disease; however, as the disease progresses, phase 1 insulin secretion may become completely impaired and phase 2 insulin secretion becomes delayed and/or inadequate in response to meals. Therefore, patients with type 2 diabetes may be treated with oral antidiabetic agents, basal insulin, and/or preprandial insulin depending on the stage of disease and current glycemic control. Since treatment regimens often consist of multiple agents, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control. Treatment and monitoring regimens must be individualized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2135518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2135517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2135520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Use caution with ethanol; may increase risk of hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Use caution with alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle; may increase risk of hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2135504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is &gt;1% above the normal range. Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28-32 weeks of gestation. Following delivery, insulin requirements decrease rapidly. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the fetus and the mother. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2136089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2136090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Endogenous insulin distributes into  breast milk. Plasma glucose concentrations in the mother affect glucose concentrations in breast milk. The gastrointestinal tract destroys insulin when administered orally; therefore, insulin is not expected to be absorbed intact by the breast-feeding infant. All types of insulin are safe for use while breast-feeding. Due to increased calorie expenditure, women with diabetes may require less insulin while nursing.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2136097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (HumuLIN N Pen Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (3 mL): $57.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (HumuLIN N Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (10 mL): $21.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (NovoLIN N ReliOn Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (10 mL): $90.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (NovoLIN N Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (10 mL): $90.95",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2136100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diabetes mellitus: Plasma glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2135525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Therapeutic, serum insulin (fasting): 5-20 &mu;IU/mL (SI: 35-145 pmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elderly: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes mellitus (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak postprandial capillary plasma glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Basal-H-Insulin (DE);",
"     </li>",
"     <li>",
"      Biohulin NPH (KP);",
"     </li>",
"     <li>",
"      Gensulin N (TH);",
"     </li>",
"     <li>",
"      Human Insulatard (IN);",
"     </li>",
"     <li>",
"      Human Protaphane (GB, IE);",
"     </li>",
"     <li>",
"      Huminsulin \"Lilly\" Basal (NPH) (AT);",
"     </li>",
"     <li>",
"      Huminsulin Basal (NPH) (CH, DE);",
"     </li>",
"     <li>",
"      Humulin I (IT);",
"     </li>",
"     <li>",
"      Humulin N (AE, AU, BB, BF, BG, BH, BJ, BM, BR, BS, BZ, CI, CO, CR, CY, DO, EE, EG, ET, GH, GM, GN, GT, GY, HK, HN, IL, IQ, IR, JM, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, OM, PA, PE, PK, PY, QA, SA, SC, SD, SL, SN, SR, SV, SY, TH, TN, TT, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Humulin NPH (DK, GR, PH, SE, TW);",
"     </li>",
"     <li>",
"      Humulina (ES);",
"     </li>",
"     <li>",
"      Humuline NPH (BE);",
"     </li>",
"     <li>",
"      Insulatard (DK);",
"     </li>",
"     <li>",
"      Insulatard HM (AE, BE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Insulatard Innolet (FR);",
"     </li>",
"     <li>",
"      Insulin \"Novo Nordisk\" Insulatard HM (AT);",
"     </li>",
"     <li>",
"      Insulin Insulatard Human (DE, TH);",
"     </li>",
"     <li>",
"      Insulin Protaphane HM (DE);",
"     </li>",
"     <li>",
"      Insulina Humulin (AR, CN);",
"     </li>",
"     <li>",
"      Insuline Humuline NPH (NL);",
"     </li>",
"     <li>",
"      Insuline Insulatard (NL);",
"     </li>",
"     <li>",
"      Insuline Isuhuman Basal (NL);",
"     </li>",
"     <li>",
"      Insuman (EC);",
"     </li>",
"     <li>",
"      Insuman Basal (DE);",
"     </li>",
"     <li>",
"      Novolet N (KP);",
"     </li>",
"     <li>",
"      Novolin N (CL, KP, MX);",
"     </li>",
"     <li>",
"      Protaphane HM (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, HK, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, OM, PH, QA, SA, SC, SD, SL, SN, SY, TH, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Ranisulin-N (PH);",
"     </li>",
"     <li>",
"      Scilin N (HK, PH);",
"     </li>",
"     <li>",
"      Umuline NPH (FR);",
"     </li>",
"     <li>",
"      Umuline Protamine Isophane (FR);",
"     </li>",
"     <li>",
"      Wosulin-N (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2135523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Saccharomyces cerevisiae",
"     </i>",
"     . Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin NPH, an isophane suspension of human insulin, is an intermediate-acting insulin.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2136093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Rate of absorption, onset, and duration of activity may be affected by site of injection, exercise, presence of lipodystrophy, local blood supply, and/or temperature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peak effect: 4-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 14-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/7/10359/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/7/10359/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies M, Storms F, Shutler S, et al, &ldquo;Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2005, 28(6):1282-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/7/10359/abstract-text/15920040/pubmed\" id=\"15920040\" target=\"_blank\">",
"        15920040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 20078, 32(Suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/7/10359/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/7/10359/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/7/10359/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverstein J, Klingensmith G, Copeland K, et al, &ldquo;Care of Children and Adolescents With Type 1 Diabetes: A Statement of the American Diabetes Association,&rdquo;",
"      <i>",
"       Diabetes Care,",
"      </i>",
"      2005, 28(1):186-212.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/7/10359/abstract-text/15616254/pubmed\" id=\"15616254\" target=\"_blank\">",
"        15616254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9028 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-BE5EBB4FC7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_7_10359=[""].join("\n");
var outline_f10_7_10359=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135494\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136088\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135498\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135530\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135529\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2328823\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2186290\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102728\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104236\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950126\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135496\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136098\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136092\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135501\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102725\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136087\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135511\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136091\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135506\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135518\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135517\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135520\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135504\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136089\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136090\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136097\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422166\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136100\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135525\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869460\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135523\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136093\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9028\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9028|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/55/42868?source=related_link\">",
"      Insulin NPH: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/23/3446?source=related_link\">",
"      Insulin NPH: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_7_10360="Role of systemic glucocorticoid therapy in COPD";
var content_f10_7_10360=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of systemic glucocorticoid therapy in COPD",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/7/10360/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/7/10360/contributors\">",
"     Marcia L Erbland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/7/10360/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/7/10360/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/7/10360/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/7/10360/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/7/10360/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;After decades of use and study, there now appears to be only a limited role for systemic glucocorticoids (also called corticosteroids or steroids) in patients with chronic obstructive pulmonary disease (COPD), primarily in the setting of acute exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. Key issues regarding systemic glucocorticoid use in COPD will be addressed here. General issues regarding management of COPD, including the role of inhaled glucocorticoids, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5463?source=see_link\">",
"     \"Role of inhaled glucocorticoid therapy in stable COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both systemic and inhaled glucocorticoids are widely prescribed for patients with COPD. In part, the use of these agents in the management of COPD has been an extension of their use in asthma. In addition, this approach has been based on hypotheses that glucocorticoids might suppress inflammatory processes unique to COPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     The asthma perspective",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids have been shown to be beneficial in both acute and chronic asthma, and inhaled glucocorticoids have become a cornerstone in the management of persistent asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. Although most experts regard asthma and COPD as distinct diseases, some patients with obstructive lung disease cannot be clearly categorized even after careful clinical evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Whenever asthma remains a diagnostic possibility, glucocorticoids therapy may have an important role. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link&amp;anchor=H4#H4\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\", section on 'Interrelationships of COPD subtypes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, a small percentage of patients who have been carefully assessed as having typical COPD will manifest benefit, most often measured as an increase in FEV1, after a course of oral glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. Given the degree of overlap in diagnosis and treatment response, separate treatment approaches for asthma and COPD may seem futile in clinical practice, and even objective data from COPD studies may never fully dispel these concerns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Inflammation and COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with COPD suffer from chronic destructive changes in the lungs, in addition to acute exacerbations. The basic mechanisms of acute and chronic illness appear to be different, but some form of inflammation plays a role in each setting. The earliest lesion in smoking-related COPD may be chronic inflammation of distal airways, and inflammatory factors have also been proposed as a cause for some acute exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/5,16,17\">",
"     5,16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6089?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Risk factors and risk reduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=see_link\">",
"     \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL EVIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical value of systemic glucocorticoid therapy has been assessed both in patients with acute exacerbations, and in those with stable COPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acute exacerbations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because acute exacerbations contribute substantially to the morbidity and medical cost of COPD, treatment that could prevent or ameliorate exacerbations is of great interest. Two major systematic reviews combined the results of double blind, randomized, placebo-controlled trials of systemic glucocorticoids in patients with acute exacerbations of COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/7,18\">",
"     7,18",
"    </a>",
"    ]. Although the quality and results of individual trials varied widely, the reviewers concluded that systemic (oral or intravenous) glucocorticoids reduced treatment failure and increased the rate of improvement in lung function and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/7,18\">",
"     7,18",
"    </a>",
"    ]. The benefits of glucocorticoids appear to be greatest in the first 72 hours after administration; risks associated with glucocorticoid therapy include hyperglycemia and other adverse drug reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hospitalized patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have demonstrated that patients hospitalized for COPD exacerbations benefit from systemic glucocorticoid therapy. The optimal dose and duration remain unclear. However, examination of the data suggests that 10 to 14 day regimens of systemic glucocorticoid that begin with either a high or moderate dose can improve clinical outcomes (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"UTD.htm?41/61/42972\">",
"     table 1",
"    </a>",
"    ). Direct comparisons of high versus lower-dose regimens are needed to determine the ideal initial dose. Oral therapy appears adequate when patients are able to eat. Details of the studies that have led to these conclusions are discussed in the following paragraphs.",
"   </p>",
"   <p>",
"    In the most comprehensive trial to date, the Veterans Affairs Cooperative Study of Systemic Corticosteroids in COPD Exacerbations (SCCOPE) randomly assigned 271 patients (FEV1 at entry 767 mL) to receive either a 2-week or an 8-week course of systemic glucocorticoids or placebo, starting within a few hours after hospital admission [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/3\">",
"     3",
"    </a>",
"    ]. Active treatment consisted of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (125 mg IV every six hours) for three days, followed by a tapering course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . Other aspects of treatment were standardized, and the patients were followed for six months.",
"   </p>",
"   <p>",
"    The primary endpoint was a composite of treatment failure, comprised of intensification of pharmacologic therapy, readmission for COPD, intubation, or death; secondary endpoints included length of stay and changes in FEV1. The 2-week and 8-week glucocorticoid-treated groups behaved similarly and were combined for further analysis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 30 and 90 days, the rate of treatment failure was about 10 percent lower in the glucocorticoid-treated patients than in the placebo group (30 day failure rate 23 percent versus 33 percent, p = 0.04; at 90 days, 37 percent versus 48 percent, p = 0.04).",
"     </li>",
"     <li>",
"      By six months, about one-half of all patients suffered at least one treatment failure regardless of therapy.",
"     </li>",
"     <li>",
"      The glucocorticoid group had a shorter hospital stay (8.5 versus 9.7 days) and more rapid improvement in FEV1.",
"     </li>",
"     <li>",
"      Compared with placebo, glucocorticoid therapy caused more hyperglycemia severe enough to require addition or change in glucose-controlling medication, but which did not require stopping the study medication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the SCCOPE data were analyzed according to planned subgroups, the reduction in early treatment failures appeared to have occurred primarily in patients who had been hospitalized for COPD within the prior two years. While some critics would discount even planned subgroup analyses, there were 184 patients in this subgroup, making it larger than the total number enrolled in several other studies altogether, and giving some weight to these findings.",
"   </p>",
"   <p>",
"    The benefit of glucocorticoid therapy was confirmed in a smaller study, which compared a lower dose of oral glucocorticoids to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/4\">",
"     4",
"    </a>",
"    ]. In this trial, 56 patients hospitalized for acute exacerbations were randomly assigned to receive either 30 mg of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    or placebo daily for 14 days. The prednisolone group had a more rapid increase in FEV1, fewer withdrawals, and a significantly shorter hospital stay (median length of stay 7 versus 9 days).",
"   </p>",
"   <p>",
"    The duration of systemic glucocorticoid therapy required to achieve a reasonable benefit has also been assessed in one small study. In a randomized single blind trial of 36 patients, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    was administered four times daily for three days only compared with three days of the same methylprednisolone plus seven more days on a tapering schedule (total of 10 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/19\">",
"     19",
"    </a>",
"    ]. The 10-day group had greater improvements in the primary endpoints of FEV 1 and PaO2 and a small but statistically significant improvement in dyspnea on exertion. Exacerbation rates over the next six months were not different between groups. The authors concluded that a 10-day treatment protocol was superior to a three-day treatment; however, the study did not demonstrate that these differences were linked to clinical recovery or rates of relapse.",
"   </p>",
"   <p>",
"    Oral and intravenous glucocorticoid administration have been found equally effective in the treatment of asthma exacerbations, which is not surprising due to the excellent bioavailability of oral glucocorticoids (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    ). To address the same question in hospitalized patients with COPD, a non-superiority trial of 210 patients compared regimens of intravenous versus oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , 60 mg once daily for five days, followed by oral prednisolone in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/20\">",
"     20",
"    </a>",
"    ]. The study concluded that oral glucocorticoid was not inferior to intravenous for the primary endpoint of treatment failure. A potential confounding factor was that the large majority of patients (77 percent) had been treated with oral glucocorticoids in the 30 days prior to admission, though post-hoc subgroup analyses suggested that this did not influence the results. However, this factor may explain why the hospital length of stay and overall treatment failure rate were higher in this study than other similar studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Outpatient exacerbations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Though they differ in severity, inpatient and outpatient exacerbations probably have similar etiologies. However, determining what constitutes an exacerbation and defining successful resolution can be more problematic in the outpatient setting, making it difficult to determine if glucocorticoid therapy improves outcome. In general, it appears that glucocorticoids have a small, but significant clinical effect in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/6,21\">",
"     6,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A well-executed randomized placebo-controlled trial prospectively evaluated 147 patients discharged from the emergency department after presenting with an acute exacerbation of COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients received oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (40 mg) or placebo for ten days. Patients who received prednisone were less likely to return to the emergency department or their clinician with increasing dyspnea within 30 days (27 versus 43 percent) (",
"    <a class=\"graphic graphic_figure graphicRef60719 \" href=\"UTD.htm?40/20/41293\">",
"     figure 1",
"    </a>",
"    ). In addition to a lower rate of relapse (the primary end point of the study), prednisone therapy was associated with decreased dyspnea and a greater improvement in FEV1 (34 versus 15 percent) on day 10.",
"   </p>",
"   <p>",
"    All of the studies in acute exacerbations excluded patients who had recently used systemic glucocorticoids, which in some cases eliminated nearly one-half of all screened patients. This exclusion does not create a major treatment dilemma, since clinicians would not be likely to withhold glucocorticoids from a glucocorticoid-dependent patient during periods of acute illness. However, it could affect the magnitude of the treatment benefits that would occur in an unselected population of hospitalized COPD patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Stable COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aside from the studies described above, most information on systemic glucocorticoids in outpatients with COPD has been derived from small, short-term studies in stable patients. These studies have differed widely in design and results, making overall conclusions difficult. The findings of several representative studies are presented below.",
"   </p>",
"   <p>",
"    One study has often been cited in favor of glucocorticoid use [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/15\">",
"     15",
"    </a>",
"    ]. Forty-six stable outpatients with COPD received either oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (32 mg per day) or placebo for two weeks in a double blind, crossover trial. Since increases in FEV1 of almost 30 percent could be seen with placebo, \"glucocorticoid response\" was defined as an increase in FEV1 ranging from 29 to more than 50 percent. Six of the 46 patients (14 percent) were determined to be \"glucocorticoid-responders\" by these criteria.",
"   </p>",
"   <p>",
"    Other authors found no benefit and determined that much of the favorable FEV1 response in previous studies could be explained by selection bias rather than by a therapeutic glucocorticoid effect [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/22\">",
"     22",
"    </a>",
"    ]. Relatively few studies have examined other outcomes along with FEV1; in one such report, neither exercise capacity nor FEV1 improved, and there was no correlation between the two [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three groups of authors have used meta-analysis to evaluate combined data from the best-designed outpatient studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/1,2,24\">",
"     1,2,24",
"    </a>",
"    ]. One group found that, while trials favoring a glucocorticoid benefit tended to have better design than negative trials, the evidence for efficacy was still unconvincing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent report evaluated ten studies that met certain quality criteria, and concluded that only 10 percent of patients had a significant (defined as 20 percent or more) glucocorticoid-related increase in FEV1 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/1\">",
"     1",
"    </a>",
"    ]. Finally, a review by the Cochrane group found no evidence of benefit for low-dose oral glucocorticoid therapy (10 to 15 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ) and noted significant short-term effects only at higher daily doses (20 to 30 mg prednisolone) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/24\">",
"     24",
"    </a>",
"    ]. Higher doses were also associated with an increased risk of complications over time, including osteoporosis, hypertension and diabetes, thus the authors concluded that long-term use of oral glucocorticoids was not helpful for the large majority of patients.",
"   </p>",
"   <p>",
"    All of these meta-analyses identified significant methodologic problems in even the best of the available trials, and few were carried out in a way that is completely relevant to the questions asked in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Clinical implications of prednisone response",
"    </span>",
"    &nbsp;&mdash;&nbsp;It appears unlikely that the response to a brief trial of oral glucocorticoids can predict which patients will have a more favorable response to chronic therapy with inhaled glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. The largest study that examined this question was a retrospective analysis of data collected during the ISOLDE trial (n=524) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/27\">",
"     27",
"    </a>",
"    ]. The change in FEV1 during a 14 day trial of systemic glucocorticoid therapy (0.6 mg per kg oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    per day) did not predict the change in FEV1 over three years of subsequent therapy with inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    . Other clinically relevant COPD outcomes were not reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5463?source=see_link\">",
"     \"Role of inhaled glucocorticoid therapy in stable COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another question is whether responsiveness to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    might help to predict prognosis in COPD. In a year long trial, investigators studied a group of patients with COPD who had a significant FEV1 response following a two-week course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/26\">",
"     26",
"    </a>",
"    ]. These prednisolone \"responders\", all of whom were treated with inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    (800",
"    <span class=\"nowrap\">",
"     mcg/day),",
"    </span>",
"    were compared to similar patients without a significant initial response to prednisolone. After one year, prednisolone responders had significantly better pulmonary function than non-responders. Non-responders had no improvement in FEV1, regardless of whether they received inhaled glucocorticoids. Because there was no randomization of prednisolone-responders to a placebo group, this observational study could not determine whether the outcomes in the prednisolone-responders were a result of the subsequent treatment with inhaled glucocorticoids, or were simply indicative of a different baseline prognosis.",
"   </p>",
"   <p>",
"    Despite continued efforts to study glucocorticoid responsiveness, definitive data on the role of glucocorticoid-response testing in COPD patients are lacking, perhaps due to the overall difficulty in assessing response or differences in patient populations tested. However, many important questions about the role of inhaled glucocorticoids in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    -responders have simply not been studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Chronic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic daily doses of oral glucocorticoids have been prescribed for some patients. This practice develops in response to various clinical situations, including expectations that acute benefits might be prolonged or that therapy would alter the natural course of the disease. Only two published studies have addressed whether long-term glucocorticoid therapy might retard the progression of COPD, and both suffered from a retrospective design [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    in doses above 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    appeared to have a beneficial effect on FEV1, but a reduction in mortality could not be demonstrated.",
"   </p>",
"   <p>",
"    Patients and their clinicians may also relate worsening symptoms or exacerbations to the reduction or withdrawal of systemic glucocorticoids. In this setting, patients may be labeled \"glucocorticoid-dependent\" and kept on oral glucocorticoids indefinitely, with patients and practitioners alike reluctant to make any changes.",
"   </p>",
"   <p>",
"    This issue was addressed in a prospective, randomized, blinded trial of 38 \"glucocorticoid-dependent\" COPD patients who were assigned either to continue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at their usual daily doses (continuous group) or to follow a planned taper-and-stop schedule (demand group) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/30\">",
"     30",
"    </a>",
"    ]. There were no differences in exacerbations, spirometry, dyspnea, or health-related quality of life between the two groups during the six-month study, even though the demand group took considerably less prednisone than the continuous group. Both groups had fairly high exacerbation rates. These results suggest that \"glucocorticoid dependence\" may be more a function of a treatment imperative in severe COPD than of glucocorticoid benefit. The study's limitations include small size and possible selection bias due to enrollment of only a fifth of target subjects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential for serious adverse effects is a key element of the glucocorticoid dilemma. Adverse effects attributed to systemic glucocorticoids therapy include weight gain, easy bruisability, hypertension, glucose intolerance, epigastric complaints, infection, osteoporosis and fractures, myopathy, adrenal suppression, and cataracts [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/7,31\">",
"     7,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Short-term therapy and complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a general perception that short-term therapy, even at high doses, is relatively innocuous, but these effects have not been fully studied in patients with COPD. The SCCOPE trial was the first to prospectively evaluate a number of specific complications in COPD patients treated with glucocorticoids. SCCOPE assessed the incidence of hyperglycemia, infections, hypertension, GI bleeding, and psychiatric disorders in patients treated with two-week and eight-week courses of systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/3\">",
"     3",
"    </a>",
"    ]. Only hyperglycemia was more common in the glucocorticoid-treated groups, although part of the excess could be attributed to the fact that more diabetics were, by chance, assigned to the glucocorticoids groups. More miscellaneous adverse effects were reported in the glucocorticoid group, but these could not be identified as glucocorticoid effects.",
"   </p>",
"   <p>",
"    The overall rate of infections observed in SCCOPE was no different among treatment groups, but patients who received the eight-week course of glucocorticoids had a tendency to have more severe infections, particularly pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/3\">",
"     3",
"    </a>",
"    ]. Other authors have reported severe infections related to immunosuppression in patients with COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In addition, patients treated with short-term, high-dose glucocorticoids for septic shock have a significantly increased risk of secondary bacterial infection and an increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link&amp;anchor=H27#H27\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Risks of chronic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged courses of glucocorticoid therapy are generally thought to pose a greater risk for complications, particularly osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Systemic glucocorticoid therapy has been shown to be associated with a greater number and severity of vertebral fractures in COPD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Respiratory muscle dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effects of glucocorticoids on respiratory muscle function are well described [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/38\">",
"     38",
"    </a>",
"    ], and a glucocorticoid-induced respiratory muscle myopathy has been clearly demonstrated in a number of animal studies. Human subjects with autoimmune disease have developed significant reductions in inspiratory strength and endurance after eight weeks of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/39\">",
"     39",
"    </a>",
"    ]. One study in patients with COPD admitted to the hospital for exacerbations suggested that higher average daily doses of glucocorticoids prior to hospitalization caused reductions in inspiratory and quadriceps muscle strength [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/40\">",
"     40",
"    </a>",
"    ]. Although not conclusive, these data raise additional concerns about glucocorticoid treatment in COPD patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28549?source=see_link\">",
"     \"Respiratory muscle training and resting in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/52/14148?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some form of glucocorticoid-responsive inflammation appears to be present in a percentage of acute exacerbations. Overall, benefits in acutely ill patients are modest and benefits in stable patients are uncommon, reflecting COPD as a generally non-glucocorticoid-sensitive process that is distinct from asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Acute exacerbations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids hasten recovery, reduce hospital stay, and reduce early treatment failure in patients with acute exacerbations of COPD. No more than two weeks of therapy are needed; shorter courses may achieve adequate outcomes but need further study. Although the optimum initial daily dose remains to be determined, there is no reason to believe that intravenous therapy is better than oral therapy for patients who are able to take oral medication.",
"   </p>",
"   <p>",
"    When treating patients with severe exacerbations of COPD, we use a compromise approach to dosing; we administer one or more high doses (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    80 to 125 mg) in the first 24 hours with rapid conversion to lower-dose therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    40 to 60 mg per day) if the patient is improving (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"UTD.htm?41/61/42972\">",
"     table 1",
"    </a>",
"    ). A reasonable alternative is to use a regimen of prednisone or its equivalent in doses of 30 to 60 mg per day for the duration of therapy.",
"   </p>",
"   <p>",
"    While the above studies provide a rationale for treating all patients with COPD exacerbations with a short course of systemic glucocorticoids, data from SCCOPE would support some targeting of therapy based on prior hospitalizations, risk of adverse effects and clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/3\">",
"     3",
"    </a>",
"    ]. Selected outpatients with acute exacerbations may also benefit from a course of systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10360/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Stable COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since not all patients with obstructive lung disease can be placed in precise subgroups of COPD or asthma, it is likely that glucocorticoids will always have a role in selected patients with COPD. Better morphologic studies may one day be helpful in selecting specific subgroups of patients for glucocorticoid studies and treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link&amp;anchor=H4#H4\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\", section on 'Interrelationships of COPD subtypes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    About 10 percent of stable COPD patients will manifest improvement, most often in terms of an increase in FEV1, after a course of oral glucocorticoids. This finding encourages therapeutic trials in selected stable patients. However, the most commonly observed improvements are small and of uncertain clinical relevance, and there are a number of potential pitfalls in the conduct and evaluation of glucocorticoid trials. Compulsory systemic glucocorticoid trials in all symptomatic COPD outpatients cannot be supported by existing data. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By prescribing only a short course of systemic glucocorticoids when necessary for an individual exacerbation, applying some clinical skepticism in evaluating and treating \"glucocorticoid-dependent\" patients, and optimizing all other proven therapies, practitioners may be able to reduce the total systemic glucocorticoids exposure of COPD patients while achieving as good or better outcomes.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/1\">",
"      Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 1991; 114:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/2\">",
"      Stoller JK, Gerbarg ZB, Feinstein AR. Corticosteroids in stable chronic obstructive pulmonary disease: reappraisal of efficacy. J Gen Intern Med 1987; 2:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/3\">",
"      Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/4\">",
"      Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/5\">",
"      Boushey HA. Glucocorticoid therapy for chronic obstructive pulmonary disease. N Engl J Med 1999; 340:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/6\">",
"      Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003; 348:2618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/7\">",
"      Walters JA, Gibson PG, Wood-Baker R, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009; :CD001288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/8\">",
"      Kay AB. Asthma and inflammation. J Allergy Clin Immunol 1991; 87:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/9\">",
"      Loren ML, Chai H, Leung P, et al. Corticosteroids in the treatment of acute exacerbations of asthma. Ann Allergy 1980; 45:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/10\">",
"      Fanta CH, Rossing TH, McFadden ER Jr. Glucocorticoids in acute asthma. A critical controlled trial. Am J Med 1983; 74:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/11\">",
"      Littenberg B, Gluck EH. A controlled trial of methylprednisolone in the emergency treatment of acute asthma. N Engl J Med 1986; 314:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/12\">",
"      Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 1987; 136:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/13\">",
"      Gross NJ. COPD: a disease of reversible air-flow obstruction. Am Rev Respir Dis 1986; 133:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/14\">",
"      Anthonisen NR, Wright EC. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/15\">",
"      Mendella LA, Manfreda J, Warren CP, Anthonisen NR. Steroid response in stable chronic obstructive pulmonary disease. Ann Intern Med 1982; 96:17.",
"     </a>",
"    </li>",
"    <li>",
"     Niewoehner, DE, McGowan, SE. Cigarette smoking and the development of chronic airflow obstruction. In: Current Pulmonology, Simmons, D (Eds), Year Book Medical Publishers, Chicago 1986. Vol Vol. 7, p.23.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/17\">",
"      Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/18\">",
"      Singh JM, Palda VA, Stanbrook MB, Chapman KR. Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review. Arch Intern Med 2002; 162:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/19\">",
"      Sayiner A, Aytemur ZA, Cirit M, Unsal I. Systemic glucocorticoids in severe exacerbations of COPD. Chest 2001; 119:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/20\">",
"      de Jong YP, Uil SM, Grotjohan HP, et al. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest 2007; 132:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/21\">",
"      Thompson WH, Nielson CP, Carvalho P, et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/22\">",
"      Eliasson O, Hoffman J, Trueb D, et al. Corticosteroids in COPD. A clinical trial and reassessment of the literature. Chest 1986; 89:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/23\">",
"      Strain DS, Kinasewitz GT, Franco DP, George RB. Effect of steroid therapy on exercise performance in patients with irreversible chronic obstructive pulmonary disease. Chest 1985; 88:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/24\">",
"      Walters JA, Walters EH, Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; :CD005374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/25\">",
"      Shim CS, Williams MH Jr. Aerosol beclomethasone in patients with steroid-responsive chronic obstructive pulmonary disease. Am J Med 1985; 78:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/26\">",
"      Davies L, Nisar M, Pearson MG, et al. Oral corticosteroid trials in the management of stable chronic obstructive pulmonary disease. QJM 1999; 92:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/27\">",
"      Burge PS, Calverley PM, Jones PW, et al. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003; 58:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/28\">",
"      Postma DS, Steenhuis EJ, van der Weele LT, Sluiter HJ. Severe chronic airflow obstruction: can corticosteroids slow down progression? Eur J Respir Dis 1985; 67:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/29\">",
"      Postma DS, Peters I, Steenhuis EJ, Sluiter HJ. Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? Eur Respir J 1988; 1:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/30\">",
"      Rice KL, Rubins JB, Lebahn F, et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. Am J Respir Crit Care Med 2000; 162:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/31\">",
"      Dujovne CA, Azarnoff DL. Clinical complications of corticosteroid therapy. A selected review. Med Clin North Am 1973; 57:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/32\">",
"      Wiest PM, Flanigan T, Salata RA, et al. Serious infectious complications of corticosteroid therapy for COPD. Chest 1989; 95:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/33\">",
"      Smyllie HC, Connolly CK. Incidence of serious complications of corticosteroid therapy in respiratory disease. A retrospective survey of patients in the Brompton hospital. Thorax 1968; 23:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/34\">",
"      Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/35\">",
"      Lieberman, P, Patterson, R, Kunske, R. Complications of long-term glucocorticoid therapy for asthma. J Allergy Clin Immunol 1972; 19:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/36\">",
"      Kwong FK, Sue MA, Klaustermeyer WB. Corticosteroid complications in respiratory disease. Ann Allergy 1987; 58:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/37\">",
"      McEvoy CE, Ensrud KE, Bender E, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/38\">",
"      Gallagher CG. Respiratory steroid myopathy. Am J Respir Crit Care Med 1994; 150:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/39\">",
"      Weiner P, Azgad Y, Weiner M. The effect of corticosteroids on inspiratory muscle performance in humans. Chest 1993; 104:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10360/abstract/40\">",
"      Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994; 150:11.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1438 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_7_10360=[""].join("\n");
var outline_f10_7_10360=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      The asthma perspective",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Inflammation and COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL EVIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acute exacerbations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hospitalized patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Outpatient exacerbations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Stable COPD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Clinical implications of prednisone response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Chronic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Short-term therapy and complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Risks of chronic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Respiratory muscle dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Acute exacerbations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Stable COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1438\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1438|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/20/41293\" title=\"figure 1\">",
"      Glucocorticoids outpt COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1438|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/61/42972\" title=\"table 1\">",
"      Relative potency glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6089?source=related_link\">",
"      Chronic obstructive pulmonary disease: Risk factors and risk reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=related_link\">",
"      Management of infection in acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/52/14148?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28549?source=related_link\">",
"      Respiratory muscle training and resting in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5463?source=related_link\">",
"      Role of inhaled glucocorticoid therapy in stable COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_7_10361="Management and outcome of thoracic aortic aneurysm";
var content_f10_7_10361=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management and outcome of thoracic aortic aneurysm",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/7/10361/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/7/10361/contributors\">",
"     Y Joseph Woo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/7/10361/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/7/10361/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/7/10361/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/7/10361/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/7/10361/contributors\">",
"     Edward Verrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/7/10361/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/7/10361/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/7/10361/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/7/10361/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thoracic aortic aneurysm can produce a variety of symptoms and complications, some of which are life-threatening such as acute aortic regurgitation and aortic leakage or rupture. Thus, appropriate medical and surgical therapy may be critical in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history, management, and outcome of thoracic aortic aneurysms will be reviewed here. Issues related to etiology, clinical presentation, and diagnosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22712?source=see_link\">",
"     \"Clinical features and diagnosis of thoracic aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although natural history data are not widely available, it has been suggested that patients with untreated large ascending or descending thoracic aneurysms are more likely to die of complications associated with their aneurysms than from any other cause [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/2\">",
"     2",
"    </a>",
"    ]. In several series of patients, aneurysm rupture occurred in 32 to 68 percent of medically treated patients and rupture accounted for 32 to 47 percent of deaths; the one-, three-, and five-year survival of unoperated thoracic aneurysms was 65, 36, and 20 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. However, the presence of concomitant cardiovascular disease may have an impact on mortality and, after rupture, is the most common cause of death (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53799 \" href=\"UTD.htm?40/9/41107\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The most important determinant of rupture is the size of the aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. One study of 133 patients found that the five-year risk of rupture was 0 percent for aneurysms less than 4.0 cm compared with 16 and 31 percent for aneurysms 4.0 to 5.9 and &ge;6.0 cm, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/6\">",
"     6",
"    </a>",
"    ]. In another series of 370 patients, the median diameter at the time of rupture or dissection was 5.9 cm for ascending aneurysms and 7.2 cm for descending aneurysms; a diameter greater than 6.0 cm increased the risk of rupture or dissection by 25 percent for an ascending aneurysm, while a diameter greater than 7.0 cm increased the risk by 37 percent in a descending aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/8\">",
"     8",
"    </a>",
"    ]. Aneurysms appear to rupture at smaller sizes in patients with Marfan syndrome or other connective tissue disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22712?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features and diagnosis of thoracic aortic aneurysm\", section on 'Etiology and pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a prospective study of 721 patients, the rate of dissection or rupture were 2, 3, and 7 percent per year for aneurysms less than 5.0 cm, 5.0 to 5.9 cm, and &ge;6.0 cm, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/9\">",
"     9",
"    </a>",
"    ]. Among patients with aneurysms &ge;6.0 cm, the combined end-point of rupture, dissection, or death occurred at a rate of 15.6 percent per year. The five-year rate of survival in patients with aneurysms &gt;6.0 cm was 56 percent. In patients who did not undergo surgery (diameter not specified), 54 percent were alive at five years. In comparison, elective surgery restored survival to a rate similar to a matched control population.",
"   </p>",
"   <p>",
"    However, even though the dissection rate increases with aortic diameter, most patients who present with dissection have smaller aneurysms because there are many more individuals in the population with thoracic aortic aneurysm diameters between 4.0 and 5.5 cm. This was demonstrated in a review of 591 patients with type A dissection (mean diameter 5.3 cm) enrolled in the International Registry of Acute Aortic Dissection (IRAD) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/10\">",
"     10",
"    </a>",
"    ]. Nearly 60 percent of patients had diameters &lt;5.5 cm, and 40 percent had aortic diameters &lt;5.0 cm. Current recommendations for elective surgery include patients with aneurysm size between 5.0 to 6.0 cm. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Indications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Aneurysm diameter increases by 1 to 10 mm per year [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/9,11,12\">",
"     9,11,12",
"    </a>",
"    ]. The rate of growth is related to the initial diameter, with larger aneurysms growing more quickly. This was illustrated in a study of 67 patients with thoracic aortic aneurysm who underwent serial CT imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/12\">",
"     12",
"    </a>",
"    ]. The rate of expansion was much greater for aneurysms more than 5.0 cm in diameter (7.9 versus 1.7 mm per year in smaller aneurysms) (",
"    <a class=\"graphic graphic_figure graphicRef59360 \" href=\"UTD.htm?12/46/13037\">",
"     figure 1",
"    </a>",
"    ); a history of hypertension did not affect the rate of aneurysm expansion.",
"   </p>",
"   <p>",
"    The anatomic location of the aneurysm is another factor associated with the rate of expansion. In a series of 87 patients who underwent serial CT or MRI imaging, aneurysms located within the mid portion of the descending aorta showed the most rapid growth, while those in the ascending aorta had the slowest expansion rate, despite having the greatest initial diameter (",
"    <a class=\"graphic graphic_figure graphicRef51157 \" href=\"UTD.htm?41/34/42541\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MEDICAL MANAGEMENT OF ASYMPTOMATIC ANEURYSMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic thoracic aortic aneurysms are detected on routine chest x-ray or during surveillance in a patient at risk from an underlying disorder such as Marfan syndrome or giant cell arteritis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79278 graphicRef66051 \" href=\"UTD.htm?37/10/38054\">",
"     image 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72571 \" href=\"UTD.htm?30/52/31566\">",
"     image 3",
"    </a>",
"    ). Asymptomatic patients with an aneurysm are initially managed medically, while surgery is indicated for symptomatic patients and for asymptomatic patients with rapid aneurysm expansion or a diameter greater than 5 to 6 cm in diameter, depending on body size. The cause of aortic dilation and other clinical factors are discussed below.",
"   </p>",
"   <p>",
"    For smaller patients, including many women, we recommend elective repair for aneurysms greater than twice the size of the nonaneurysmal aorta (normal segment) or for those with rapid expansion, defined as growth of more than 0.5 cm during a six-month interval.",
"   </p>",
"   <p>",
"    In the asymptomatic patient, medical management includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aggressive blood pressure control, with beta blockers being part of the regimen in an attempt to slow aneurysm growth.",
"     </li>",
"     <li>",
"      Surveillance for the development of signs and symptoms that may be associated with the aneurysm through patient education.",
"     </li>",
"     <li>",
"      Serial imaging of the aneurysm to evaluate growth and structure. The preferred imaging technique is CT scanning or MR angiography (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81919 graphicRef58395 \" href=\"UTD.htm?42/44/43714\">",
"       image 4A-B",
"      </a>",
"      ). Imaging should be repeated at six months after the initial study [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/1\">",
"       1",
"      </a>",
"      ]. Further imaging can be performed at yearly intervals if there is no growth, or at three to six months (according to aneurysm size) if there is a significant increase in aneurysm size from one study to another. Ideally, the serial studies should be performed with the same technique in the same center.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Beta blockers may be of particular benefit for reducing the rate of aortic dilatation, particularly in adults with Marfan syndrome. In a study in which 70 patients with Marfan syndrome were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    or no beta blocker therapy, the treated group had a 73 percent slower rate of aortic dilatation and a lower mortality after the first four years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/13\">",
"     13",
"    </a>",
"    ]. Beta-blockers are thought to act by decreasing left ventricular contractility",
"    <span class=\"nowrap\">",
"     (dp/dt)",
"    </span>",
"    and shear stress. The goal systolic pressure is 105 to 120 mmHg if tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not known if these results can be extrapolated to patients without Marfan syndrome, but it is biologically plausible to attempt such therapy. The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    valvular disease guidelines state that it is reasonable to give beta blockers to patients with bicuspid aortic valves and dilated aortic roots (diameter greater than 4.0 cm; consider lower threshold for patients of smaller stature) who are not candidates for surgical correction and who do not have moderate or severe aortic regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest beta blocker therapy in patients with thoracic aortic aneurysm who are being followed nonoperatively. Because of the possible benefit on aneurysm expansion, beta blockers are a preferred drug for the treatment of hypertension or angina. The adequacy of beta blockade is usually judged by the heart rate response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     THORACIC ANEURYSM REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repair of thoracic aortic aneurysm is often recommended prophylactically to prevent the morbidity and mortality associated with aneurysm rupture. However, the optimal timing of surgery for a thoracic aortic aneurysm is uncertain since the natural history is variable, particularly for aneurysms less than 5.0 cm in size [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/9\">",
"     9",
"    </a>",
"    ], and the majority of patients have concomitant cardiovascular disease that increases the risks associated with surgery. Thus, many patients die of other cardiovascular causes before the aneurysm ruptures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for repair of thoracic aortic aneurysm include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of symptoms, although most thoracic aortic aneurysms are asymptomatic.",
"     </li>",
"     <li>",
"      An end-diastolic aortic diameter of 5 to 6 cm for an ascending aortic aneurysm and 6 to 7 cm for a descending aortic aneurysm; often &ge;7 cm in high-risk patients [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/8,15\">",
"       8,15",
"      </a>",
"      ]. For smaller patients, including many women, elective repair is performed for aneurysms greater than twice the size of the nonaneurysmal aorta (normal segment).",
"     </li>",
"     <li>",
"      Replacement",
"      <strong>",
"       before",
"      </strong>",
"      aortic size index (aortic diameter (cm) divided by body surface area (m2)) for the ascending of aorta is 2.75",
"      <span class=\"nowrap\">",
"       cm/m2",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Accelerated growth rate (&ge;10 mm per year) in aneurysms less than 5 cm in diameter [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Evidence of dissection",
"     </li>",
"     <li>",
"      An ascending thoracic aortic aneurysm &gt;4.5 cm in diameter at the time of aortic valve surgery.",
"     </li>",
"     <li>",
"      In patients with aortic regurgitation of any severity and primary disease of the aortic root or ascending aorta (such as Marfan syndrome), the 2006",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      valvular disease guidelines recommend aortic valve replacement and aortic root reconstruction when the degree of dilatation is &ge;5 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/14\">",
"       14",
"      </a>",
"      ]. The guidelines note that some have recommended surgery for this group at a lower level of dilatation (4.5 cm) or based on a rate of increase of 0.5 cm per year or greater in surgical centers with established expertise in repair of the aortic root and ascending aorta [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Management of thoracic aortic dilation among patients with Marfan syndrome is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"       \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Preoperative evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to surgical intervention, the patient should undergo evaluation for risk assessment and the presence of atherosclerotic disease of other vessels. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preoperative assessment should include evaluation of left ventricular function and potential concomitant coronary artery disease.",
"     </li>",
"     <li>",
"      Patients with ascending aortic and particularly arch disease should undergo carotid artery duplex ultrasound examination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link\">",
"       \"Evaluation of carotid artery stenosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with descending thoracic aortic disease require left thoracotomy and should undergo pulmonary function testing if clinical symptoms of pulmonary disease are present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"       \"Overview of pulmonary function testing in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with thoracoabdominal aneurysm extension require delineation of any claudication history and a thorough arterial pulse examination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=see_link\">",
"       \"Examination of the arterial pulse\"",
"      </a>",
"      .) If the history or physical findings suggest peripheral artery disease (PAD), then noninvasive lower extremity pulse-volume recordings and pressures are indicated to determine the level and severity of disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link\">",
"       \"Noninvasive diagnosis of arterial disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Perioperative monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard cardiac surgery anesthetic techniques are applied in the perioperative setting. These include: monitoring of arterial, central venous, and pulmonary arterial pressures; establishing vascular access appropriate for high volumes and vasoactive agent infusion; intubation with a single or double lumen endotracheal tube as indicated; and active blood product management including recycling systems. Continuous transesophageal echocardiography to monitor both cardiac function and vascular flows is used routinely [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/20\">",
"     20",
"    </a>",
"    ]. Some surgeons routinely use somatosensory evoked potential monitoring during and after surgery for early detection of abnormal signals indicating spinal cord ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Open surgical technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location of the surgical incision depends upon the location of the aneurysm.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The standard incision for ascending and arch aneurysm repair is a median sternotomy.",
"     </li>",
"     <li>",
"      The standard incision for descending aneurysms is a left thoracotomy.",
"     </li>",
"     <li>",
"      For thoracoabdominal aneurysms, a left thoracotomy incision is extended across the costal margin for a retroperitoneal approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Open surgical repair of thoracic aneurysms resembles standard abdominal aortic aneurysm repair with proximal and distal vascular control, minimal aneurysm manipulation, and prosthetic graft repair. The most common technique of aneurysm repair entails Dacron graft interposition. End-organ revascularization is achieved with the distal anastomosis, native arterial reimplantation with or without endarterectomy, or bypass grafting with saphenous venous or prosthetic conduit.",
"   </p>",
"   <p>",
"    Aortic root involvement generally necessitates coronary artery reimplantation and may or may not require aortic valve replacement or repair [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. In a review of 203 patients (50 with Marfan syndrome) undergoing surgery for an aortic root aneurysm (involving the sinuses of Valsalva, the sinotubular junction, and the proximal ascending aorta) between 1971 and 2000, 149 underwent replacement of both the aortic root and the aortic valve, and 54 underwent aortic root reconstruction with preservation of the valve [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Vascular control",
"    </span>",
"    &nbsp;&mdash;&nbsp;One important difference between thoracic and abdominal aneurysm repair is the means for obtaining proximal vascular control during thoracic aneurysm repair. Thoracic aneurysm repair often requires cardiopulmonary bypass with a cardioplegia-arrested heart and specific circulatory measures to address end-organ protection of the brain, spinal cord, kidneys, liver, bowel, or lower extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In ascending aneurysm repair, protection against end-organ damage is accomplished with cardiopulmonary bypass and antegrade aortic perfusion distal to the aneurysm.",
"     </li>",
"     <li>",
"      In arch aneurysm repair, the need for open vascular access to the brachiocephalic orifices mandates interruption of cerebral blood-flow and the need for cerebral protection [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/28,29\">",
"       28,29",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Cerebral protection'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      In descending aortic aneurysm repair, the utility of adjunctive end-organ protective measures is unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/30\">",
"       30",
"      </a>",
"      ]. The degree of risk for this patient was illustrated in a series of over 1500 patients: paraparesis or paraplegia developed in 16 percent, while acute renal failure severe enough to require dialysis occurred in 7 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Initial reports found that a quick operation without adjunctive measures was sufficient for thoracoabdominal aneurysm repair [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. However, newer studies suggest that measures such as distal aortic perfusion via bypass circuitry [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/37\">",
"     37",
"    </a>",
"    ]; selective perfusion of renal, segmental, and visceral arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/27,38\">",
"     27,38",
"    </a>",
"    ]; cerebrospinal fluid drainage combined with intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/2/37923?source=see_link\">",
"     papaverine",
"    </a>",
"    in high-risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/39\">",
"     39",
"    </a>",
"    ]; intercostal reimplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/40\">",
"     40",
"    </a>",
"    ]; and profound hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/41,42\">",
"     41,42",
"    </a>",
"    ] markedly decrease the likelihood of renal, mesenteric and spinal ischemia, which can result in paraplegia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. As an example, one retrospective study of 132 patients found that reimplantation of the vessels between the eight thoracic intercostal and the second lumbar arteries reduced operative mortality (4.9 versus 13.2 percent for no reimplantation) and the incidence of postoperative paraplegia (0 versus 8.8 percent) or the overall rate of spinal cord dysfunction (2.4 versus 9.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perioperative monitoring of spinal pressure and active management of spinal perfusion (mean arterial pressure &ndash; spinal pressure of greater than 80 mmHg) has been shown to dramatically reduce and even reverse spinal cord injury in both open surgical as well as closed (endovascular) surgery, especially in higher-risk patients including those with renal dysfunction, PAD, long segment surgery and prior abdominal aortic aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not use selective renal perfusion or intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/2/37923?source=see_link\">",
"     papaverine",
"    </a>",
"    . We use hypothermia in selected cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cerebral protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three common methods of providing cerebral protection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With selective cerebral perfusion (SCP), antegrade cerebral blood-flow is reestablished via a graft anastomosed to the brachiocephalic vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/47\">",
"       47",
"      </a>",
"      ]. Although SCP is metabolically optimal, it is technically cumbersome and risks cerebral embolism and carotid dissection. A variation of SCP with a trifurcated graft and initial perfusion via the right axillary artery has also been described. This approach may reduce embolic complications [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/48,49\">",
"       48,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypothermic circulatory arrest (HCA) involves the use of cardiopulmonary bypass with the establishment of profound systemic hypothermia, followed by controlled exsanguination and total body circulatory standstill [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. HCA provides the best operative field visualization; however, stroke rates increase significantly after 45 minutes of arrest [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/52-54\">",
"       52-54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Retrograde cerebral perfusion (RCP) in which hypothermic circulatory arrest is used in conjunction with retrograde jugular venous perfusion with cold oxygenated blood [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/55-58\">",
"       55-58",
"      </a>",
"      ]. Deoxygenated blood containing cellular metabolic by-products returns via the carotid orifices. There is a significantly reduced risk of stroke with RCP compared with HCA. Controversy exists over whether RCP functions by providing neuronal metabolic support, by preserving cerebral autoregulation, or by enhancing cerebral cooling and permitting retrograde evacuation of air and debris from the intracranial circulation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/59-65\">",
"       59-65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Bicuspid aortic valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bicuspid aortic valves are often associated with ascending aortic aneurysms even in the absence of significant valve disease. In addition, the bicuspid valve usually becomes sclerotic, with progressive aortic stenosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regurgitation that ultimately requires valve replacement in over 75 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link&amp;anchor=H22#H22\">",
"     \"Course and management of chronic aortic regurgitation in adults\", section on 'Aortic disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend surgery to repair the aortic root or replace the ascending aorta in patients with bicuspid aortic valves if the diameter of the aortic root or ascending aorta is greater than 5 cm or if the rate of increase in diameter is 0.5 cm per year or more [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/14\">",
"     14",
"    </a>",
"    ]. A threshold lower than 5 cm is suggested for patients of small stature.",
"   </p>",
"   <p>",
"    In some patients, repair of the aortic aneurysm becomes necessary before aortic valve repair is indicated. In such cases, the bicuspid valve is often replaced at the time of aortic surgery. However, preservation of the native valve has been attempted in some cases. This approach was evaluated in a series of 21 patients from the Mayo Clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/66\">",
"     66",
"    </a>",
"    ]. At a median follow up of 2.5 years, only one patient required repeat surgery for aortic valve replacement.",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend that among patients with bicuspid aortic valves undergoing aortic valve replacement because of severe aortic stenosis or severe aortic regurgitation, repair of the aortic root or replacement of the ascending aorta is indicated if the diameter of the aortic root or ascending aorta is greater than 4.5 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/14\">",
"     14",
"    </a>",
"    ]. A lower threshold is suggested for patients of small stature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link&amp;anchor=H22#H22\">",
"     \"Course and management of chronic aortic regurgitation in adults\", section on 'Aortic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Endovascular repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of catheter-based intraluminal stent grafting in descending thoracic or thoracoabdominal aortic disease is undergoing active clinical investigation in both elective and emergency settings. Thoracic endovascular aortic repair is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37240?source=see_link\">",
"     \"Thoracic endovascular aneurysm repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morbidity and mortality in thoracic aneurysm repair are higher than most other elective vascular procedures given the anatomic constraints and operative complexity. The subsets of aortic arch and Crawford type II (proximal descending to infrarenal aorta) aneurysms have the highest morbidity and mortality rates.",
"   </p>",
"   <p>",
"    In studies documenting outcomes in open surgical procedures performed through the mid-1990s, it was not unusual to see overall 30-day postoperative mortality rates exceeding 10 percent, stroke rates of 20 percent with ascending and arch aneurysm repair, and spinal and renal injury rates of 15 percent with repair of a descending aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/31,53,58\">",
"     31,53,58",
"    </a>",
"    ]. In one series of 1509 patients who underwent open descending aneurysm repair, the overall mortality was 8 percent at 30 days and paraparesis or paraplegia developed in 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/31\">",
"     31",
"    </a>",
"    ]. In another report from the same group, the incidence of postoperative acute renal failure severe enough to require dialysis was 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/32\">",
"     32",
"    </a>",
"    ]. The long-term mortality and morbidity were related to other cardiovascular events, such as aneurysm in other areas, MI, and stroke.",
"   </p>",
"   <p>",
"    The risk of morbidity and mortality has decreased significantly in more recent series, perhaps attributable to improving technology and increased use of the end-organ protective adjuncts described above [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/27,39-41,43,44,67\">",
"     27,39-41,43,44,67",
"    </a>",
"    ]. The following illustrates the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 108 patients, the use of noninvasive diagnostic modalities and newer surgical techniques, including retrograde cerebral perfusion, led to a reduction in operative mortality (26 versus 3 percent), overall morbidity, and shorter hospital stay in 1994 to 1997 compared with 1987 to 1993 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/67\">",
"       67",
"      </a>",
"      ]. The 10-year actuarial survival was 57 percent; 93 percent of survivors were in NYHA class I or II.",
"     </li>",
"     <li>",
"      In a review of 360 patients with repair of the ascending aorta and arch, 95 patients with repair of the descending aorta, and 35 patients with thoracoabdominal aorta repair, the operative mortality for these predominantly elective procedures performed between 1995 and 2004 was 2.9, 3.0, and 11.9 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/68\">",
"       68",
"      </a>",
"      ]. The 10-year survival for the combined group was 73 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In order to establish factors associated with an adverse 30-day outcome (death, paraplegia, paraparesis, stroke, or acute renal failure requiring dialysis) after surgery for a thoracoabdominal aneurysm, one study retrospectively reviewed data on 1108 patients undergoing elective surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/69\">",
"     69",
"    </a>",
"    ]. The main adverse predictors included preoperative renal insufficiency, increasing age, symptomatic aneurysms, and Crawford type II aneurysms (proximal descending to infrarenal aorta).",
"   </p>",
"   <p>",
"    Emergency surgery for open thoracoabdominal aneurysm that has ruptured or dissected is associated with a substantial morbidity and mortality. In one series of 19 patients, for example, the 30 day mortality was 42 percent; there were serious postoperative complications in the surviving patients, including renal failure (36 percent of surviving patients), respiratory failure (36 percent), and paraplegia or paraparesis (27 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small number of patients who have undergone open repair of an ascending aorta or aortic root aneurysm may require reoperation because of insufficiency or stenosis of an aortic valve substitute, true or false aneurysm formation, acute dissection, or prosthetic valve endocarditis. In one study of 134 patients who required reoperation, hospital mortality was 6.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/71\">",
"     71",
"    </a>",
"    ]. Predictors of death were preoperative NYHA functional class III or IV, an interval of less than six months between the first and second surgeries, elevated preoperative creatinine level and need for postoperative dialysis, and acute aortic dissection as indication for repeat surgery. Freedom from repetitive reoperation was 98 percent at 5 and 10 years.",
"   </p>",
"   <p>",
"    The outcomes for endovascular repair of thoracic aortic aneurysm are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37240?source=see_link&amp;anchor=H9#H9\">",
"     \"Thoracic endovascular aneurysm repair\", section on 'Outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757960246\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The natural history of thoracic aortic aneurysm depends upon the location of the aneurysm, the maximal diameter of the aneurysm, and associated conditions (eg, Marfan syndrome). Aneurysm diameter increases by 1 to 10 mm per year with larger diameter aneurysms expanding more rapidly. Aneurysms located within the midportion of the descending aorta have a more rapid expansion rate compared with those in the ascending aorta, even though ascending aneurysms have a greater initial diameter. The most important determinant of rupture of thoracic aortic aneurysm is the diameter of the aneurysm, with aneurysm diameter &gt;6.0 cm associated with a 15.6 percent per year combined end-point of rupture, dissection, or death. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic thoracic aortic aneurysms and aneurysms in patients who are not candidates for repair are treated medically with blood pressure control using beta blocker therapy and serial evaluation. The goal systolic pressure is 105 to 120 mmHg. Beta-blockers are thought to act by decreasing left ventricular contractility and shear stress. The 2006",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      valvular disease guidelines state that it is reasonable to give beta blockers to patients with bicuspid aortic valves and dilated aortic roots (diameter greater than 4.0 cm; consider lower threshold for patients of smaller stature) who are not candidates for surgical correction and who do not have moderate or severe aortic regurgitation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Medical management of asymptomatic aneurysms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The asymptomatic patient with thoracic aortic aneurysm should be followed for the development of signs and symptoms that may be associated with the aneurysm. Serial imaging is performed using computed tomography (CT) scanning or magnetic resonance (MR) angiography six months after the initial study [",
"      <a class=\"abstract\" href=\"UTD.htm?10/7/10361/abstract/1\">",
"       1",
"      </a>",
"      ]. If the diameter of the aneurysm remains stable, further imaging can be performed annually. Ideally, serial studies should be performed using the same imaging technique at the same center. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Medical management of asymptomatic aneurysms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Repair of thoracic aortic aneurysm is performed to reduce the morbidity and mortality associated with aneurysm rupture. The timing of surgery for a thoracic aortic aneurysm depends upon the location of the aneurysm, maximal diameter, the patient&rsquo;s comorbidities and the presence of specific etiologies such as connective tissue disorders or aortic valve disease. The majority of patients have concomitant cardiac, pulmonary, or vascular disease that increase the risks associated with surgery and thus preoperative risk-assessment and implementing strategies to reduce the risk of perioperative morbidity and mortality are important. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Thoracic aneurysm repair'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Repair of thoracic aortic aneurysm is indicated for the reasons listed above. (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Open repair of thoracic aortic aneurysm affecting the ascending aorta is performed via a median sternotomy, with cardiopulmonary bypass including cardioplegia, and often requires aortic root replacement. Open repair for descending thoracic aortic aneurysm is usually via a thoracotomy, and often does not often require full cardiopulmonary bypass or cardioplegia; however, measures to protect the spinal cord are usually important. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Open surgical technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Morbidity and mortality rates following open thoracic aortic aneurysm repair are high. Aortic arch and Crawford type II (proximal descending to infrarenal aorta) aneurysms have the highest morbidity and mortality rates. Morbidity is due to cardiovascular and pulmonary events, spinal cord dysfunction, and renal dysfunction that can require renal replacement therapy. Factors associated with an adverse 30-day outcome (death, paraplegia, paraparesis, stroke or acute renal failure) after open surgery for thoracoabdominal aneurysm include preoperative renal insufficiency, advanced age, symptomatic aneurysm, and Crawford type II aneurysm (proximal descending to infrarenal aorta). Emergency surgery for thoracoabdominal aneurysm that has ruptured or dissected is associated with a mortality rate of at least 40 percent with serious postoperative complications occurring in about 30 percent of patients. Long-term morbidity and mortality is related to other cardiovascular events such as myocardial infarction, stroke, and large vessel aneurysm in other locations. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Morbidity and mortality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/1\">",
"      Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation 2005; 111:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/2\">",
"      Griepp RB, Ergin MA, Lansman SL, et al. The natural history of thoracic aortic aneurysms. Semin Thorac Cardiovasc Surg 1991; 3:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/3\">",
"      Bickerstaff LK, Pairolero PC, Hollier LH, et al. Thoracic aortic aneurysms: a population-based study. Surgery 1982; 92:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/4\">",
"      Pressler V, McNamara JJ. Thoracic aortic aneurysm: natural history and treatment. J Thorac Cardiovasc Surg 1980; 79:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/5\">",
"      Crawford ES, DeNatale RW. Thoracoabdominal aortic aneurysm: observations regarding the natural course of the disease. J Vasc Surg 1986; 3:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/6\">",
"      Clouse WD, Hallett JW Jr, Schaff HV, et al. Improved prognosis of thoracic aortic aneurysms: a population-based study. JAMA 1998; 280:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/7\">",
"      Juvonen T, Ergin MA, Galla JD, et al. Prospective study of the natural history of thoracic aortic aneurysms. Ann Thorac Surg 1997; 63:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/8\">",
"      Coady MA, Rizzo JA, Hammond GL, et al. Surgical intervention criteria for thoracic aortic aneurysms: a study of growth rates and complications. Ann Thorac Surg 1999; 67:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/9\">",
"      Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg 2002; 73:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/10\">",
"      Pape LA, Tsai TT, Isselbacher EM, et al. Aortic diameter &gt;or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD). Circulation 2007; 116:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/11\">",
"      Bonser RS, Pagano D, Lewis ME, et al. Clinical and patho-anatomical factors affecting expansion of thoracic aortic aneurysms. Heart 2000; 84:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/12\">",
"      Dapunt OE, Galla JD, Sadeghi AM, et al. The natural history of thoracic aortic aneurysms. J Thorac Cardiovasc Surg 1994; 107:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/13\">",
"      Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 1994; 330:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/14\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/15\">",
"      Elefteriades JA. Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. Ann Thorac Surg 2002; 74:S1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/16\">",
"      Davies RR, Gallo A, Coady MA, et al. Novel measurement of relative aortic size predicts rupture of thoracic aortic aneurysms. Ann Thorac Surg 2006; 81:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/17\">",
"      Lobato AC, Puech-Le&atilde;o P. Predictive factors for rupture of thoracoabdominal aortic aneurysm. J Vasc Surg 1998; 27:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/18\">",
"      Gott VL, Pyeritz RE, Magovern GJ Jr, et al. Surgical treatment of aneurysms of the ascending aorta in the Marfan syndrome. Results of composite-graft repair in 50 patients. N Engl J Med 1986; 314:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/19\">",
"      Ergin MA, Spielvogel D, Apaydin A, et al. Surgical treatment of the dilated ascending aorta: when and how? Ann Thorac Surg 1999; 67:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/20\">",
"      Moskowitz DM, Kahn RA, Konstadt SN, et al. Intraoperative transoesophageal echocardiography as an adjuvant to fluoroscopy during endovascular thoracic aortic repair. Eur J Vasc Endovasc Surg 1999; 17:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/21\">",
"      Galla JD, Ergin MA, Lansman SL, et al. Use of somatosensory evoked potentials for thoracic and thoracoabdominal aortic resections. Ann Thorac Surg 1999; 67:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/22\">",
"      Zehr KJ, Orszulak TA, Mullany CJ, et al. Surgery for aneurysms of the aortic root: a 30-year experience. Circulation 2004; 110:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/23\">",
"      WHEAT MW Jr, WILSON JR, BARTLEY TD. SUCCESSFUL REPLACEMENT OF THE ENTIRE ASCENDING AORTA AND AORTIC VALVE. JAMA 1964; 188:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/24\">",
"      Cabrol C, Pavie A, Gandjbakhch I, et al. Complete replacement of the ascending aorta with reimplantation of the coronary arteries: new surgical approach. J Thorac Cardiovasc Surg 1981; 81:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/25\">",
"      David TE, Feindel CM, Bos J. Repair of the aortic valve in patients with aortic insufficiency and aortic root aneurysm. J Thorac Cardiovasc Surg 1995; 109:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/26\">",
"      Lewis CT, Cooley DA, Murphy MC, et al. Surgical repair of aortic root aneurysms in 280 patients. Ann Thorac Surg 1992; 53:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/27\">",
"      Jacobs MJ, Eijsman L, Meylaerts SA, et al. Reduced renal failure following thoracoabdominal aortic aneurysm repair by selective perfusion. Eur J Cardiothorac Surg 1998; 14:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/28\">",
"      Crawford ES, Coselli JS. Replacement of the aortic arch. Semin Thorac Cardiovasc Surg 1991; 3:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/29\">",
"      Coselli JS, B&uuml;ket S, Djukanovic B. Aortic arch operation: current treatment and results. Ann Thorac Surg 1995; 59:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/30\">",
"      Fehrenbacher JW, McCready RA, Hormuth DA, et al. One-stage segmental resection of extensive thoracoabdominal aneurysms with left-sided heart bypass. J Vasc Surg 1993; 18:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/31\">",
"      Svensson LG, Crawford ES, Hess KR, et al. Experience with 1509 patients undergoing thoracoabdominal aortic operations. J Vasc Surg 1993; 17:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/32\">",
"      Svensson LG, Coselli JS, Safi HJ, et al. Appraisal of adjuncts to prevent acute renal failure after surgery on the thoracic or thoracoabdominal aorta. J Vasc Surg 1989; 10:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/33\">",
"      Livesay JJ, Cooley DA, Ventemiglia RA, et al. Surgical experience in descending thoracic aneurysmectomy with and without adjuncts to avoid ischemia. Ann Thorac Surg 1985; 39:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/34\">",
"      Mauney MC, Blackbourne LH, Langenburg SE, et al. Prevention of spinal cord injury after repair of the thoracic or thoracoabdominal aorta. Ann Thorac Surg 1995; 59:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/35\">",
"      Crawford ES, Mizrahi EM, Hess KR, et al. The impact of distal aortic perfusion and somatosensory evoked potential monitoring on prevention of paraplegia after aortic aneurysm operation. J Thorac Cardiovasc Surg 1988; 95:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/36\">",
"      Crawford ES, Svensson LG, Hess KR, et al. A prospective randomized study of cerebrospinal fluid drainage to prevent paraplegia after high-risk surgery on the thoracoabdominal aorta. J Vasc Surg 1991; 13:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/37\">",
"      Coselli JS, LeMaire SA. Left heart bypass reduces paraplegia rates after thoracoabdominal aortic aneurysm repair. Ann Thorac Surg 1999; 67:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/38\">",
"      Ueda T, Shimizu H, Mori A, et al. Selective perfusion of segmental arteries in patients undergoing thoracoabdominal aortic surgery. Ann Thorac Surg 2000; 70:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/39\">",
"      Svensson LG, Hess KR, D'Agostino RS, et al. Reduction of neurologic injury after high-risk thoracoabdominal aortic operation. Ann Thorac Surg 1998; 66:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/40\">",
"      Hollier LH, Money SR, Naslund TC, et al. Risk of spinal cord dysfunction in patients undergoing thoracoabdominal aortic replacement. Am J Surg 1992; 164:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/41\">",
"      Kouchoukos NT, Rokkas CK. Hypothermic cardiopulmonary bypass for spinal cord protection: rationale and clinical results. Ann Thorac Surg 1999; 67:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/42\">",
"      Kouchoukos NT, Masetti P, Rokkas CK, et al. Safety and efficacy of hypothermic cardiopulmonary bypass and circulatory arrest for operations on the descending thoracic and thoracoabdominal aorta. Ann Thorac Surg 2001; 72:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/43\">",
"      Connolly JE. Hume Memorial lecture. Prevention of spinal cord complications in aortic surgery. Am J Surg 1998; 176:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/44\">",
"      Robertazzi RR, Cunningham JN Jr. Intraoperative adjuncts of spinal cord protection. Semin Thorac Cardiovasc Surg 1998; 10:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/45\">",
"      Ross SD, Kron IL, Parrino PE, et al. Preservation of intercostal arteries during thoracoabdominal aortic aneurysm surgery: a retrospective study. J Thorac Cardiovasc Surg 1999; 118:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/46\">",
"      McGarvey ML, Cheung AT, Szeto W, Messe SR. Management of neurologic complications of thoracic aortic surgery. J Clin Neurophysiol 2007; 24:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/47\">",
"      Kazui T, Inoue N, Yamada O, Komatsu S. Selective cerebral perfusion during operation for aneurysms of the aortic arch: a reassessment. Ann Thorac Surg 1992; 53:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/48\">",
"      Spielvogel D, Strauch JT, Minanov OP, et al. Aortic arch replacement using a trifurcated graft and selective cerebral antegrade perfusion. Ann Thorac Surg 2002; 74:S1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/49\">",
"      Strauch JT, Spielvogel D, Lauten A, et al. Technical advances in total aortic arch replacement. Ann Thorac Surg 2004; 77:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/50\">",
"      Griepp RB, Stinson EB, Hollingsworth JF, Buehler D. Prosthetic replacement of the aortic arch. J Thorac Cardiovasc Surg 1975; 70:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/51\">",
"      Livesay JJ, Cooley DA, Duncan JM, et al. Open aortic anastomosis: improved results in the treatment of aneurysms of the aortic arch. Circulation 1982; 66:I122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/52\">",
"      Coselli JS, Crawford ES, Beall AC Jr, et al. Determination of brain temperatures for safe circulatory arrest during cardiovascular operation. Ann Thorac Surg 1988; 45:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/53\">",
"      Svensson LG, Crawford ES, Hess KR, et al. Deep hypothermia with circulatory arrest. Determinants of stroke and early mortality in 656 patients. J Thorac Cardiovasc Surg 1993; 106:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/54\">",
"      Ergin MA, Galla JD, Lansman sL, et al. Hypothermic circulatory arrest in operations on the thoracic aorta. Determinants of operative mortality and neurologic outcome. J Thorac Cardiovasc Surg 1994; 107:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/55\">",
"      Safi HJ, Brien HW, Winter JN, et al. Brain protection via cerebral retrograde perfusion during aortic arch aneurysm repair. Ann Thorac Surg 1993; 56:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/56\">",
"      Lin PJ, Chang CH, Tan PP, et al. Protection of the brain by retrograde cerebral perfusion during circulatory arrest. J Thorac Cardiovasc Surg 1994; 108:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/57\">",
"      Deeb GM, Jenkins E, Bolling SF, et al. Retrograde cerebral perfusion during hypothermic circulatory arrest reduces neurologic morbidity. J Thorac Cardiovasc Surg 1995; 109:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/58\">",
"      Bavaria JE, Woo YJ, Hall RA, et al. Retrograde cerebral and distal aortic perfusion during ascending and thoracoabdominal aortic operations. Ann Thorac Surg 1995; 60:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/59\">",
"      Okita Y, Takamoto S, Ando M, et al. Mortality and cerebral outcome in patients who underwent aortic arch operations using deep hypothermic circulatory arrest with retrograde cerebral perfusion: no relation of early death, stroke, and delirium to the duration of circulatory arrest. J Thorac Cardiovasc Surg 1998; 115:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/60\">",
"      Levy WJ, Levin SK, Bavaria JE. Cerebral oxygenation during retrograde perfusion. Ann Thorac Surg 1995; 60:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/61\">",
"      Nojima T, Mori A, Watarida S, Onoe M. Cerebral metabolism and effects of pulsatile flow during retrograde cerebral perfusion. J Cardiovasc Surg (Torino) 1993; 34:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/62\">",
"      Filgueiras CL, Winsborrow B, Ye J, et al. A 31p-magnetic resonance study of antegrade and retrograde cerebral perfusion during aortic arch surgery in pigs. J Thorac Cardiovasc Surg 1995; 110:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/63\">",
"      Oohara K, Usui A, Murase M, et al. Regional cerebral tissue blood flow measured by the colored microsphere method during retrograde cerebral perfusion. J Thorac Cardiovasc Surg 1995; 109:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/64\">",
"      Boeckxstaens CJ, Flameng WJ. Retrograde cerebral perfusion does not perfuse the brain in nonhuman primates. Ann Thorac Surg 1995; 60:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/65\">",
"      Neri E, Sassi C, Barabesi L, et al. Cerebral autoregulation after hypothermic circulatory arrest in operations on the aortic arch. Ann Thorac Surg 2004; 77:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/66\">",
"      Veldtman GR, Connolly HM, Orszulak TA, et al. Fate of bicuspid aortic valves in patients undergoing aortic root repair or replacement for aortic root enlargement. Mayo Clin Proc 2006; 81:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/67\">",
"      Shapira OM, Aldea GS, Cutter SM, et al. Improved clinical outcomes after operation of the proximal aorta: a 10-year experience. Ann Thorac Surg 1999; 67:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/68\">",
"      Achneck HE, Rizzo JA, Tranquilli M, Elefteriades JA. Safety of thoracic aortic surgery in the present era. Ann Thorac Surg 2007; 84:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/69\">",
"      LeMaire SA, Miller CC 3rd, Conklin LD, et al. A new predictive model for adverse outcomes after elective thoracoabdominal aortic aneurysm repair. Ann Thorac Surg 2001; 71:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/70\">",
"      Mastroroberto P, Chello M. Emergency thoracoabdominal aortic aneurysm repair: clinical outcome. J Thorac Cardiovasc Surg 1999; 118:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/7/10361/abstract/71\">",
"      Schepens MA, Dossche KM, Morshuis WJ. Reoperations on the ascending aorta and aortic root: pitfalls and results in 134 patients. Ann Thorac Surg 1999; 68:1676.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8189 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-66B715A8D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_7_10361=[""].join("\n");
var outline_f10_7_10361=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H757960246\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MEDICAL MANAGEMENT OF ASYMPTOMATIC ANEURYSMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      THORACIC ANEURYSM REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Preoperative evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Perioperative monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Open surgical technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Vascular control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cerebral protection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Endovascular repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H757960246\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8189\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8189|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/9/41107\" title=\"diagnostic image 1\">",
"      Ruptured thoracic aortic aneurysm on chest film",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/42/44707\" title=\"diagnostic image 2A\">",
"      Thoracic aortic aneurysm plain chest film",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/48/19215\" title=\"diagnostic image 2B\">",
"      Aortic root aneurysm in Marfan syndrome on chest film",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/52/31566\" title=\"diagnostic image 3\">",
"      Thoracic aortic aneurysm in giant cell arteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/26/7584\" title=\"diagnostic image 4A\">",
"      Thoracic aortic dissection on computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/51/36670\" title=\"diagnostic image 4B\">",
"      Thoracic aortic dissection on reconstructed computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8189|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/46/13037\" title=\"figure 1\">",
"      Expansion rates of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/34/42541\" title=\"figure 2\">",
"      Thoracic aortic aneurysm expansion by location",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22712?source=related_link\">",
"      Clinical features and diagnosis of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=related_link\">",
"      Clinical manifestations and diagnosis of bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=related_link\">",
"      Course and management of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=related_link\">",
"      Evaluation of carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=related_link\">",
"      Examination of the arterial pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=related_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37240?source=related_link\">",
"      Thoracic endovascular aneurysm repair",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_7_10362="Pelvic nerve plexus";
var content_f10_7_10362=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 615px\">",
"   <div class=\"ttl\">",
"    Nerve plexus of the pelvis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 595px; height: 553px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Autonomic nerves are demonstrated. The superior hypogastric plexus is a continuation of the aortic (intermesenteric) plexus. It divides into left and right hypogastric nerves as it enters the pelvis. The hypogastric and pelvic splanchnic nerves merge to form the inferior hypogastric plexuses, which thus consist of both sympathetic and parasympathetic fibers. Autonomic (sympathetic) fibers also enter the pelvis via the sympathetic trunks and periarterial plexuses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_7_10362=[""].join("\n");
var outline_f10_7_10362=null;
var title_f10_7_10363="WHO gr mucoepidermoid carc";
var content_f10_7_10363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    WHO grading of mucoepidermoid carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Histologic feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaplasia (marked cytologic &amp; nuclear atypia)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;4 mitoses per 10 high power (400x) fields",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of necrosis",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perineural invasion present",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumor &lt;20 percent cystic",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: World Health Organization Classification of Tumors: Pathology and Genetics: Head and Neck Tumors. Barnes, L, Everson, JW, Reichart, P, Sidransky, D, (eds). WHO Press (Switzerland) 2005; p.219. Copyright &copy;2005 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_7_10363=[""].join("\n");
var outline_f10_7_10363=null;
var title_f10_7_10364="Abdominal pain history PI";
var content_f10_7_10364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F75335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F75335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Abdominal pain history",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        When did it start? Is it better, worse, or about the same?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        When does it occur? Is it sharp, dull, crampy?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is it constant or does it come and go?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Where does it hurt? Does it move to other areas?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How severe is the pain?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the pain wake the child from sleep?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How do you know the child is in pain?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How does the family respond to the child's pain?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have any tests been done by other healthcare providers? If so, bring records.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does anything make the pain worse or better? (eg, bowel movement, walking, resting, medications)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Has the child lost weight? Was it intentional or unintentional?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Are there other symptoms? (eg, reduced appetite, nausea, gas, diarrhea)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do specific foods or meals cause pain?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Are there respiratory symptoms? (eg, coughing, wheezing, hoarse voice)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Habits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have the child's eating habits changed? (eg, restricting foods, binge eating)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How frequently does the child move his/her bowels? Is he/she ever \"too busy\" to finish a bowel movement?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have there been episodes of unintentional fecal loss (soiling) recently?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Social history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Has the child's attendance at school or social activities been affected by his/her pain?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Are there any known stressors for the child or adolescent? (eg, divorce, move, death, school performance)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_7_10364=[""].join("\n");
var outline_f10_7_10364=null;
var title_f10_7_10365="TNM clin staging mel conj";
var content_f10_7_10365=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM clinical staging of melanoma of the conjunctiva",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td>",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td>",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T(is)",
"      </td>",
"      <td>",
"       Melanoma confined to the conjunctival epithelium",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Malignant conjunctival melanoma of the bulbar conjunctiva",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"2\">",
"       T1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       T1a",
"      </td>",
"      <td class=\"sublist_other\">",
"       Less than or equal to 1 quadrant*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       T1b",
"      </td>",
"      <td class=\"sublist_other\">",
"       More than 1 but less than or equal to 2 quadrants",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       T1c",
"      </td>",
"      <td class=\"sublist_other\">",
"       More than 2 but less than or equal to 3 quadrants",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       T1d",
"      </td>",
"      <td class=\"sublist_other\">",
"       Greater than 3 quadrants",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Malignant conjunctival melanoma of the nonbulbar (palpebral, forniceal caruncular)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"2\">",
"       T2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       T2a",
"      </td>",
"      <td class=\"sublist_other\">",
"       No caruncular, less than or equal to 1 quadrant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       T2b",
"      </td>",
"      <td class=\"sublist_other\">",
"       No caruncular, greater than 1 quadrant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       T2c",
"      </td>",
"      <td class=\"sublist_other\">",
"       Any caruncular, with less than or equal to 1 quadrant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       T2d",
"      </td>",
"      <td class=\"sublist_other\">",
"       Any caruncular, with greater than 1 quadrant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Any malignant conjunctival melanoma with local invasion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"2\">",
"       T3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       T3a",
"      </td>",
"      <td class=\"sublist_other\">",
"       Globe",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       T3b",
"      </td>",
"      <td class=\"sublist_other\">",
"       Eyelid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       T3c",
"      </td>",
"      <td class=\"sublist_other\">",
"       Orbit",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       T3d",
"      </td>",
"      <td class=\"sublist_other\">",
"       Sinus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T4",
"      </td>",
"      <td>",
"       Tumor invades the central nervous system",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       Regional lymph node (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td>",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0a (biopsied)",
"      </td>",
"      <td>",
"       No regional lymph node metastasis, biopsy performed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0b (not biopsied)",
"      </td>",
"      <td>",
"       No regional lymph node metastasis, biopsy not performed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       Regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       Metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td>",
"       Distant metastasis",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Quadrants are defined by clock hour, starting at the limbus (eg, 6, 9, 12, 3) extending from the central cornea, to and beyond the eyelid margins. This will bisect the caruncle.",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_7_10365=[""].join("\n");
var outline_f10_7_10365=null;
var title_f10_7_10366="Antiepileptic drugs in children part I";
var content_f10_7_10366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68462%7EPEDS%2F80434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68462%7EPEDS%2F80434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug therapy for seizures in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Blood level",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Laboratory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Starting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Maintenance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"       <td>",
"        10-20 mg/kg/day",
"       </td>",
"       <td>",
"        10-35 mg/kg/day",
"       </td>",
"       <td>",
"        4-12 mcg/mL",
"       </td>",
"       <td>",
"        CBC after initial 4-6 weeks, then prn. If initial WBC low (particularly AMC) repeat as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Clobazam&nbsp;",
"       </td>",
"       <td>",
"        Children &lt;2 y.o. 0.5-1 mg/kg/day&nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        0.5-1 mg/kg/day (max 40 mg/day)&nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        Not established&nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        Routine lab tests not recommended&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children 2-16 y.o. 5 mg/day&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clonazepam",
"       </td>",
"       <td>",
"        0.01-0.03 mg/kg/day",
"       </td>",
"       <td>",
"        0.1-0.2 mg/kg/day",
"       </td>",
"       <td>",
"        Not used",
"       </td>",
"       <td>",
"        If clinically indicated (bruising, unexplained fevers, etc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clorazepate",
"       </td>",
"       <td>",
"        0.3 mg/kg",
"       </td>",
"       <td>",
"        0.5-3.0 mg/kg",
"       </td>",
"       <td>",
"        Not used",
"       </td>",
"       <td>",
"        Not required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethosuximide",
"       </td>",
"       <td>",
"        15&nbsp;mg/kg/day",
"       </td>",
"       <td>",
"        15-40 mg/kg/day",
"       </td>",
"       <td>",
"        40-100 mcg/mL (any increase to 150)",
"       </td>",
"       <td>",
"        CBC/plts after first 1-2 months, prn thereafter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felbamate",
"       </td>",
"       <td>",
"        15 mg/kg/day",
"       </td>",
"       <td>",
"        15-45 mg/kg/day",
"       </td>",
"       <td>",
"        50-100 mcg/mL",
"       </td>",
"       <td>",
"        CBC/plts every 2-4 weeks, hepatic function tests every month",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gabapentin",
"       </td>",
"       <td>",
"        10-15 mg/kg/day",
"       </td>",
"       <td>",
"        40-50 mg/kg/day",
"       </td>",
"       <td>",
"        Not established (probably 7-12 mcg/mL)",
"       </td>",
"       <td>",
"        CBC/plts every 3 months for first 6 months, chemical panel prn (routine monitoring may not be necessary)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Lamotrigine+&nbsp;",
"       </td>",
"       <td>",
"        Monotherapy 0.3 mg/kg/day&nbsp;",
"       </td>",
"       <td>",
"        &nbsp;4.5-7.5 mg/kg/day",
"       </td>",
"       <td rowspan=\"3\">",
"        4-15 mcg/mL",
"       </td>",
"       <td rowspan=\"3\">",
"        CBC/plts every 3 months for first 6 months, chemical panel prn (routine monitoring may not be necessary)&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Add to VPA 0.15 mg/kg/day&nbsp;",
"       </td>",
"       <td>",
"        &nbsp;1-5 mg/kg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Add to inducer (PB, CBZ, PHT) 0.6 mg/kg/day&nbsp;",
"       </td>",
"       <td>",
"        &nbsp;5-15 mg/kg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levetiracetam&nbsp;",
"       </td>",
"       <td>",
"        20 mg/kg/day&nbsp;",
"       </td>",
"       <td>",
"        40-60 mg/kg/day&nbsp;",
"       </td>",
"       <td>",
"        Not established&nbsp;",
"       </td>",
"       <td>",
"        Routine lab tests not recommended&nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     +: dosing for children 2-12 years of age; AMC: absolute monocyte count; CBC: complete blood count; CBZ: carbamezepine; max: maximum; PB: phenobarbital; PHT: phenytoin; plts: platelets; VPA: valproate; y.o.: years old",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug therapy for seizures in children (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Blood level",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Laboratory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Starting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Maintenance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxcarbazepine&nbsp;",
"       </td>",
"       <td>",
"        8-10 mg/kg/day&nbsp;",
"       </td>",
"       <td>",
"        30-40 mg/kg/day&nbsp;",
"       </td>",
"       <td>",
"        8-35 mcg/mL&nbsp;",
"       </td>",
"       <td>",
"        CBC/plts every 3 months for first 6 months, chemical panel prn (routine monitoring may not be necessary)&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Phenytoin, fosphenytoin (intravenous)",
"       </td>",
"       <td>",
"        5&nbsp;mg/kg/day",
"       </td>",
"       <td rowspan=\"2\">",
"        4-8 mg/kg/day (older children, adolescents 300 mg/day)",
"       </td>",
"       <td rowspan=\"2\">",
"        10-20 mcg/mL&nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        Routine lab tests not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Status elilepticus 20 mg/kg (fosphenytoin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Phenobarbital",
"       </td>",
"       <td rowspan=\"2\">",
"        3-4 mg/kg/day",
"       </td>",
"       <td>",
"        Infants 5-6 mg/kg/day",
"       </td>",
"       <td rowspan=\"2\">",
"        10-40 mcg/mL",
"       </td>",
"       <td rowspan=\"2\">",
"        Routine lab tests not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children 1-5 y.o.&nbsp;6-8 mg/kg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primidone",
"       </td>",
"       <td>",
"        1-2 mg/kg/day",
"       </td>",
"       <td>",
"        10-25 mg/kg/day",
"       </td>",
"       <td>",
"        5-12 mcg/mL (phenobarbital level 1.2 x higher)",
"       </td>",
"       <td>",
"        Routine lab tests not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rufinamide&nbsp;",
"       </td>",
"       <td>",
"        10 mg/kg/day&nbsp;",
"       </td>",
"       <td>",
"        45 mg/kg/day&nbsp;",
"       </td>",
"       <td>",
"        Not established&nbsp;",
"       </td>",
"       <td>",
"        Routine lab tests not recommended&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topiramate",
"       </td>",
"       <td>",
"        1-3 mg/kg/day",
"       </td>",
"       <td>",
"        5-9 mg/kg/day",
"       </td>",
"       <td>",
"        5-20 mcg/mL",
"       </td>",
"       <td>",
"        CBC/plts, hepatic function tests, serum K when maximum dose reached or at 3-6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Tiagibine",
"       </td>",
"       <td>",
"        &lt;12 years 0.5 mg/kg/day",
"       </td>",
"       <td>",
"        Weekly increase 0.5-1 mg/kg/day with max 4-8 mg/kg/day (3-4 divided daily doses)",
"       </td>",
"       <td rowspan=\"2\">",
"        Not established",
"       </td>",
"       <td rowspan=\"2\">",
"        Routine lab tests not recommended&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         &gt;12 years 4 mg/day",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Increase 4 mg/week to max 32 mg/day (2-4 divided daily doses)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valproate&nbsp;",
"       </td>",
"       <td>",
"        10-15 mg/kg/day&nbsp;",
"       </td>",
"       <td>",
"        30-60 mg/kg/day&nbsp;",
"       </td>",
"       <td>",
"        50-150 mcg/mL&nbsp;",
"       </td>",
"       <td>",
"        Hepatic function tests every 1-2 months&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zonisamide&nbsp;",
"       </td>",
"       <td>",
"        1-2 mg/kg/day&nbsp;",
"       </td>",
"       <td>",
"        5-8 mg/kg/day&nbsp;",
"       </td>",
"       <td>",
"        10-40 mcg/mL&nbsp;",
"       </td>",
"       <td>",
"        Serum electrolytes&nbsp;when maximum dose is reached or at 3-6 months&nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBC: complete blood count; max: maximum; plts: platelets; y.o.: years old",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_7_10366=[""].join("\n");
var outline_f10_7_10366=null;
var title_f10_7_10367="Outcome from medical terminatio";
var content_f10_7_10367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Pregnancy termination with mifepristone and oral misoprostol",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 346px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_7_10367=[""].join("\n");
var outline_f10_7_10367=null;
